e roche annual report key figures key figures indexed figures annual report exceptional items full index global reporting initiative gri proposed board directors indicators used report see development phase iv wwwrochecomreportingandindices calculation ecoefficiency rate see wwwrochecomenvironment e roche ance report roche annual r eport fhopfufmbalnshnelda roche ltd f bhaosfefml asnwnitzear lranodc trademarks legally protec ted wwwrochecom excellence science umschlagausgeschossenengindd key figures key figures indexed figures annual report exceptional items full index global reporting initiative gri proposed board directors indicators used report see development phase iv wwwrochecomreportingandindices calculation ecoefficiency rate see wwwrochecomenvironment lrochearengkey figuresindd year brief group group sales increase billion swiss francs swiss francs us dollars divisions gain market share operating profit exceptional items increases swiss francs billion swiss francs due strong sales growth continuing productivity improvements time investments research development increase billion swiss francs effective march roche obtains full ownership genentech price billion us dollars billion swiss francs genentech integration completed net income billion swiss francs compared previous year due exceptional items relating genentech transaction integration excluding exceptional items genentech transaction already contributing income income attributable roche shareholders increases billion swiss francs core eps constant exchange rates swiss francs board proposes dividend increase swiss francs rd consecutive year dividend growth would increase payout ratio pharmaceuticals pharma sales grow swiss francs us dollars almost twice global market growth rate driven leading cancer medications tamiflu influenza medicine well lucentis ophthalmology medicine tamiflu sales grow sharply billion swiss francs following substantially increased demand pandemic influenza ahn virus swine flu outbreak operating profit margin exceptional items increases percentage points constant exchange rates percentage points swiss francs strong rd pipeline ten new molecular entities latestage clinical testing six new compounds entered phase iii clinical trials actemra approved us treatment rheumatoid arthritis january diagnostics sales increase swiss francs us dollars billion swiss francs twice market growth rate operating profit margin constant exchange rates increases percentage points percentage points swiss francs outlook fullyear sales pharmaceuticals group expected grow midsingledigit range expected decrease tamiflu sales billion swiss francs diagnostics sales expected grow well ahead market planned research development expenses decline slightly compared roche confirms target doubledigit core earnings per share growth based strong operating free cash flow roche expects reduce debt progressively return net cash position maintaining attractive dividend policy unless otherwise stated growth rates local currencies without tamiflu sales constant exchange rates barring unforeseen events lrochearenghighlightsindd pharmaceuticals pipeline focused compounds firstinclass bestinclass potential phase phase ii phase iii registration project id projectproduct indication project id projectproduct indication project id projectproduct indication project id projectproduct indication oncology oncology oncology oncology rg secretase inh solid tumours rg avastin multiple myeloma rg mabtherarituxan indolent nhl maint stline rg mabtherarituxan chronic lympocytic leukemia rg antiegfr humab solid tumours rg avastin metastatic melanoma rg xelodaavastin adj colon cancer stline rg cifmek inh solid tumours rg pertuzumab neoadj breast cancer rg xeloda adj breast cancer rg mabtherarituxan chronic lympocytic leukemia rg solid tumours rg trastuzumabdm metastatic bc rdline rg avastinmabthera diffuse large b cell lymphoma relapsed rg antiplgf mab solid tumours rg trastuzumabdm metastatic bc stline rg avastin adj colon cancer rg xeloda adj colon cancer combo rg antinrp mab solid tumours rg hedgehog pathway inh basal cell carcinoma rg avastin prostate cancer oxaliplatin rg mdm antag solid hematologic tumours rg hedgehog pathway inh colocrectal cancer rg avastin adj breast cancer rg avastin mbc stline combo docetaxel rg dulanermin cancer rg hedgehog pathway inh ovarian cancer rg avastin ovarian cancer stline rg avastin mbc stline combo standard rg mek inh solid tumours rg anticd humab nonhodgkins lymphoma rg avastinherceptin mbc stline chemotherapies rg pi kinase inh solid hematologic tumours rg antimet humab metastatic nsclc rg avastin adj nsclc rg herceptin met gastric cancer rg pi kinase inh solid tumours rg abt solid hematologic tumours rg avastin met gastric cancer rg tarceva nsclc stline maintenance rg antiegfl mab solid tumours chu topoisomerase inh gastric cancer rg avastin adj breast cancer chu antiglypican mab liver cancer rg avastin adj bc triple negative inflammation autoimmune disorders inflammation autoimmune disorders rg avastin mbc combo hormonal rg mabtherarituxan rheumatoid arthritis dmard inflammation autoimmune disorders rg palovarotene emphysema therapy inadequate responders rg antibeta rhumab ulcerative colitis rg lebrikizumab asthma rg avastin ovarian cancer platinum rg xolair pediatric asthma rg antilt alpha mab rheumatoid arthritis rg oxl humab asthma sensitive chu eldecalcitol ed osteoporosis bti vap inflammatory diseases rg rontalizumab systemic lupus erythematosus rg avastin mbc ndline rg xolair chronic idiopathic urticaria rg avastin highrisk carcinoid virology virology rg avastin gbm stline rg valcyte cytomegalovirus extension chu serine palmitoyltrans hepatitis c virology rg herceptin sc formulation bc treatment ferase inh rg hpv immunotherapy cervical neoplasia rg herceptin adj bc yr treatment chu nitazoxanide hepatitis c rg nucleoside inh prodrug hepatitis c rg pertuzumab mbc ophthalmology rg protease inh hepatitis c rg tarceva nsclc egfr mutation rg lucentis retinal vein occlusion cardiovascular metabolic diseases positive stline rg yr peptide agonist type diabetes cardiovascular metabolic diseases rg tarceva adj nsclc others rg antip selectin humab peripheral vascular disease rg aleglitazar cardiovascular risk reduction rg tarcevaavastin nsclc maint stline chu epogin epoch chemoinduced anemia rg hsd inh type diabetes rg sglt inh type diabetes rg anticd humab chronic lymphocytic leukemia rg hsd inh type diabetes rg braf inh malignant melanoma rg abca inducer dyslipidemia central nervous system rg trastuzumabdm mbc ndline rg craf inh polycystic kidney disease rg ocrelizumab relapsingremitting ms rg antioxldl mab secondary prevention rg glyt inh schizophrenia inflammation autoimmune disorders cardiovascular events rg nicotinic receptor alzheimers disease rg mabtherarituxan ancaassociated vasculitis rg bht type diabetes agonist rg actemraroactemra jia systemic onset rg mglur antag treatmentresistant depression rg actemraroactemra early rheumatoid arthritis central nervous system rg ocrelizumab rheumatoid arthritis pjd rg gantenerumab alzheimers disease rg xolair asthma addon therapy rg mglur antag depression rg gabaa agonist alzheimers disease selected abbreviations cardiovascular metabolic diseases legend rg igf peg amyotrophic lateral sclerosis adj adjuvant treatment inh inhibitor rg taspoglutide type diabetes therapeutic protein biologic rg triple reuptake inh depression amd agerelated macular jia juvenile idiopathic arthritis rg dalcetrapib dyslipidemia small molecule degeneration mab monoclonal antibody rg taar partial agonist depression blue type first indication antag antagonist maint maintenance treatment rg antiamyloid peptide alzheimers disease bc breast cancer met metastatic cancer ophthalmology black type additional indications mab combo combined ms multiple sclerosis rg lucentis diabetic macular edema dmard diseasemodifying nhl nonhodgkins lymphoma evo nmda receptor antag treatmentresistant depression antirheumatic drug nsclc nonsmall cell lung cancer rg lucentis amd high dose rgno roche andor genentech managed gbm glioblastoma multiforme pjd prevention joint chu chugai managed ophthalmology herpositive destruction others bti biotie optin hernegative r recombinant evo evotec rg antifactor mab geographic atrophy hpv human papilloma virus sc subcutaneous rg tnkase catheter clearance hu humanised phase initial studies healthy volunteers possibly patients phase ii efficacy tolerability dosefinding studies patients phase iii largescale studies patients statistical confirmation safety efficacy registra marketing applications filed eu us andor japan tion approved eu current january umschlagausgeschosseneng indd business innovation answer medical challenges daily work saving patients lives helping millions people around world excellence science focus unsolved medical problems years roche played pioneer include cancers viral infections metabolic ing role healthcare today world leader central nervous system disorders inflammatory vitro diagnostics supply wide range diag diseases roche pioneer personalised health nostic instruments tests rapid reliable care aim fit treatments closely pos sible disease detection monitoring doctors labora patients needs make healthcare better safer tories patients worlds largest costeffective biotech company roche brought many highly effective drugs market become worlds leading supplier prescription drugs cancer treatment daily work focuses disease areas medical needs great lrochearengtable contentsindd contents key figures inside cover pharmaceuticals pipeline inside cover year brief letter shareholders roche group group results outlook group strategy pharmaceuticals pharmaceuticals division brief results sales review development highlights research development diagnostics diagnostics division brief results business area highlights research development corporate governance remuneration report corporate governance remuneration report corporate responsibility brief responsible practices patients people society safety security health environmental protection independent assurance report gri statement lrochearengtable contentsindd roche business report letter shareholders letter shareholders franz b humer dear shareholders despitethesustainedglobalfinancialandeconomiccrisiswasaverysuccessfulyearforrochesales inboththepharmaceuticalsandthediagnosticsdivisiongrewtwiceasfastasthemarketgroupsales increasedbyinlocalcurrenciestobillionswissfrancsmainlydrivenbyourleadingmedicines totreatpatientswithcancerviralinfectionsagerelatedblindnessandotherseriousdiseasessalesof theinfluenzamedicinetamifluatbillionswissfrancsalsocontributedsignificantlytorevenuegrowth operatingprofitbeforeexceptionalitemsgrewevenmorestronglythansalesadvancinginlocal currenciestobillionswissfrancs willberememberedasoneofthemostimportantyearsinyourcompanyslonghistoryfollowingthe mergeragreementwithgenentechinmarchandtherapidfinalisationofthetransactionwewere abletocompletetheintegrationbytheendoftheyearbycombiningrocheandgenentechwearenotonly increasingoperationalefficiencybutalsopromotinginternalknowledgetransferwearecommittedto strengtheningtherochegroupsinnovativepowerinthelongtermandto providingpatientswithinno vativemedicinesthroughresearchofthehighestquality excellentresearchisandwillremainabasicrequirementforthedevelopmentoftherapiesthataredecisive forpatientshealthandqualityoflifeafterconcludingthegenentechintegrationwewillcontinueto systematicallypursuediverseresearchapproachesforinnovativehealthcaresolutionsthiscreatesscope forcreativityandincreasesthechancesofdevisingsustainablemedicalandtherapeuticprogressfor thisreasongenentechresearchandearlydevelopmentwillcontinuetofunctionasanindependentunit lrochearengletter shareholdersindd severin schwan inadditioncombiningtheactivitiesofthetwocompaniesintheareasofproductdevelopmentproduction andsaleshasalreadygeneratedsignificantincreasesinproductivityouraimistoachievepretaxannual savingsofapproximatelybillionswissfrancsby theoperatingfreecashflowofthegroupincreasedbytobillionswissfrancsdespitesignificant negativecurrencyeffectsrochesstrongoperatingperformanceisalsoclearlyreflectedincoreearnings persharewhichadvancedinlocalcurrenciesinswissfrancs asaresultofexceptionalcostsofbillionswissfrancswhichwereprimarilyintegrationrelated thegroupsoperatingprofitindeclinedbyinlocalcurrenciesinswissfrancstobillion swissfrancsexceptionalitemsalsoimpactednetincomewhichdeclinedbycomparedwiththe previousyearperiodtobillionswissfrancsexcludingexceptionalitemsnetincomeattributableto rocheshareholdersincreasedby inviewofrochesstrongfullyearoperatingresultsattheannualgeneralmeetingtheboardofdirectors willproposeanincreaseofinthedividendfortoswissfrancspershareandnonvoting equitysecurityswissfrancssubjecttoyourapprovalthiswillbetherdconsecutive annualdividendincrease lrochearengletter shareholdersindd roche business report letter shareholders therapidspreadofthepandemicahninfluenzavirusswinefluwhichbeganinaprilpre sentedamajorchallengenotonlyforgovernmentsworldwidebutalsoforrocheduringthepastyearwe havebeensupportingtheworldhealthorganizationwhoandnationalgovernmentsinglobalefforts tofightthenewvirusinmayrocheannouncedthatanadditionalmilliontreatmentcoursesoftamiflu wouldbedonatedtoreplenishthewhosregionalandrapidresponsestockpileswehadpreviously grantedsublicencestothreemanufacturerstoproducegenericoseltamivirforpandemicuseinchina indiaandspecifieddevelopingcountriestoensurethatlocalpopulationsintheseareashaveaccessto themedicationinadditioninjulyweinitiatedthetamiflureservesprogramtofurtherimprovetamiflu accessindevelopingcountriesinresponsetotheincreasedwhopandemicthreatlevelournetworkof manufacturingpartnersscaledupproductiontoapproximatelymilliontreatmentcoursespermonth andwearenowabletosupplyuptomillionpacksannuallyifrequired therochegroupreceivedsignificantrecognitionforachievementsinseveralareasduringthepastyear thedowjonessustainabilityindexesnamedrochethenewsupersectorleaderinhealthcare rankingusasthemostsustainablehealthcarecompanyworldwiderocheandgenentechwerealso againvotedbestemployerinanumberofcountries wewouldliketotakethisopportunitytothankthemorethangroupemployeesworldwideforthe outstandingdedicationandprofessionalismduringthiseventfulandchallengingtime scientificexcellenceandinnovationinourcorepharmaanddiagnosticsbusinesseswillcontinuetobethe foundationofoursuccessasidefromoncologywearedevelopingnewtherapeuticsformetabolicand autoimmunediseasesviralinfectionsanddisordersofthecentralnervoussystemastheworldslargest biotechcompanywehaveoneofthemostpromisingrdpipelinesintheworldfromatotalofnew molecularentitiesinclinicaltestingtenarealreadyinlatestagedevelopmentwhichisremarkablebyany standardsinourindustryinthelastyearalonesixnewcompoundsenteredlatephasedevelopment includingpotentialnewtherapiesforbreastcancerandtypediabetes duringtheyearwepublishedexcitingearlyphaseclinicaltrialdataonatargetedtreatmentandcom paniondiagnosticinmalignantmelanomapatientswhosecancercellscarryaspecificgeneticmutation malignantmelanomaisthedeadliestformofskincancerthenewcompoundeffectivelyslowedtumor progressionandincreasedpatientsqualityoflifethisisabeaconofhopeinthefightagainstacancer thatuntilnowhasbeenregardedasvirtuallyuntreatable amongthekeyachievementsinourdiagnosticsdivisionarethestartoftherolloutofthecobas modularanalyserseriesforlargemedicallaboratoriesandthelaunchofnewproductsintheaccuchek lineofbloodglucosemonitorsforpeoplewithdiabetes attheendofwilliammburnsceoofthepharmaceuticalsdivisionjrgenschwiezerceoofthe diagnosticsdivisionandjonathankcknowlesheadofrochegroupresearchleftthecorporate executivecommitteeasplannedeachofthemhasmadesignificantcontributionstorochessuccessand helpedwriteanimportantchapterinthecompanyshistoryeverygenerationofmanagershasthetask ofensuringrocheshealthyfutureasanindependentcompanybillburnsjonathanknowlesandjrgen schwiezerhavefulfilledthistaskinanexemplarymannerdrivenbyprofoundconvictiontheyhave lrochearengletter shareholdersindd bringing genentech fully roche group major step road creating stronger even innovative organisation significantlycontributedtorochesstrongmarketpositionandsuccessonbehalfoftheentireboardof directorsandthecorporateexecutivecommitteewewouldliketothankthemfortheirmanyyearsof invaluableserviceloyaltytorocheandforthegreatworkingrelationshipweenjoyed inviewoftheiroutstandingindustryknowledgetheboardofdirectorswillproposeappointingwilliam mburnsandarthurdlevinsonchairmanofgenentechboardofdirectorstotheboardofdirectorsof rocheholdingltdattheannualgeneralmeetingonmarch profhorstteltschikandpeterbrabeckhavedecidednottostandforreelectionattheannual generalmeetingweareverygratefulfortheirvaluablecontributionstothecompanyoveraperiodofmany years barringunforeseeneventsweexpectsalesinforthepharmaceuticalsdivisionandforthegroup toincreaseinthemidsingledigitrangeinlocalcurrenciesinthediagnosticsdivisionweexpectfullyear salestogrowconsiderablyaheadofthemarketfurthermoreweareaimingtoachievedoubledigit coreearningspersharegrowthatconstantexchangeratesinweanticipatethatwewillalreadyhave repaidofthedebtraisedtofinancethegenentechtransactionbytheendofbasedonthe groupsstrongoperatingfreecashflowrocheexpectstoreturntoanetcashpositionbytheendof wewillsimultaneouslymaintainourattractivedividendpolicy franzbhumer severinschwan chairmanoftheboard chiefexecutiveofficer excluding tamiflu sales lrochearengletter shareholdersindd bildstreckeengsindd shes working starvation diet aggressive brain tumours roche tackling modern medicines greatest challenges search medicines combat serious illnesses effective treatment exists quest requires sophisticated technological capabilities deep insights molecular biology select optimal targets drug treatment first need understand complex biological mechanisms driving disease case avastin targeted blockade bloodvessel growth factor approach first developed genentech scientists starves tumours nutrients oxygen need grow spread fundamentally changed way fight cancer avastin currently approved treat five types cancer investigated possible treatment different tumour types giving hope thousands patients avastin monoclonal antibody used treat advanced colorectal breast nonsmall cell lung kidney cancer also approved us eleven countries treatment relapsed glioblastoma multiforme aggressive type brain tumour bildstreckeengsindd roche group strong operating performance group sales ope rating profit exceptional items core earnings per share increased double digits roche anticipates another doubledigit rise core eps group remains firmly focused prescription drugs vitro diagnostics following successful integration genentech roche better equipped ever healthcare innovator lrochearenggroupindd roche group thegroupsoperatingfreecashflowincreased stronglyrisinginlocalcurrenciesinswiss strong sales trading results francstobillionswissfrancsthegroups totalsalesgrewbyinlocalcurrenciesin freecashflowremainedstronginincreasingby swissfrancsinusdollarstobillionswiss billionswissfrancstobillionswissfrancs francswiththepharmaceuticalsdivisionaccounting forofgroupsalesandthediagnosticsdivision coreepswhichexcludesexceptionalitems contributingsalesgrowthinbothdivisions andamortisationandimpairmentofintangibleassets exceededmarketgrowth increasedinlocalcurrenciesinswiss francs salesbythepharmaceuticalsdivisionincreased inlocalcurrenciesinswissfrancsin significant impact genentech integration usdollarstobillionswissfrancsoralmost changes group organisation doubletheglobalmarketgrowthratedemandfor effectivemarchthegroupobtainedfull thegroupscancermedicinesavastinherceptin ownershipofgenentechsubsequentlythegroup mabtherarituxantarcevaandxelodacontinuedto commencedarestructuringofitsuspharmaceuticals growstronglyadditionalmajorgrowthdriversin businessaswellasanumberofglobalfunctions thepharmaceuticalsdivisionweretamifluinvirology duringrestructuringandintegrationcostsof andlucentisinophthalmology billionswissfrancswereincurredmainlyin connectionwiththediscontinuationofaconstruction thediagnosticsdivisionachievedsalesgrowthof projectatthemanufacturingsiteatvacavillecalifornia inlocalcurrenciesinswissfrancsinusdol terminationcostsfortheclosureofmanufacturing larstobillionswissfrancstherebystrengthening operationsatnutleynewjerseytheclosureofthe thedivisionsleadingmarketshareofaround researchanddevelopmentsiteatpaloaltocalifornia andcostsassociatedwiththeconsolidationofthe thegroupsoperatingprofitbeforeexceptionalitems usadministrativefunctionsinsouthsanfrancisco increasedbyinlocalcurrenciesinswiss approximatelybillionswissfrancsoftheseexcep francstobillionswissfrancsoperatingprofit tionaloperatingexpensesarenoncash itemsrelated inlocalcurrenciesgrewtobillionswiss mainlytoimpairmentsofmanufacturingassets francsbeforeexceptionalitemsinthepharmaceuticals divisionandtobillionswissfrancsinthe thegroupfinancedthegenentechtransactionby diagnosticsdivision acombinationofthegroupsownfundsbondsnotes andcommercialpaperthegroupraisednetpro atconstantexchangeratesthegroupsoperating ceedsofbillionswissfrancsthroughaseries profitmarginbeforeexceptionalitemsincreased ofbondandnoteofferingsasaconsequenceinterest percentagepointswiththepharmaceuticalsdivi expensesincreasedsubstantiallyinand sionimprovingpercentagepointsandthedia financingcostsexceededfinancialincomebybil gnosticsdivisionpercentagepointsduetoan lionswissfrancsbytheendofthegroup unfavourablecombinationofexchangeratemove hadalreadyrepaiddebtofbillionswissfrancs mentshoweverthegroupsoperatingprofitmargin beforeexceptionalitemsinswissfrancsincreased comparedtonetincomedecreasedbyto onlyslightlybypercentagepointstowith billionswissfrancsprimarilyduetoexceptional thepharmaceuticalsdivisionimprovingpercent itemsnetincomeattributabletorocheshareholders agepointstoandthediagnosticsdivision declinedtobillionfrancsexcludingexcep decreasingpercentagepointsto tionalitemsnetincomewasdownandnetincome lrochearenggroupindd roche business report roche group attributabletorocheshareholderswashigher weexpecttorepayofthedebtraisedtofinance comparedto thegenentechtransactionbytheendof bythegroupaimstoachievepretaxannual thenetdebtpositionofthegroupisbillion synergiesofapproximatelybillionswissfrancs swissfrancsamovementofbillionswissfrancs basedonthegroupsstrongoperatingfreecashflow fromanetcashpositionofbillionswissfrancs weexpecttoreducedebtprogressivelyandto ondecemberduetothebillionswiss returntoanetcashpositionbywewillsimulta francsusedinthegenentechtransaction neouslymaintainourattractivedividendpolicy outlook barringunforeseeneventsrocheexpectssales inforthepharmaceuticalsdivisionandfor thegrouptoincreaseinthemidsingledigit range inlocalcurrenciesexcludingtamifluinthe diagnosticsdivisionweexpectfullyear salesto growsignificantlyaheadofthemarketdespite ananticipateddecreaseintamiflusalesfrom tobillionswissfrancsweareaimingtoachieve doubledigit coreearningspersharegrowthat constantexchangerates rocheexpectsresearchanddevelopmentexpendi turestodeclineslightlyinhoweverthegroups focusremainsfirmlyoninnovationanditwill continuetoinvesttosupportitsrichpharmaceuticals developmentpipelinewhichcurrentlyincludes tennewmolecularentitiesandadditionalindica tionsforexistingproductsinlatestagedevelopment overthenextmonthsthepharmaceuticals divisionexpectstofilemarketingapplicationsfor severalmajorlineextensionsofourkeycancermedi cinesincludingavastinmabtherarituxanand xelodaaswellasfortaspoglutidefortypediabetes lrochearenggroupindd corporate sustainability key achievements responsible named healthcare super sector leader dow jones sustainability indexes djsi practices reselected djsi world stoxx indices ftsegood index produced five new position papers stem cells cloning nanotechnology biobanks personalised healthcare value products services launched groupwide phone line webbased system reporting violations code conduct developed new supplier code conduct describe requirements ethics safety health environment innovation supplier diversity economic sustainability social responsibility patients access oneworld health completed first screening roches chemical compound library healthcare find new drugs treat diarrhea joined publicprivate partnership novo nordisk world diabetes foundation improve care children diabetes africa donated million additional tamiflu courses replenish stockpiles launched tamiflu reserves program increase access developing countries provided free treatment patients us rochegenentech access programmes disclosed financial inkind support patient organisations website people global employee listening survey resulted employees expressing job satisfaction roche genentech voted science magazines top employer seventh time rolled globally aligned performance management compensation principles began align genentech roche expanded global leadership programme portfolio providing key programmes every stage leadership development talent pipeline society launched new corporate policy philanthropic donations noncommercial sponsorship launched cancer awareness campaign rural south africa trains nursing staff offers free screening breast cervical prostate cancers raises awareness disease safety health produced manual energy efficient design standards buildings environmental launched elearning programme safety security health environmental protection protection employees launched roche environmental awareness chemical technology react programme reduce environmental impact products learn roches achievements areas see corporate responsibility section report pages lrochearenggroupindd roche business report roche group group strategy roche focus developing medicines diagnostics help patients live longer better lives strive address unmet medical needs excellence science genentech fully integrated roche group research development teams collaborate projects share resources never part integration however also ensured future organisation maintain diversity approaches essential successful innovation lrochearenggroupindd roche business model changing practice medicine focus fitting treatments patients distinctiveness excellence science delivery value stakeholders roche group business webelievethatmedicallydifferentiatedproducts whilethedemandfornewandimprovedtreatments aremorelikelytoobtainregulatoryapprovalandbe keepsgrowingsodoesthepressuretocontrol acceptedbypatientsphysiciansandpayers healthcarecostsinthischangingandchallenging environmentweseektodevelopmedicallydif delivery ferentiatedproductsmedicinesanddiagnostics rocheaimstobenefitallstakeholders offeringsignificantclinicalandhealtheconomic wewanttoimprovethetreatmentoptions benefitsoverexistingoptionstoadvancethisgoal availabletopatientsanddoctorsenablemedical wehaverefinedourbusinessmodelalongthree laboratoriestoworkmoreefficientlyandhelp dimensionsourfocusourdistinctivenessandour societiescontainhealthcarecostsweseekto delivery ensurethatpeoplewhoneedourmedicines anddiagnosticshaveaccesstothemseepages focus oursuccessasacompanyisbuiltonscientific peoplewhoworkatrochehaveachancetomake discoveryandinnovationwefocusonprescription theirmarkandimprovelivesweseektoprovide pharmaceuticalsandin vitrodiagnosticsandhave everyrocheemployeewithopportunitiesto nointentionofbranchingoutintootherhealthcare contributeexcellearnandgrowinroche sectorssuchasgenericsoverthecounter medi andgenentechagainreceivedbestemployer cinesormedicaldevices awardsinanumberofcountries weaimtoprovideourinvestorswithatotal innovationisessentialtoaddressingthemanymedi shareholderreturninthetopquartileofour calneedsthatarestillunmetdespitesignificant industrypeerset progressinthefightagainstsomeofmankindsmost weconductourbusinessesresponsiblyandseek seriousdiseasestherearestillsomediseases tohaveasustainablepositiveimpactonsociety forwhichnotreatmentexistsandpatientsresponse andtheenvironmentinwewereratedasthe ratestomanyavailabletreatmentsareunsatisfactory newsupersectorleaderinhealthcareonthe todaybreakthroughsinscienceandtechnology dowjonessustainabilityindexesrankingusas aretransformingourunderstandingofdiseasebiology theworldsnocompanyforsustainabilityinour andpromisetotransformthepracticeofmedicine sector atrocheweareworkingtoharnessthesediscoveries tomaketomorrowstreatmentssafermoreeffective andmorepersonalisedtobetterfitthemto patientsgeneticprofilesandothercharacteristics lrochearenggroupindd roche business report roche group excellence science distinctiveness roches approach innovation excellence science distinctive four ways wepromotea diversity approaches inourpursuitof innovationgenentechresearchandearlydevelopment gredpharmaresearchandearlydevelopment predrochediagnosticsandchugaioperateinde pendentlywithinthegroupformingthehubsofan innovationnetworkthatincludesallianceswithover outsidecompanies wetakea longterm perspective backedby astablemajorityownershipdatingbackoveryears wekeepoursightsonsustainablelongterm growth ratherthanshortterm gainsthisisreflectedinthecom panysincentivesystemandapproachtosuccession managementandinfarsighted businessmovessuch asourearlyinvestmentsinbiotechnology weseamlessly integrate pharma diag nosticscapabilitiesalongthewholevaluechain fromdiscoverytocommercialisationourworldclass pharmaceuticalsanddiagnosticsresearchorganisations areworkingtogethertocreatebettermorecost effectivetreatmentoptionstailoredtopatientsneeds c oec lh ono glo ygies n flm amet mh ao tid os n n e u r c e n c e e tb ai bo ol lo isg virolo dp gh iaa gr nm oa stics u se tinu rv c ep ir hs na np io goh r n ta la hoslr el gm nyaa le tv bc hede rs u oie n et ui x sc gp ua hine sls itr ntrta hy tin eis sl rd e e nfa id ai edn lli da nmg egn w vo io ehnls le oct eci phc lu l mes tl c h ead e nr ui v tabi acls ni oo po dnrln oo ts aipg n ceh u qra e utv b ie soo nh tionsthisexpertiseequipsrochetoplayapioneering roleinadvancingpersonalisedhealthcare gnnaatns aetunesvt pred gred chugai pharmaceuticals research early development cinical development commercialsaion tsaelgecet io n lgeeande r aio phase phase phase ii phase ii flng pha ar sk ee iv btarogmeta idkeenrt idiecvaetloonpment c peaoatmseinpbtai snietiyo e nac nd idoia n ugtnloisytic tdaxi oaeudn cphrespcorsbtnga uanncdh aosnsieosrsinmgent diagnostics rna inrm ee rd fe ri nn e nbl cic eo eci sns cu ecuebased duna gn dte ech sn io gog ny omuatonssec mes vra resstance neurodegeneratio sn ignalng pathways ango mge yn ee lsi os ap n ncp e alo l ts es b moo mg uy niy glycoengneeing cell boogy dna l sifee nq su mm iec cbnie oc e rn rgcg ae ye n ss cobas r el ai g tih mec pc cl rer mmunom assu acl soi bp al sex potein anx acc lyoc se b ie sl sl ai ng ae ynscise lrochearenggroupindd roche management model enabling innovationdriven culture people integrity courage passion decision making accountable transparent structure built innovation roche group management structure ourmanagementmodelisaimedatsustainingand ourorganisationalstructureisdesignedforinnova strengtheningourcultureofinnovationlikeour tionourautonomousresearchanddevelopment businessmodelithasthreeelementsourpeople centresandallianceswithexternalpartnersfoster ourdecisionmakingandourstructure diversitythetrulyglobalscaleofthegroupsre searchdevelopmentmanufacturingandmarketing people operationsprovidesleverageaswellasaglobal oursuccessindrugresearchanddevelopmentour reachforinnovationandmarketsuccess abilitytodeployourcombinedexpertiseinpharma ceuticalsanddiagnosticstoadvancepersonalised healthcareandourskillinbalancinglongerterm investmentdecisionswithneartermdeliverablesall ultimatelydependononethingourpeoplesee pagesrochesemployeesrepresent everycontinentandvirtuallyeverycountryonthe globeandtheybringtotheirworkadiversityof perspectivesandexperiencesthatareakeyingredi entofcreativityrespectfordiversityasharedset ofstandardsofintegritythecouragetoreachbeyond boundariesandapassionaboutwhatwedoarethe elementsthatbindustogetherasacompany decision making thesecondcomponentofourmanagementmodel dse et cs iso iu ot np sr nin ec ei dpl te os bfo er inef fofe rc mti ev de bd yec ais dio ian lom ga uk ein thg tis systematicfactbasedopenandtransparentfor everydecisionthereshouldbeasingleaccountable decisionmakerwhocollectsandcriticallyreviews informationandcompetingviewsempowermentis crucialsofaraspossibledecisionmakingshould bedelegatedtothelowestqualifiedlevelinthe organisation lrochearenggroupindd bildstreckeengsindd hes paving way new drug rheumatoid arthritis searching safe effective new medicine like looking needle haystack one many thousands potential candidates ever completes journey idea pharmacy shelf know diversity approaches produces prom ising ideas faster roche built unique innovation network independent research development r centres add tion roches pharmaceutical diagnostic r units com prises genentech research early development us chugai r laboratories japan well alliances around partners worldwide one recent products successful collaboration kind actemraroactemra biological medicine new target use patients rheu matoid arthritis discovered chugai codeveloped roche actemraroactemra made available patients world thanks global reach roche group actemraroactemra firstinclass monoclonal antibody treatment rheumatoid arthritis binds interleukin receptor blocks effects signalling protein il key driver inflammation rheumatoid arthritis bildstreckeengsindd pharmaceuticals demand key medicines efficiency gains resulted doubledigit increases sales operating profit thirteen major marketing approvals positive results phase iii clinical trials confirmed divisions growth potential pharmaceuticals division focused translating excellence science effective medicines patients combines cuttingedge research roche genentech us chugai japan partners worldwide global scale reach clinical development manufacturing commercial operations lrochearengpharmaceuticalsindd pharmaceuticals division brief key figures change change millions chf chf local currencies sales sales united states western europe japan international asiapacific cemai latin america canada others operating profit exceptional items operating free cash flow research development cemai central eastern europe middle east africa central asia indian subcontinent pharma executive committee december william burns ceo division roche pharmaceuticals george b abercrombie north america jennifer allerton informatics silvia ayyoubi human resources ian clark global product strategy jeanjacques garaud development peter hug western europe jonathan kc knowles group research dominic p moorhead finance controlling christopher murray commercial operations chugai pascal soriot commercial operations ceo genentech klaus strein pharma research jan van koeveringe global technical operations dan zabrowski pharma partnering december see also corporate governance january ceo genentech clark chief operating ofiicer pharmaceuticals division p soriot extended team ad interim lrochearengpharmaceuticalsindd roche business report pharmaceuticals pharmaceuticals division sales region operational terms wasatransformationalyearforthepharma another ceuticalsdivisionafterobtainingfullownershipof united states good year genentechinmarchrochemovedswiftlyto asiapacific pharmaceuticals combinethetwocompaniesclinicaldevelopment latin america division double manufacturingandcommercialoperationsgenentech regions digit increases sales researchandearlydevelopmentremainsaninde cemai operating profit pendentunitwithintherochegrouppreservingthe integration diversityofscientificapproacheswebelievehelps genentech pro todriveinnovationtheintegrationofgenentechwas western europe ceeded swiftly largelycompletebytheendoftheyear japan largely complete end italics growth rates local currencies inoperationaltermswasanotherverygood year cemai central eastern europe middle east africa yearforthepharmaceuticalsdivisionwithdouble central asia indian subcontinent digitincreasesachievedinbothsalesandoperating profitabovemarketsalesgrowthwasdriven primarilybystrongdemandforkeymedicinesfrom rdpipelineisnowoneoftherichestinthe thegroupsvirologyandoncologyportfoliosthe industrywitheightnewmolecularentitiescurrently globalspreadofthepandemicahn inphaseiiiregistrationinphaseiiandin influenzavirusledtounprecedenteddemandfor phaseiclinicaldevelopment tamiflufromthesecondquarteronrocheiscooper atingwiththeworldhealthorganizationandnational governmentstoaddressthethreatposedbythe results main newinfluenzastrainandhasincreasedproduction business developments capacitytoensureadequatesuppliesoftamiflu inadditiontomarketingauthorisationforthetar salesbythepharmaceuticalsdivisionrosein getedbiologicactemraroactemraforrheumatoid localcurrenciesinswissfrancsandusdollars arthritisintheeuropeanunionandinjanuary tobillionswissfrancsoralmostdoublethe theunitedstatesthedivisionalsogainedapprovals globalpharmaceuticalsmarketgrowthratethe fornewindicationsformarketedproductssuch worldwidespreadofthepandemicahn asavastincancerandmabtherarituxancancer influenzavirusledtoverystrongdemandfortamiflu rheumatoidarthritisprogrammesaimedat fromthesecondquarteronoveralltamiflucon expandingtheuseofkeyproductsorsupporting tributedbillionfrancsorpercentagepoints plannedmarketingapplicationsfornewcompounds tofullyearpharmaceuticalssalesgrowthexcluding resultedinpositivedatafrommajorphaseiii tamifluthedivisionssalesincreaseddriven clinicaltrialssomeoftheseresultshavealreadybeen bydemandforkeyproductsincludingavastin usedtosupportregulatoryfilingsgoodprogress herceptinmabtherarituxanlucentismircera wasmadeintheclinicaldevelopmentofpromising tarcevaactivasetnkaseandactemraroactemra newproductcandidatessuchasocrelizumab rheumatoidarthritismultiplesclerosistdm breastcancerrgmalignantmelanoma pharmaceutical market growth according ims taspoglutidetypediabetesandrg end september schizophreniathecombinedrocheandgenentech unless otherwise stated growth rates local currencies lrochearengpharmaceuticalsindd integration genentech operational restructuring made transformational year pharmaceuticals division yearonyearsalesgrowthinthefourthquarter combinedrocheandgenentechportfolioseebelow washeavilyimpactedbyplannedreductionsin pformoreinformationonthedivisionsoperat wholesalerinventorylevelsinseveralmajormarkets ingresultsseethefinancereportpartofthis theseresultedinpartfromacomprehensivereview annualreport ofdistributionchannelexposureagainsttheback groundoftheglobalfinancialcrisisinaddition thedivisioncontinuedtogenerateastrongcashflow theharmonisationofdistributionsystemsintheus inoperatingfreecashflowincreasedin followingthemergerofgenentechandroche localcurrenciesinswissfrancstobillion pharmaceuticalstriggeredareviewofwholesaler swissfrancsdrivenbythestrongoperatingper inventorypolicyandsubsequentdestocking formancecontinuouscostmanagementandcash flowgenerationarekeyprioritiesatrochethis allregionscontributedtothedivisionsstrongsales isreflectedinongoingglobalinitiativestoincrease growthintheunitedstatesgrowthofkeyoncology operationalefficiencyandproductivityinareas productstamifluandlucentismorethancompen suchasinformationtechnologymanufacturingand satedforlowersalesofcellceptandbonivaandthe administrationfurtherstimulusisnowbeingprovided voluntarywithdrawalofraptivasalesinwestern bythegenentechintegrationwhichinvolveda europeweredrivenbydemandfortamifluavastin majorreorganisationnotonlyofuspharmaceutical mabtheraandmircerawhichmorethanoffset operationsbutalsoofthedivisionsglobalfunctions decliningsalesofneorecormonsalesbychugaiin synergiesarealreadybeinggeneratedasaresult japanincreasedstronglyduetodemandfortamiflu oftheconsolidationinsouthsanfranciscoofadmin keycancermedicinesandactemrasalesinthe istrativefunctionsforthecombinedusorganisation internationalregionasiapacificcemailatin theclosureofthepaloaltositeandthereshapingof americacanadaothersweredrivenbydemand globalmanufacturingoperationsseemanufacturing fortamiflukeycancermedicinesandpegasys infrastructure belowweaimtoachievepretax annualsynergiesofapproximatelybillionswiss inthepharmaceuticalsdivisionsoperating francsby profitbeforeexceptionalitemsadvancedsignificantly fasterthansalesrisinginlocalcurrencies inswissfrancstobillionswissfrancsthisstrong manufacturing infrastructure increasewasdrivenmainlybytheperformanceof ourkeypharmaceuticalproductsandongoingmea thecompanyiswellontrackwiththeintegrationand surestoimproveefficiencytheoperatingprofit optimisationofthecombinedrocheandgenentech marginincreasedpercentagepointsinlocalcur supplynetworkandisreshapingitsglobalmanu renciespercentagepointsinswissfrancsto facturingorganisationtoconcentrateactivitiesalign despiteincreasedinvestmentsfornewproduct capacityrequirementsandimproveefficiencyaspart launchesandinresearchanddevelopmentthe oftherealignmentasecondbulkdrugproduction significantincreaseinrdcostsuptobillion unitatgenentechsvacavilleusafacilitywillnotbe swissfrancsreflectsinvestmentinthedivisions commissionedandanewunitatrochespenzberg stronglatestage pipelineincludingpromisingcom germanyplantwillnotbecompleted poundssuchasdalcetrapibtaspoglutidepertuzumab andtdmtheriseinrdexpenseswasalso thepharmaceuticalsdivisioncurrentlyoperates drivenbyhigherimpairmentsofintangibleassetsat productionsitesworldwidealthoughconsolidation milliontheseweremillionfrancshigherthan indueprimarilytotheterminationofanumber central eastern europe middle east africa central asia ofprojectsfollowingacomprehensivereviewofthe indian subcontinent lrochearengpharmaceuticalsindd roche business report pharmaceuticals collaboration istakingplaceinmanufacturingrochecontinuesto andresearchandtechnologycollaborationsin external partners investinitssupplynetworktoensuredeliveryof additiontenproductoutlicensingagreementswere integral part marketedmedicinesandproductsinclinicaldevelop signedamongthemaintransactionswereasecond roches r strategy mentinmayrocheopenedanadditionallargescale licensingagreementwithplexxikonannounced roche multipurposechemicalproductionunitinflorence injanuaryforplxrganovelkinase genentech signed new southcarolinausaanewproductioncentre inhibitorforpolycystickidneydiseaseandafurther partnering agree inkaiseraugstswitzerlandforthemanufactureof agreementwithevotecannouncedinmarchfor ments medicinesinsterileformsincludingliquidand phaseiidevelopmentofevtfortreatment including product lyophilisedvialsandprefilledsyringeswasinaugu resistantdepressionrocheenteredintoaproduct transactions ratedinjuneinaugustrocheexercisedanoption developmentagreementwithtekmirapharmaceuticals research technol previouslyheldbygenentechtopurchaseabiologic inmaytoadvancerochesfirsttwornainterfer ogy collaborations manufacturingfacilitybuiltbylonzainsingapore enceproductcandidatesintohumanclinicaltesting thestateoftheartfacilitywhichismechanically bothproductcandidateswillbebasedontekmiras completehasbeenmergedwithanexistingbiologic stablenucleicacidlipid particlesnalptechnol manufacturingfacilitybuiltbygenentechthecom ogy binedsingaporeoperationsrochesfirstsuch facilitiesinasiawillplayakeyroleinthegroups genentechpartneringcompletedfourproducttrans globalmanufacturingnetworkinnovemberthe actionsoneoutlicensingdealandresearch toppingout ceremonyforanewtechnicalresearch andtechnologycollaborationsduringtheyearthese anddevelopmentbuildinginbaselswitzerland includeanagreementsignedinjunewithbayhill tookplacethenewfacilityscheduledforcompletion therapeuticsforanexclusivecollaborationforbayhills inwillhouseacentreforthedevelopmentof promisingdrugcandidatebhtcurrentlyin productionmethodsandthemanufactureofclinical phaseidevelopmentfortypediabetesinoctober trialssamples genentechsignedanagreementwithsurmodics grantinggenentechanexclusivelicencetouse inresponsetotheworldwidespreadofthepandemic surmodicsproprietarybiodegradablemicroparticles ahninfluenzavirusourmanufacturingorgani drugdeliverysystemtodevelopandcommercialise sationandsupplychainmanagementalsometthe asustaineddrugdeliveryformulationoflucentisthe challengeofensuringadequatetamiflusuppliesto agreementalsoprovidesrocheandgenentech patientsworldwiderocheanditsmanufacturing withopportunitiestodevelopadditionalcompounds partnersrapidlyincreasedproductioncapacityfor forthetreatmentofophthalmicdiseases tamiflutoapproximatelymilliontreatmentcourses permonthandarenowabletosupplyuptomil lionpacksannuallyifrequired sales review selected key products pharma partnering update thepharmaceuticalsdivisionssalesgrowthis collaborationwithexternalpartnersisanintegralpart broadlybasedinelevenproductsfromsix ofrochesrdstrategyaccesstoexternalinno therapeuticareasgeneratedsalesofoverbillion vationthroughlicensingandtargetedacquisitionsis swissfrancseachofthesemedicinesthetop asignificantmeansofstrengtheningtherdportfolio threeachievedsalesofoverbillionswissfrancs andexpandingthegroupstechnologycapabilities eachcombinedsalesofthegroupstoppharma inrochepharmaceuticalssignedatotalof ceuticalsamountedtobillionswissfrancsor newagreementsincludingfourproducttransactions oftotaldivisionalsales lrochearengpharmaceuticalsindd eleven products six therapeutic areas generated sales billion francs sales therapeutic area oncology inflammatory autoimmune diseases transplantation central nervous system respiratory metabolic diseases bone diseases infectious diseases cardiovascular diseases virology others renal anemia ophthalmology italics growth rates local currencies salesofthedivisionsoncologyportfoliorose canceruptakeinjapanwhereavastiniscurrently sales divisions tobillionswissfrancsinledbythekey marketedforadvancedcolorectalcancerremains oncology portfolio productsavastinherceptinmabtherarituxan particularlystrongandisexpectedtobeenhanced rose billion swiss francs tarcevaandxelodatogetherthesefivemedicines bytheproductsrecentapprovalforadvancednon led avastin accountedforaroundhalfoftotalpharmaceutical smallcelllungcancersalesgrowthintheunited herceptin mabthera salesanincreaseofbillionswissfrancs statesisbeingdrivenmainlybyuseinadvanced rituxan tarceva insalesofantiviralmedicinesforafullyeartotalof breastcancerandthenewindicationsglioblastoma xeloda together billionfrancswasdrivenprimarilybydemand andkidneycancerwhilehighpenetrationrates five medicines fortamifluoverallsalesoftherenalanemiaportfolio weremaintainedinestablishedindicationssuchas accounted around half total pharma remainedstableatbillionswissfrancsinan lungandcolorectalcancer ceutical sales increasinglycompetitivecostsensitivemarketsales inthecombinedinflammationautoimmunetransplan overallsalesoncologyandrheumatoidarthritisof tationportfoliodeclinedtobillionfrancswith mabtherarituxanrituximabfornonhodgkins theexpectednegativeimpactofthecellceptpatent lymphomanhlchroniclymphocyticleukemia expiryintheunitedstateslargelyoffsetbythe cllandrheumatoidarthritisraroseto continuedsuccessofmabtherarituxaninrheuma billionswissfrancssustainedgrowthinthe toidarthritisaswellasstronguptakeofactemra oncologysegmentwasdrivenbyuptakeincll roactemrainjapananditsinitiallaunchmarketsin followingapprovalintheeuforfirstline treatment westerneuropeandelsewhere andintherelapsedrefractorydiseasesettinginthe firstandthirdquartersrespectivelylowersales oncology growthintheusreflectsthehighlevelsofadoption salesofavastinbevacizumabforadvanced ofrituxaninitscancerindicationssalesinthera colorectalbreastlungandkidneycancerandfor segmentwereanestimatedmillionswissfrancs relapsedglioblastomaatypeofbraintumourrose oroftheproductstotalsalesgrowthinthis tobillionswissfrancssoliddoubledigit segmentisbeingdrivenbyincreasingandearlieruse growthwasrecordedinallregionsdrivenprimarily bycontinueduptakeincolorectalbreastandlung firstline treatment initial treatment given diagnosis lrochearengpharmaceuticalsindd roche business report pharmaceuticals excellence science unique diversity approaches partners understanding complex biology disease biggest challenge face developing new better medicines diagnostics scientific breakthroughs likely occur scientists free tackle problems different angles different ways scientists freedom believe diversity views cultures approaches promotes creativity especially research early development autonomous research development hubs augmented alliances provide natural climate innovation pred gred chugai gred pred genentechresearchand rochepharmaresearchand earlydevelopment earlydevelopment nmes phase ii oncology followingtheintegrationofgenentechpredandgredoperate asautonomousinnovationcentresfocusingonnewdrug targetsandnewmolecularentitiesnmestheyhavetheirown inflammation immunology budgetsandexternalnetworksandtakedifferentapproaches toturningexcellentscienceintoadvancesinmedicalcarethisnew central nervous system organisationalstructurepreservesthevaluesandculturethat enabledthegenentechsuccessstorywhileatthesametime strengtheningrochepharmasabilitytodevelopnovelmedicines ophthalmology italsomakesiteasierforourpharmaceuticalsanddiagnostics researcherstoshareknowledgeandtechnologiesacrossdivisional virology boundaries metaboliccardiovascular lrochearengpharmaceuticalsindd ofmabtherarituxaninpatientswithaninadequate virology roche cooperating responsetooneormoretumournecrosisfactor globalsalesoftheantiinfluenza medicinetamiflu closely world tnfinhibitorsmabtheraiswellestablishedasthe oseltamiviramountedtobillionswissfrancsin health organization governments medicineofchoicefollowinginadequateresponse anincreaseoforbillionswissfrancs worldwide support totnfinhibitortreatmentandiscurrentlythemarket comparedwiththisveryhighgrowthwas pandemic prepared leaderinthatsegmentintheeu drivenbyunprecedenteddemandfromgovernments ness supply andintheretailpharmacysectorfollowingthepan tamiflu patients salesofherceptintrastuzumabforherpositive demicahninfluenzavirusswineflu need breastcancerincreasedtobillionswiss outbreakwhichbeganinaprilandspreadrapidly francssolidgrowththroughouttheyearwasdriven worldwidesalesforpandemicstockpilingamounted bycontinuinguptakeforearlybreastcancerespe tobillionfrancsforthefullyear ciallyinjapanandanumberofemergingmarkets aswellasincreasingmarketpenetrationineastern rocheisworkingwithnationalhealthauthoritiesto europemoderatesalesgrowthintheusand expandapprovalforpandemicuseoftamifluto westerneuropereflectsthehighmarketpenetration includechildrenunderoneyearofageaswellas achievedinbothearlyandadvancedbreastcancer pregnantandlactatingwomenandtogainregulatory intheseregions approvalforalternativemethodsofadministeringthe medicinetoinfantsandyoungchildrenthecompany salesoftarceva erlotinibforadvancedlungand alsocontinuestocooperatecloselywiththeworld pancreaticcancerincreasedtobillionswiss healthorganizationandgovernmentsworldwideto francsdemandisbeingdrivenbyincreaseduse supportpandemicpreparednessandsupplytamifluto ofthemedicineinsecondlinenonsmall celllung allpatientsinneed cancernsclcoutsidetheusandinmetastatic pancreaticcancerthemainsalescontributionscame salesofpegasyspeginterferonalfaa forhepatitis fromwesterneuropeandtheunitedstatesthemore bandctotalledbillionswissfrancsin modestgrowthinussalesreflectsstablepenetration anincreaseofoverthepreviousyeardrivenby innsclcandpancreaticcancerthecompetitive marketshare gainsinmajormarketsgrowthis environmentandreserveadjustmentstakenduring beinghelpedbynewstudydatademonstratingthe theyearprimarilyforgovernmentprogrammes superiorityofpegasysoverothertreatmentoptions involvingdiscounts increaseduseinthetreatmentofhepatitisband increasingratesofhepatitisdiagnosisandtreatment salesofxelodacapecitabineforcolorectal inemergingmarkets stomachandbreastcancerincreasedtobillion francsdrivenprimarilybystronggainsintheunited ophthalmology statesjapanandchinagrowthisbeingdriven ussalesoflucentisranibizumabforwetage byuseinmetastaticbreastcanceradjuvantcolon relatedmaculardegenerationamdthemost cancerandmetastaticcolorectalcancerinchina commonformofagerelated blindnessroseto themajorityofgrowthiscomingfromuseinpatients billionswissfrancsstrongdoubledigit growth withadvancedstomachcancerwhileinjapanchugai throughoutwasdrivenprimarilybyanincrease recordedsignificantadditionalgrowthinthefourth inthenumberofinjectionsadministeredtopatients quarterfollowingapprovalofanexpandedmetastatic colorectalcancerindication secondline treatment given initial firstline treatment work cancer stops responding adjuvant treatment given surgical removal tumour lower risk relapse lrochearengpharmaceuticalsindd roche business report pharmaceuticals topselling pharmaceuticals roche group millions chf avastin mabtherarituxan herceptin tamiflu pegasys active substance active substance active substance active substance active substance bevacizumab rituximab trastuzumab oseltamivir peginterferon alfaa indications indications indications indications indication colorectal cancer breast nonhodgkins lymphoma herpositive breast treatment prevention hepatitis b c cancer nonsmall cell chronic lymphocytic cancer influenza b lung cancer kidney leukemia rheumatoid cancer glioblastoma arthritis lrochearengpharmaceuticalsindd abovemarket sales growth driven primarily strong demand key virology oncology medicines cellcept neorecormon epogin tarceva xeloda lucentis active substance active substance active substance active substance active substance mycophenolate mofetil epoetin beta erlotinib capecitabine ranibizumab indications indication indications indication indications transplantation anemia advanced nonsmall cell colorectal cancer breast wet agerelated macular lung cancer advanced cancer stomach cancer degeneration pancreatic cancer images scale yearonyear sales growth local currencies jointly marketed genentech novartis lrochearengpharmaceuticalsindd roche business report pharmaceuticals may fda inthefirstandsecondyearoftreatmentgrowthinthe transplantation granted accelerated numberofpatientstreatedforwetamdandeasier salesofcellceptmycophenolatemofetilforthe approval reimbursement preventionofsolidorgantransplantrejection use avastin decreasedcomparedwithtobillion relapsed glioblas anemia swissfrancssalesintheustheproductslargest toma aggressive form inahighlycompetitivepricesensitive marketsales marketdeclinedsharplyfrommayonwardsfollowing brain tumour oftherenalanemiamedicationmirceramethoxy expiryoftheuspatentthecontinuingerosionof january polyethyleneglycolepoetinbetawhichisnow ussalesthroughgenericcompetitionisbeingoffset agency approved availableinovermarketsworldwideshowed tosomeextentbysolidgrowthelsewhereespecially actemra treat consistentgrowththroughoutrisingto inlatinamericaandjapan ment adult patients millionswissfrancssalesarebeingdriven rheumatoid primarilybythesuccessoftheproductinthepre others arthritis responded tnf dialysissegmentcombinedsalesofthegroups atthebeginningofaprilrocheandgenentech inhibitor therapy establishedanemiamedicinesrochesneorecormon announcedaphasedvoluntarywithdrawalofthe andchugaisepoginepoetinbetadeclinedto psoriasismedicineraptivaefalizumabfromthe billionswissfrancsoutsidejapanthecombined usmarketthedecisionreflectsourcommitment marketshareofrochesanemiafranchisemircera topatientsafetyandwasbasedontheassociation andneorecormoncontinuestoincreasedespite ofraptivawithanincreasedriskofprogressive competitionfromnewmarketentrantsthedecline multifocalleukoencephalopathypmlarareand inneorecormonsalesofwasduemainlyto usuallyfataldiseaseofthecentralnervoussystem increasedpricepressureasnewbiosimilarsenterthe aspartofthemeasuresagreedbetweentheus marketincontrasttheslightdeclineofepoginin foodanddrugadministrationfdaandgenentech japanreflectsstabilisationoftheproducts theraptivamarketinglicencewasrevokedinjuly marketshareinthedialysissegmentandcontinued genentechcontinuestomonitorpatientsafety expansioninthepredialysissetting inflammation autoimmune disorders development highlights followingeumarketingapprovalinjanuaryby key marketed products yearendthenovelrheumatoidarthritisramedicine roactemratocilizumabknownasactemraoutside europehadbeenlaunchedinteneucountries inthepharmaceuticalsdivisionfiledmajor includinggermanyfrancespainandtheunited newmarketingapplicationsandgainedmajor kingdomsalesuptakeintheinitialeuropeanlaunch regulatoryapprovalsseetableppositiveresults marketshasbeenstrongfollowinglaunchesin frommajorphaseiiiclinicaltrialsinvestigating additionalmarketsincludingswitzerlandindiaand additionalindicationsforexistingkeyproductsorwith brazilactemraroactemraisnowavailableinover newproductssuchastaspoglutideandocrelizumab countriesworldwidetheresponsefromphysicians werealsoreportedseetablepthefollowing isveryencouragingglobalsalesroseto summariespresentapprovalsfilingsandmajor millionswissfrancsininjapanwhereactemra clinicaltrialresultsforkeymarketedproductsby wasapprovedforrainadultsandforrelatedpedi indication atricindicationsinapriladoptionandmarket penetrationareprogressingwellwithdoctorsalready actemraroactemra usingthemedicineasafirstlinebiologictreatmentin approvals injanuarytheusfoodand manypatientssalesinjapanamountedtomillion drugadministrationfdaapprovedactemrafor swissfrancsanincreaseof thetreatmentofadultpatientswithmoderatelyto lrochearengpharmaceuticalsindd division filed major marketing applications gained major approvals major regulatory filings product active substance indication andor dosage form country avastin bevacizumab relapsed glioblastoma multiforme switzerland firstline metastatic breast cancer combination eu usa japan standard chemotherapy switzerland ed eldecalcitol osteoporosis japan epogin epoetin beta chemotherapyinduced anemia japan herceptin trastuzumab advanced herpositive gastric cancer eu switzerland lucentis ranibizumab macular edema following retinal vein occlusion usa mabthera rituximab rheumatoid arthritis patients inadequate eu switzerland rituxan response diseasemodifying antirheumatic drug prevention joint damage firstline chronic lymphocytic leukemia usa relapsed refractory chronic lymphocytic leukemia eu usa switzerland rg methoxy renal anemia japan mircera poly ethylene glycolepoetin beta tarceva erlotinib nonsmall cell lung cancer firstline maintenance eu usa switzerland chemotherapy advanced pancreatic cancer japan xeloda capecitabine adjuvant colon cancer combination oxaliplatin eu switzerland major regulatory approvals product active substance indication andor dosage form country avastin bevacizumab relapsed glioblastoma multiforme usa switzerland metastatic breast cancer combination docetaxel eu switzerland firstline metastatic renal cell carcinoma combination usa interferon alfaa unresectable advanced recurrent nonsquamous japan nonsmall cell lung cancer mabthera rituximab relapsed refractory chronic lymphocytic leukemia eu switzerland rituxan firstline chronic lymphocytic leukemia eu rheumatoid arthritis guidance retreatment patients usa inadequate response antitnf therapy actemra tocilizumab rheumatoid arthritis signs symptoms eu usa roactemra xeloda capecitabine advanced refractory colorectal cancer combination japan oxaliplatin without avastin includes supplemental indications updated january third indication use patients previously treated methotrexate longer pursued see p accelerated approval fda lrochearengpharmaceuticalsindd roche business report pharmaceuticals excellence science taking longterm view biotech milestones sales biotech medicines sales estimatedsales biotechmedicinesorbiologics todayaccountforof rochespharmaceuticalsales apercentagethathasrisen significantlyinrecentyears biologicsnormallyhaveamore targetedeffectandarebetter toleratedthanconventional chemicalmedicines rochefounds researchon rocheand recombinant roferona rocheacquires mabthera neorecormon avastin actemra institutefor monoclonal genentechs insulin rituxan herceptin roactemra molecular antibody firstjoint genentech biology production project discovering developing commercialising new medicines takes time vision stay leading edge innovation essential invest early promising new technologies one first pharmaceutical companies embrace biotechnology led acquiring majority stake genentech today biotech products helping improve lives countless patients variety disease areas number one maker biologics also invested polymerase chain reaction pcr technology still infancy decision helped us become global market leader molecular diagnostics one technologies investing today rna interference rnai offers way target turn specific genes rnaibased medicines could prove ground breaking new approach fighting disease helping patients lrochearengpharmaceuticalsindd avastin tested studies different tumour types positive outcomes achieved major phase iii trials disease area product indication study oncology mabtherarituxan indolent nonhodgkins lymphoma prima firstline maintenance treatment avastin secondline metastatic breast cancer ribbon xeloda adjuvant treatment colon cancer xeloxa herceptin herpositive stomach cancer toga tarceva nonsmall cell lung cancer firstline maintenance treatment saturn overall survival data tarceva avastin nonsmall cell lung cancer firstline maintenance treatment atlas inflammation actemra rheumatoid arthritis progression joint damage lithe year data actemra juvenile idiopathic arthritis systemic onset tender ocrelizumab rheumatoid arthritis patients inadequate response stage previous treatment methotrexate ophthal lucentis macular edema following central retinal vein occlusion cruise mology lucentis macular edema following branch retinal vein occlusion bravo metabolism taspoglutide type diabetes temerge severelyactiverheumatoidarthritisrawhohave regulatoryfilingsinthisindicationsjiaadebilitating hadaninadequateresponsetooneormoretumour anddifficulttotreat diseasethataffectsthewhole necrosisfactortnfinhibitorsactemrathefirst bodyrepresentsanareaofhighunmetmedicalneed interleukin receptorinhibiting monoclonalanti bodyapprovedtotreatramaybeusedaloneorin avastin combinationwithmethotrexateorotherdisease theglobaldevelopmentprogrammeforavastinisone modifyingantirheumaticdrugs ofthemostcomprehensiveundertakingsincancer researchsincechemotherapymorethanclinical filings inseptemberrochefiledanapplication trialsworldwidewitharoundpatientsare withtheeuseuropeanmedicinesagencyemea currentlyinvestigatingtheuseofavastininapproxi toexpandthemarketingauthorisationforroactemra matelydifferenttumourtypesincludingcolorectal toincludeinhibitionoftheprogressionofjointdamage breastnonsmallcelllungbrainstomachovarian andimprovementofphysicalfunctioninpatients prostateandothersandindifferentsettings withratheeufilingissupportedbypositivetwo advancedorearlystagediseaseresultsfrom yeardatafromthephaseiiilithetrial phaseiiitrialsinvestigatingthemedicinespotential inpatientswithmetastaticprostateovarianand clinical milestones aninternationalphaseiii stomachcancerareexpectedin studytendermetitsprimaryendpointinnovem bershowingthatactemraroactemrasignificantly approvals inmaythefdaapprovedtheuseof improveddiseasesignsandsymptomsinchildren avastininpatientswithpreviouslytreatedrelapsed withsystemiconsetjuvenileidiopathicarthritissjia glioblastomamultiformegbmthemostaggressive andconfirmingtheresultsofearlierjapanese formofbraintumourundertheagencysaccelerated studiesrocheplanstousethedatatosupportglobal approvalprogrammetheeuscommitteefor lrochearengpharmaceuticalsindd roche business report pharmaceuticals following eu medicinalproductsforhumanusechmpissueda suggestthatavastinisactiveinpatientswithearly marketing application negativeopinioninseptemberregardingroches stagecoloncancerfurthertrialsinvestigatingavastin roche sep applicationforapprovalofthesameindicationthe intheadjuvantsettingearlystage diseaseafter tember chmp usandeufilingswerebasedonstrongclinical surgerytoremovethetumourincolonbreastand issued positive resultsfromthephaseiibrainstudyseveral lungcancerareongoingresultsareexpectedin recommendation december investigatorled studiescontinuetoexploretherole fromaseparaterochesponsoredinternational use herceptin ofavastininrelapsedgbminadditionalarge phaseiiistudyavantassessingavastinincom advanced rochesponsoredphaseiiistudyavaglioinover binationwithchemotherapyforearlystage colon positive stomach patientswithnewlydiagnosedgbmiscurrently cancerinoctoberpatientrecruitmentwascompleted cancer filing underwaywiththeaimofglobalfilings forbeatriceaphaseiiitrialinvestigatingavastin based strong inearlyhernegativeandhormonereceptor phase iii data show rochereceivedeuapprovalinjulyforavastinin negativebreastcancer ing herceptin extend survival combinationwithdocetaxelacommonlyusedchemo patients therapyinthefirstline treatmentofmetastatic fullresultsofribbonaphaseiiitrialofavastin operable breastcancertheexpandedindicationfollowseu assecondline treatmentinwomenwithadvanced positive stomach approvalforcombinedavastinandpaclitaxelin hernegativebreastcancerwhohadpreviously cancer inadditioninaugustthefdaapprovedavastinin receivedchemotherapywerepresentedatthesan combinationwithinterferonalfaa forthetreatment antoniobreastcancersymposiumindecemberthe ofmetastaticrenalcellcarcinomathemostcommon studymetitsprimaryendpointshowingthatwomen typeofkidneycancerthisfollowseuapprovalof whoreceivedavastinincombinationwithcommonly thesameindicationin usedchemotherapiesassecondline treatmenthad aimprovementinprogressionfree survival innovemberchugaireceivedapprovalinjapanfor comparedwithchemotherapyalonegenentechand avastinforthetreatmentofadvancednonsmallcell rocheplantofiletheribbondataintheus lungcancer andtheeuin filings chugaifiledasupplementaryapplication herceptin inoctobertoexpandtheapprovedindicationsfor filings followinganeumarketingapplicationby avastininjapantoincludemetastaticbreastcancer rocheinseptemberthechmpissuedapositive basedontheresultsoftheeavadoand recommendationindecemberfortheuseofherceptin ribbon trialsandjapanesestudiesinnovember inadvancedmetastaticherpositivestomach genentechfiledtheavadoandribbon datawith cancerthisrecommendationwasissuedinrecord thefdawiththeaimofconvertingthecurrent timereflectingthehighunmetmedicalneedandthe acceleratedapprovalforhernegative breastcancer strengthofthedatafromtogaseebelow receivedintofullapprovalandallowing avastintobecombinedwithfurtherstandard clinical milestones resultsfromtheinternational chemotherapiesinnovemberrochealsofiledthe phaseiiitogatrialpresentedattheascomeetingin ribbon datawiththeeuauthorities juneshowedthatcombiningherceptinwithstandard chemotherapyxelodaorintravenousfluorouracil clinical milestones fullresultsofthefirstphaseiii pluscisplatinextendsthelivesofpatientswith trialofavastininearlystagecoloncancernsabp cwerepresentedattheannualmeetingofthe americansocietyofclinicaloncologyascoin may june mayalthoughthestudydidnotmeetitsprimary progressionfree survival time patients live without endpointofimprovingdiseasefreesurvivalthedata disease getting worse lrochearengpharmaceuticalsindd fiveyear followup data confirmed long term benefits one year adjuvant herceptin treatment herpositive breast cancer advancedinoperableherpositive stomachcancer mabtherarituxan oncology onaveragebynearlythreemonthstomonths approvals rochereceivedeuapprovalinfebruary patientswithtumoursexhibitinghighlevelsofher formabtheraincombinationwithchemotherapyfor experiencedevengreaterbenefitfromtheaddition previouslyuntreatedchroniclymphocyticleukemia ofherceptintheirliveswereextendedbymorethan cllandinaugustforuseinpatientswithrelapsed fourmonthstomonthsonaverage orrefractorydiseasecllisthemostcommonform ofadultleukemiainnovembertheusfoodand inoctoberrocheandhalozymeannouncedthe drugadministrationfdaissuedacomplete startofaphaseiiitrialinvestigatinginfusionfree responsetotwosupplementalbiologicslicense subcutaneousadministrationofherceptinfor applicationssubmittedbygenentechandbiogen womenwithherpositive breastcancerthenew idecforapprovalofrituxanplusstandardchemo subcutaneousformulationisbasedonhalozymes therapyinpreviouslyuntreatedortreatedcllthe enhanzetechnology fdahasnotrequestedanynewdatatocomplete itsreviewoftheseapplicationsthecompanieswill fiveyear followupdata fromtwolargestudies continuefinallabeldiscussionswiththeagencyand evaluatingadjuvantherceptininherpositive early remaincommittedtomakingrituxanincombination stagebreastcancerwerepresentedatthesan withchemotherapyanfdaapproved optionforpeople antoniobreastcancersymposiumindecembercon withcll firmingthelongterm benefitsofoneyearoftreatment withherceptinnandbcirgconducted clinical milestones inseptemberrochegenentech bythenorthcentralcancertreatmentgroupand andbiogenidecannouncedpositiveresultsfroman thebreastcancerinternationalresearchgroup internationalphaseiiistudyprimashowingthat respectively showedthatherceptinreducedtherisk mabtherarituxanmaintenancetherapycansignifi ofthecancerreturningbyaboutonethirdcompared cantlyincreasethetimeuntilthediseaseprogresses withpatientsreceivingchemotherapyaloneinboth innewlytreatedpatientswithadvancedfollicular studiesormoreofwomenreceivingoneyear lymphomaacommontypeofnonhodgkins lym ofherceptinwerealiveandfreeofthediseaseatfive phomabecauseprimametitsendpointduringa yearsfollowup preplanned interimanalysisthestudywasstopped earlyrocheandgenentechplantofiledatafrom lucentis primawiththeeuandushealthauthoritiesto filings basedontheresultsofbravoandcruise expandthecurrentmarketingapproval seebelowindecembergenentechfiledasupple mentaryapplicationwiththefdaforapprovalofuse updatedresultsfromthephaseiiicllstudywere inpatientswithmacularedemafollowingretinalvein presentedattheannualmeetingoftheamerican occlusion societyofhematologyindecembertheyshowed thatpatientswithpreviouslyuntreatedcllsurvived clinical milestones resultsofthephaseiiibravo theirdiseaselongerwhentreatedwithmabthera andcruisestudiesannouncedinjulyshowedthat rituxancomparedwithchemotherapyalonecllis lucentisimprovedvisioninpatientswithswellingin thefirsttrialtodemonstrateimprovedoverallsurvival theretinamacularedemaduetobranchretinalvein withaspecificfirstline treatmentforcll andcentralretinalveinocclusionrvorespectively rvooccurswhenbloodflowthrougharetinalvein mabtherarituxan rheumatoid arthritis becomesblockedcausingswellingmacularedema approvals inoctoberthefdaapprovedupdated andhemorrhagesintheretinawhichmayresultin rituxanprescribinginformationthatincludesguidance blurringorvisionlossinallorpartofoneeye onretreatmentoflaterstage rheumatoidarthritis lrochearengpharmaceuticalsindd roche business report pharmaceuticals rapatientswithaninadequateresponsetoanti thefdasoncologicdrugsadvisorycommittee tumournecrosisfactortherapiesclinicaltrialdataon recommendedagainstapprovingtarcevaforthisuse themedicinesabilitytoimprovephysicalfunction theagencyisnotboundbythisrecommendation andslowjointdamageforuptotwoyearswerealso injanuaryfollowingthesubmissionbyosioffurther addedatthesametimegenentechreceivedacom datathefdaextendedthereviewperiodforthe pleteresponsefromthefdafortheuseofrituxan applicationandisnowexpectedtomakeadecision plusmethotrexateinpatientswithmoderatelyto byaprilinseptemberchugaifiledasupple severelyactiverawhonolongerrespondtotreat mentarymarketingapplicationinjapanforapproval mentwithadiseasemodifyingantirheumaticdrug oftarcevainpancreaticcancer includingmethotrexategenentechisworkingwith thefdatodeterminenextstepsregardingthefiling clinical milestones resultsfromaphaseiiistudy forthisindication atlasreleasedinfebruaryshowedthattarceva incombinationwithavastinforfirstlinemaintenance filings injunerochesubmittedacombined treatmentofpatientswithadvancednsclcsignifi filingtotheeuhealthauthoritiestoextendthemar cantlydelayedthetimetodiseaseprogressioninjuly ketingapprovalformabtheraasafirstline biologic rochegenentechandosiannouncedthatthe therapyforrheumatoidarthritisrathenewindi saturntrialhadmetanimportantsecondaryend cationsbeingsoughtareforpatientswhohavehad pointofextendingoverallsurvivalinpatientswith aninadequateresponsetomethotrexatethecurrent advancednsclcwhoreceivedtarcevaimmediately standardtreatmentoptionandfortheprevention afterinitialchemotherapythisbuildsonearlier ofjointdamageacrossallrapatientpopulationsthe resultsfromsaturnshowingthattarcevaimproved combinedfilingfollowedpositiveresultsfromthe progressionfree survivalthetrialsprimaryendpoint imagesereneandmirrortrialswhichshowed thatmabtheraimprovesthesignsandsymptoms xeloda ofraandcansignificantlyreducetheprogression approvals inseptemberchugaireceivedapproval ofjointdamagerocheisnolongerpursuingapproval injapanforadditionalindicationsforxelodaand forathirdindicationoriginallyincludedinthecom avastinxelodacannowbeusedincombinationwith binedfilingforuseinpatientswhohavenothad oxaliplatinchemotherapywithorwithoutavastin previoustreatmentwithmethotrexatebasedona inthetreatmentofpatientswithmetastaticcolorectal reassessmentoftheriskbenefit ratiointhispatient cancer population filings rochefiledanapplicationintheeuin tarceva decemberforapprovalofxelodaincombinationwith approvals inseptemberthechinesehealthauthor oxaliplatinfortheadjuvantpostsurgicaltreatment itiesapprovedtarcevaforthesecondline treatment ofpatientswithearlycoloncancerbasedon ofpatientswithadvancednonsmallcelllungcancer datafromthephaseiiinoxeloxatrial nsclc filings inmarchrocheandosipharmaceuticals research development submittedapplicationstotheemeaandthefda respectivelyforapprovaloftarcevaasmaintenance toensureastrongflowofsuitablecandidatemolecules therapyinpatientswithlocallyadvancedormetastatic intoitsdevelopmentpipelinerochehasbuilta nsclcwhosediseasehasnotprogressedfollowing uniqueinnovationnetworkofindependentresearch firstline chemotherapybothfilingswerebasedon anddevelopmentcentresinadditiontorocheand datafromthephaseiiisaturntrialindecember genentechitincludeschugaiinjapanandalliances lrochearengpharmaceuticalsindd roche genentech chugai partners worldwide form unique innovation network based diversity approaches withmorethanpartnerorganisationsworldwide areabouttostartphaseiiidevelopmentatthe rg targeted thispromotesadiversityofresearchapproaches sametimewearealsoexploringnewindicationsand inhibitor abnormal aswellasenablingaccesstonewtechnologiesand formulationsforexistingproductsincludingformu braf exemplifies roche groups promisingdrugcandidates lationsofherceptinseeabovepandother personalised health biologicmedicinesthatcanbeadministeredbymore care approach genentechresearchandearlydevelopmentgred convenientsubcutaneousinjectioninsteadofintra currently latestage continuestooperateasanindependentunitsimilarly venousinfusion clinical development thenewlyformedpharmaresearchandearlydevel malignant opmentorganisationpredenjoysfulloperational followingtheintegrationofgenentechsrd melanoma roche developing autonomygredcontinuestobeinspiredbythe projectsintothegroupsglobalpharmaceuticals dia g nostic test valuesandculturethatledtogenentechssuccess portfoliorocheandgenentechconducteda identify patients whilepredwillexpandrochescapabilitiesto comprehensivereviewoftherdpipelineinthe whose tumours bringnovelmedicinestopatientsatthesametime fourthquarterthisresultedindecisionstoterminate carry abnormal subjecttoexistingthirdparty obligationsbothunits anumberofearlystage developmentprojects braf gene arenowfreetoshareinformationandtechnologies omeofwhichhaverevertedtopartnercompanies thatcansupportandenhancetheiractivities theterminationswhichwereprimarilydrivenby clinicaldataarepartofanongoingefforttoprioritise closecooperationbetweenthepharmaceuticals resourcestowardsahighlydifferentiateddevelopment divisionandrochediagnosticsisakeystrategic portfoliooffirstinclass orbestinclass medicines advantageforourcompanythetwodivisionscan shareintellectualpropertytechnologiesandresearch atthebeginningofthedivisionsrdpipeline findingsfreelyamongotherthingsthisallowsroche includedprojectsinclinicaldevelopmentphasei tocombineandleveragebothdivisionsleadership toiiioftheseinvolvednewmolecularentities inthekeyfieldofmolecularbiologyinadditionit nmesandinvolvedadditionalindicationsten enablesdiagnosticsexpertisetobeseamlesslyinte nmesareinorabouttoenterlatestage develop gratedintoallpartsofthepharmaceuticalsrd mentseetablepthirtyprojectsinvestigating processseepthisiscentraltorochesgoalof additionalindicationsforexistingproductsarein advancingpersonalisedhealthcareanapproach phaseiiithepharmaceuticalspipelineisshownin thatseekstotailortreatmentstospecificpatientsub thefoldoutinsidethefrontofcoverofthisreport populationsbasedonemergingscientificunder furtherdetailsareavailableatwwwrochecom standingofbiologyanddiseaseatthemolecularlevel oncology overthenextfewyearsthedivisionaimstoexpand rochesclinicaldevelopmentpipelineinoncology itsproductportfoliowithanewgenerationof includesnewmolecularentitiesthepharma medicinesforpatientssufferingfromcancermeta ceuticalsdivisionisfurtherstrengtheningitsoncology bolicandautoimmunediseasesviralinfections portfoliothroughnewtargetedtherapeuticoptions anddisordersofthecentralnervoussystemcns andexpandingintonewindicationsfourcompounds latestagedevelopmentofpromisinganticancer progressedintolatestageclinicaltestingin compoundssuchaspertuzumabandtdm herpositivebreastcancerrgmalignant rgplxcollaborationwithplexxikonisa melanomaandrgleukemialymphomaison targetedinhibitorofabnormalbrafthatexemplifies trackinadditiontwonovelcompoundsinthe therochegroupspersonalisedhealthcareapproach metabolicandcnsportfoliosaleglitazarcardio usingbiomarkersanddiagnostictoolsbrafisa vasculardiseaseinhighrisk typediabetespatients proteinthatrelaysgrowthsignalsinsidecellsincer andrgnegativesymptomsofschizophrenia taintypesofcancergeneticchangesmutations lrochearengpharmaceuticalsindd roche business report pharmaceuticals excellence science seamless collaboration process leading healthcare company strengths pharmaceuticals diagnostics well equipped advance personalised healthcare organisational realignment imple mented pharmaceuticals diagnostics divisions last several years enables collaborate seamlessly along whole value chain discovery commerciali sation particularly important since personalised healthcare starts early drug development process diagnostics division beginning technologies expertise help identify potential drug targets screen lesspromising candidate compounds select suitable patients clinical trials cases collaboration results drug coupled companion diagnostic guide treatment pharmaceuticals research early development clinical development commercialisation market target lead phase phase phase ii phase iii filing selection generation phase iv discovery exploratory proof confirmatory phase phase concept phase companion diagnostic biomarker development dx launchpostlaunch assessment feasibility utility target identification tailored prescribing monitoring patient selection diagnostics lrochearengpharmaceuticalsindd close cooperation pharma ceuticals diagnostics divisions key strategic advantage roche leadtoproductionofabnormalbrafthatisalways tdmgpresentedatthesanantoniobreast activeandcausesuncontrolledproliferationofcancer cancersymposiumindecembershowedanobjective cellsmutatedbrafisfoundinapproximately responsetumourshrinkageinofwomenwith ofmalignantmelanomasthemostdeadlyformofskin advancedmetastaticherpositivebreastcancer cancerfollowingpositivephaseiresultsaphaseii thathadworsenedfollowingprevioustreatment clinicaltrialwasinitiatedinseptembertoinvestigate rginpreviouslytreatedpatientswithbraf rggdccollaborationwithcurisisa mutationpositivemalignantmelanomaandaphase novelcompoundtargetingthehedgehogsignalling iiitrialinpreviouslyuntreatedpatientsbeganin pathwaywhichisthoughttobeimplicatedinseveral januaryadiagnostictestisbeingdevelopedin cancersfollowingpositivephaseiresultsapivotal collaborationwithrochemoleculardiagnosticsto phaseiistudyinvestigatingrgasapotential identifypatientswhosetumourscarrytheabnormal treatmentforadvancedbasalcellcarcinomacom brafgeneandarethereforemostappropriatefor mencedinfebruaryrgisalsobeingevaluated treatmentwithrg inphaseiistudiesasafirstline therapyformeta staticcolorectalcancerandinthemaintenancetreat rggathefirsttypeiiglycoengineered mentofovariancancer fullyhumanisedanticdmonoclonalantibody iscurrentlybeinginvestigatedinlatestageclinical inflammation autoimmune disorders trialsasapotentialtreatmentforchroniclymphocytic rochehaseightnewcompoundsindevelopmentfor leukemiacllandnonhodgkinslymphoma chronicandprogressiveautoimmuneandinflammatory nhldatafromphaseiistudieswerepresented diseasessuchasrheumatoidarthritisraand attheeuropeanhematologyassociationmeeting asthmafiveofwhichareinphaseiioriiiclinicaltest injunecllandtheamericansociety ingphaseiiiprogrammesarecurrentlyinvestigating ofhematologyindecembercllandnhl thenextgeneration anticd antibodyocrelizumab aphaseiiistudyinpatientswithcllwasinitiated inseveralrasettingsincludinginpatientswho indecember respondinadequatelytothecurrentstandardofcare methotrexateortotumournecrosisfactortnf pertuzumabrgisaherdimerisation inhibitorsthefirstofthesestageinpatientswho inhibitorthatisbeingstudiedincombinationwith didnotrespondtotreatmentwithmethotrexate herceptinandstandardtherapyinherpositive wasreportedtohavemetitsprimaryendpointin breastcanceraphaseiiistudycleopatra decemberwhileoveralladverseeventsreportedin evaluatingtheadditionofpertuzumabtoherceptin thisstudywerecomparablebetweentheocrelizumab andchemotherapyinthefirstline treatmentof andplacebotreatmentgroupsahigherpercentage patientswithadvancedmetastaticdiseaseanda ofseriousinfectionswasobservedinthepooledocre phaseiitrialneosphereinvestigatingneoadjuvant lizumabgroupscomparedwiththeplacebogroupan presurgicaltreatmentwithpertuzumabareongoing additionalmajorphaseiiistudyscriptinpatients withinadequateresponsetotnfinhibitorsisex trastuzumabdmtdm rganovelanti pectedtoreportindosinginthefilmstudy bodydrugconjugatethatcombinesanantiher inpatientsnotpreviouslytreatedwithmethotrexate monoclonalantibodyandapowerfulcytotoxicagent hasbeenstoppedfollowingreassessmentoftherisk isbeinginvestigatedinthesecondandthirdline benefitprofileinthispatientpopulationaphaseiii treatmentofmetastaticherpositivebreastcancer programmeinvestigatingocrelizumabinthetreatment aphaseiiitrialemiliainvestigatingtdm oflupusnephritisbelongwasalsodiscontinued inthesecondline treatmentsettingbeganinthe followingreassessmentoftheriskbenefit profile firstquarterpositiveresultsfromaphaseiistudy lrochearengpharmaceuticalsindd roche business report pharmaceuticals ten new molecular entities ongoing planned latestage studies compound indication status market potential ocrelizumab rheumatoid arthritis first phase iii study stage met primary endpoint best class fourth quarter results additional studies expected trastuzumabdm herpositive metastatic phase iii started first quarter first class breast cancer secondline treatment pertuzumab herpositive metastatic phase iii started first class breast cancer rg ga nonhodgkins lymphoma phase iii started fourth quarter best class chronic lymphocytic chronic lymphocytic leukemia leukemia rg plx malignant melanoma registration studies started january first class rg advanced basal pivotal phase ii started first quarter first class gdc cell carcinoma rg negative symptoms positive phase ii results fourth quarter first class schizophrenia phase iii planned start aleglitazar cardiovascular high risk phase iii planned start first quarter first class type diabetes taspoglutide type diabetes first positive phase iii results temerge fourth best class quarter additional results expected dalcetrapib dyslipidemia phase iii enrolment ongoing first class cardiovascular high risk metabolic cardiovascular diseases patientswithtypediabetesaleglitazarrg rochesmetabolicandcardiovascularportfolioof isaperoxisomeproliferatoractivatedreceptorppar newmolecularentitiesatvariousstagesofclinical coagonistwithdemonstratedeffectsonbloodfats developmentincludesthreepromisinglatestage bloodpressureandbloodglucoseforthereductionof compoundsdalcetrapibrgjttlicensed cardiovascularmorbidityandmortalityinpatientswith fromjapantobaccoisanovelcholesterolester typediabetesaphaseiiiprogrammealecar transferproteincetpinhibitorforthemanagement dioisexpectedtobeginrecruitmentearlyin ofcholesterollevelsinthebloodrecruitmentforthe phaseiiidalheart programmeisontrackanew virology imagingstudydalplaquewasannouncedinthe rochecurrentlyhastwodirectantiviralagentsin lastquarterofandpatientrecruitmenthas developmentforthetreatmentofhepatitisc commencedtaspoglutidergbim thenucleosidepolymeraseinhibitorrgcolla licensedfromipsenisaonceweekly humangluca borationwithpharmassetandtheproteaseinhibitor gonlikepeptideglphormoneanalogueforthe rgitmn collaborationwithintermune controlofbloodglucoselevelsinlateinitial bothoftheseoralagentsenteredphaseiibstudies resultsfromfivephaseiiitrialsinthetemerge duringtheyearrgandrgarebeinginves programmeshowedthattaspoglutideconsistently tigatedincombinationwithpegasysandcopegus providespowerfulanddurableglycemiccontrolin ribavirinandincombinationwitheachotherin lrochearengpharmaceuticalsindd cancer one disease group distinct disorders medical challenges aninterferonfree regimenresultsfromaphasei focus unmet medical studyinform investigatingrgcombined needs withrginhepatitiscwerepresentedatthe annualamericanassociationforthestudyofliver diseasescongressinnovembertheyshowedforthe cancer accordingtothelatestinternational glyt inhibitor firsttimethatanalloralinterferonfreeregimen agencyforresearchoncanceriarcestimate rg canleadtosignificantviralsuppressioninpreviously inovermillionpeopleworldwidewere codeveloped chugai treat untreatedpatientsandpatientsinwhomprevious diagnosedwithcancerandsomemilliondiedof ment negative treatmenthasfailed thediseasetheiarcanticipatesthatcancerwill symptoms schizo surpassheartdiseaseastheleadingcauseofdeath phrenia area central nervous system worldwideinandalsoforecaststhatby high unmet medical therocheportfoliohasnovelcompoundsin therewillbeovermillionnewcasesandmillion need rg developmentfordisordersofthecentralnervoussys deathsperyearfromcancerineuropealoneone potential enable patients temincludingschizophreniamultiplesclerosisand inthreepeoplecanexpecttodevelopcancerintheir better establish social otherseriousconditionsoneofthesecompoundsis lifetimecancerisnotonediseasebutagroupof relationships rgaglycinetransportertypeglytinhibitor morethandistinctdisorderseachwithitsown parti cipate every discoveredbyrocheitisbeingcodevelopedglobally medicalchallenges day activities withchugaiforthetreatmentofthenegativesymp ducing burden tomsofschizophreniaanareaofhighunmetmedical nonhodgkins lymphoma agroupofover patients caregivers alike needrghasthepotentialtoenablepatientsto cancersthataffectthelymphaticsystemthisclass betterestablishsocialrelationshipsandparticipate ofcancercurrentlyaffectsovermillionpeople ineverydayactivitiesreducingtheburdenforpatients worldwidefollicularlymphomaaccountsforabout andcaregiversalikeindecemberrocheannounced oneinfourofallcasesofnonhodgkinslymphoma thataphaseiitrialwithrghadmetitsprimary itcanoccuratanytimeduringadulthoodthough andsecondaryendpointsimprovingboththenegative peoplearetypicallydiagnosedduringtheirsixties symptomsandthepersonalandsocialfunctioning anditaffectsasmanymenasitdoeswomen ofpatientswithschizophreniathecompoundwas welltoleratedatalldosestestedrochehasnow chronic lymphocytic leukemia themostcommon decidedtoinitiatephaseiiiclinicaltestingwiththe typeofleukemiainadultsaccountingforapproximately firsttrialplannedtostartin ofallformsofleukemiatheincidenceof cllinwesterncountriesisaroundper alsoindecemberrocheanditsdevelopmentpartner anditistwiceascommoninmenasinwomen biogenidecreportedpositiveresultsfromaphaseii trialwiththehumanisedanticdmonoclonal colorectal cancer cancerofthelargeintestine antibody ocrelizumab rginpatientswith orrectumwhichaccountsforovermillionnew relapsingremitting multiplesclerosisoneofthelead casesaroundofallnewlydiagnosedcancers ingcausesofneurologicaldisabilityinyoungadults worldwideeachyearitisthesecondmostcommon ocrelizumabshowedastrongeffectversusplacebo causeofcancerdeathsineuropeandthethird withahighlystatisticallysignificantreductioninsigns mostcommonworldwide ofdiseaseactivityasmeasuredbybrainlesionsthe primaryendpoint kidney cancer thistypeofcancerisnewlydiag nosedinaroundpeopleandcauses deathsworldwideeveryyearratesthatareexpected toincreaserenalcellcarcinomaaccountsfor ofallkidneycancers lrochearengpharmaceuticalsindd roche business report pharmaceuticals breast cancer themostcommoncanceramong hepatitis b c thehepatitisbandcviruses womenworldwideovermillionwomenarenewly hbvhcvwhicharecommonlytransmittedthrough diagnosedandoverdiefromthedisease bloodtoblood contactcauseacuteandchronicliver eachyearasthereareseveraldifferenttypesof diseasepotentiallyleadingtoliverfailurecirrhosis breastcancerknowledgeoftumourcharacteristics andlivercancerworldwidemillionpeopleare isimportantfortreatmentdecisionssome thoughttobechronicallyinfectedwithhbvahighly ofwomenwithbreastcancerhavetumourswith infectiousvirusthatisresponsibleforanestimated abnormallyhighlevelsofaproteinknownasher onemilliondeathsannuallymorethanmillion herpositive tumoursareparticularlyaggressive peoplearoundtheworldareinfectedwithhcvand fastgrowing andlikelytorelapse tomillionnewcasesoccureachyearhepatitisc isthemainreasonforlivertransplantationarecent lung cancer themostcommonformofcancer studyonthehcvrelated burdenofdiseasein worldwideandtheleadingcauseofcancerdeaths europeancountriesestimatedthatbetweenseven thereareanestimatedmillionnewcasesannually andninemillionpeopleoroverofthepopulation nonsmall celllungcanceristhemostcommon areinfectedwithhcv formaccountingforapproximatelyofallcases influenza flu ahighlycontagiousdebilitating pancreatic cancer aparticularlyaggressivedisease viralillnessthatoccursmainlyintheautumnand thatisextremelydifficulttotreatitkillsahigher wintermonthsintemperateclimatesandyearround proportionofpatientsinthefirstyearafterdiagnosis intropicalareasitcanbeparticularlydangerous thananyothercancerthefifthleadingcauseof foryoungchildrentheelderlyandpeoplewith cancerdeathsinthedevelopedworldpancreatic chronichealthproblemswhoareatgreaterriskof cancerclaimsnearlyliveseveryyear influenzarelated complicationspandemicsorglobal epidemicsarecausedbynovelstrainsofinfluenza gastric stomach cancer accountsforovermillion towhichpeoplehavenoimmunitypandemicsoccur newcasesandsomedeathseachyearmaking everytoyearsandhavebeenassociatedwith itthesecondlargest causeofcancerdeathsworld significantlevelsofillnessanddependingontheviral widethevastmajorityofcasesoccurinasiawhere straindeathaccordingtotheworldhealthorgani withlungcanceritistheleadingmalignancyadvanced zationthecurrentlycirculatingpandemicahn stomachcancerisassociatedwithapoorprognosis influenzavirusappearstobeascontagiousas themediansurvivaltimeafterdiagnosisisapproxi seasonalinfluenzaandisspreadingfastparticularly matelymonthswithcurrentlyavailabletherapies amongpeopleagedtoyearsthediseaseis generallyclinicallymildbutsevereillnesscanoccur anemia occurswhenthelevelofredbloodcells andorthehemoglobintheycontainfallsbelow autoimmune disorders occurasaresultofa normalstarvingorgansandtissuesofoxygenitis mistakenimmuneresponsetothebodysowntissues seeninoverofpatientswithchronickidney thecausesareunknownrheumatoidarthritis renaldiseasewhichaffectsmorethanmillion multiplesclerosisandlupuserythematosusareamong peopleworldwideinadditionanemiaaffectsthree themostcommonautoimmunedisorderswhichaffect outoffourcancerpatientsundergoingchemotherapy millionsofpeopleworldwide patientswithuntreatedanemiamayneedblood transfusionsthepotentiallongterm effectsofanemia rheumatoid arthritis ra achronicprogressive includecardiovasculardiseaseinrenalpatients inflammatorydiseaseofthejointsandsurrounding whileinpatientswithcanceritisassociatedwith tissuesthatisassociatedwithintensepainirrevers diminishedqualityoflife iblejointdestructionandsystemiccomplications lrochearengpharmaceuticalsindd bcellsatypeofimmunecellareknowntoplaya keyroleintheinflammationassociatedwithra severalkeycytokinesorproteinsarealsoinvolved includingtnfalfainterleukin il andinter leukin il il hasbeenidentifiedashaving apivotalroleintheinflammationprocessaround millionpeopleworldwidearethoughttobe affectedbyra diabetes recognisedasaglobalepidemicbythe worldhealthorganizationtheinternationaldiabetes federationestimatesthatsomemillionpeople worldwidewillhavediabetesbyaccordingto thewhotypeadultonsetdiabetesaccountsfor aroundofallcasesuncontrolledtypediabetes canleadtoseverecomplicationssuchascardio vasculardiseasestrokeblindnessamputations andkidneyfailureresultinginsignificanthealthcare burdenstosociety schizophrenia aseverementaldisordercharacter isedbyprofounddisruptionsinthinkingthataffect languageperceptionandthesenseofselfaccording towhoestimatesschizophreniaaffectsapproxi matelymillionpeopleworldwideandismostcom moninadultsagedbetweenandyearsthe symptomsofschizophreniaarebroadlycategorised aspositivenegativeandcognitivepositivesymptoms arepsychoticbehaviourssuchashallucinationsand delusionsnegativesymptomsareassociatedwith disruptionofnormalbehaviourandemotionssuchas inabilitytosustainplannedactivityoralackofmotiva tionandinterestindaytoday livingcognitive symptomsincludetroublefocusingorpayingattention persistentnegativesymptomsareamajorcauseof chronicdisabilitythereiscurrentlynomarketed productavailabletotreatthenegativesymptomsof schizophrenia lrochearengpharmaceuticalsindd together theyre taking aim innovative medicine skin cancer roche world leader vitro diagnostics also syste atically apply diagnostic expertise research development new medicines helps us develop pharmaceuticals target biological mechanisms give rise cancer one example rg plx currently tested phase ii clinical trials possible treatment malignant melanoma type skin cancer rg novel highly selective braf kinase inhibitor targets destroys cancer cells harbouring specific cancer causing gene mutation called braf identify patients whose tumours carry mutation therefore considered likely respond targeted medicine roche developing companion diagnostic test rg promising compound development treatment braf mutationpositive patients malignant melanomas deadliest form skin cancer oral medicine selective kinase inhibitor developed roche collaboration plexxikon bildstreckeengsindd bildstreckeengsindd diagnostics sales grew well ahead market strong uptake new products contributing market share gains key segments immunoassays tissue diagnostics business areas launched major new products roche believes help drive abovemarket growth efforts enhance operational efficiency ongoing throughout division contributed higher operating profit division continue expand efforts order improve productivity profitability lrochearengdiagnosticsindd diagnostics division brief key figures change change millions chf chf local currencies sales sales professional diagnostics diabetes care molecular diagnostics applied science tissue diagnostics operating profit operating free cash flow research development diagnostics executive committee december jrgen schwiezer ceo division roche diagnostics manfred baier applied science roland diggelmann asiapacific dirk h ehlers professional diagnostics christian hebich finance services michael heuer emea europe middle east africa latin america alexander keller global platforms support frank lennartz human resources hany massarany tissue diagnostics daniel oday molecular diagnostics frank pitzer regulatory affairs quality management clausjoerg ruetsch legal michael tillmann north america robert yates business development december see corporate governance chief operating officer roche diagnostics since january associate member lrochearengdiagnosticsindd roche business report diagnostics diagnostics division sales region roches diagnostics rochesdiagnosticsdivisionistheworldsleading division global supplierofin vitro diagnosticsivdsivdtests europemiddle leader billion testsperformedinalaboratoryoratthepointofcare eastafrica us dollar vitro onbloodandothersamplesfrompatientsarea japan diagnostics market criticalsourceofobjectiveinformationabouthealth asiapacific division strives develop systems anddiseaserochesdiagnosticinstrumentsand make testing reagentshelpdoctorsdetectdiseasesselectappro latin america efficient provide priatetreatmentsandmonitorpatientsresponsesto results high medi careinadditionscientistsusethedivisionsresearch north america cal value productstogainabetterunderstandingofthe causesofdiseaseanddiscovernewtreatments italics growth rates local currencies inovercountriesthedivisionservescustomers spanningtheentirehealthcarespectrumfrom hospitalsandcommercialmedicallabstophysicians togetherrochespharmaceuticalsanddiagnostics topatientswithconditionsrequiringthemtoselftest divisions working advance personalised inrochehadashareoftheglobalivd healthcare activities aligned help increase marketvaluedatanestimatedbillionusdollars drug rd productivity discover targeted inannualsales medicines drive development companion diagnostics potential revalue diagnostics inform majority clinical strategic priorities decisions yet account less medical spending changingdemographicsnewtechnologiesand diagnostics division outperforming mountingpressureonbudgetsandpricingareamong market emerging seven e countries thetrendsshapingthehealthcaremarket notably china accelerate growth thediagnosticsdivisionsstrategicprioritiesare expanding local organisations designedtorespondtothesetrendsandcapitalise investing programmes bring products onthegrowthopportunitiestheypresent market quickly testing efficiency one pillar divisions division intends improve profitability business roches automated diagnostic systems combination strong sales embody decades engineering innovation growth efficiency initiatives targeting virtually future advances include enhanced workflow every area operations report contains integration capabilities supporting elec information progress made tronic patient record management testing efficiency alone enough products high medical value critical sustained competitiveness growth novel roche tests mark significant advances oncology cardiology major therapy areas increased invest ment biomarker research trials figures market growth market share market size demonstrate clinical utility new tests estimates based company independent reports roche analysis yield innovations e markets brazil russia india china south korea mexico turkey lrochearengdiagnosticsindd sales instrument placements strongly results main business onscheduleintheeuandothermarketsinthe divisional sales secondhalfoftheyearrocheexpectsthismajor growth broad developments additiontoitscobasfamilyofmodularserum based extending across five busi workareasystemstoenhanceitscompetitiveness ness areas inthediagnosticsdivisionrecordedsales significantlyinbothclinicalchemistryandimmuno major regional ofbillionswissfrancsanincreaseofinlocal assaysaltogetherthedivisionlaunchedover markets except japan currenciesinswissfrancsinusdollars majorproductsin business areas overthiswasmorethantwicetheestimated launched major ivdmarketgrowthrate thediagnosticdivisionsoperatingprofitrosein new products localcurrenciesinswissfrancstomillion allfivedivisionalbusinessareascontributedtosales swissfrancsandtheoperatingmarginatconstant growthledbyprofessionaldiagnosticsanddiabetes exchangeratesadvancedpercentagepoints careimmunoassaysandsinglestripbloodglucose theseincreaseslargelyreflectsalesgrowthtightcost monitoringsystemsremainedthesebusinesses managementandthesignificantonetimeexpenses primarygrowthdriversmoleculardiagnosticscore recordedinincludingthoserelatingtotheven bloodscreeningandvirologysegmentsdelivereda tanaacquisitioninswissfrancsthemargindecreased solidsingledigitriseinoverallsalesintheapplied bypercentagepointstoduetoaparti scienceunitstrongdemandforthemagnapureand cularlyunfavourablecombinationofexchangerate lightcyclerproductlinesfuelledfurtherabovemarket movementsformoreinformationonthedivisions growththetissuediagnosticsbusinessacquired operatingresultsseethefinancereportpart incontinuedtogrowwellaheadofthemarket ofthisannualreport drivenmainlybyitsadvancedtissuestainingportfolio instrumentplacementswereagainupsignificantly efficiency gains forthedivisionasawholeandwereamajorgrowth initiativestosimplifycoreprocessesconsolidate driver servicesstreamlineproductportfoliosandreduce timetomarketareinplaceatanumberofmajorsites geographicallytheemeaandasiapacificregions insuchinitiativescontributedtosignificant contributedmosttogrowthwithallfivebusiness costsavingsandhelpedthedivisionlimitheadcount areasrecordingsolidsalesgainsinthesemarkets growthdespitetheacquisitionofswisslaband tissuediagnosticsremainedtheprimarygrowth innovatisanddespiteasubstantialsalesforce driverinnorthamericainjapanprofessionaldiag increaseinchinanotablesuccessesincludedthe nosticsandappliedsciencegrewmoderatelyand consolidationofregionalcallcentresthecreation tissuediagnosticsachievedhighdoubledigitgrowth ofsharedservicecentresinnorthamericaand butdivisionalsalestherewereflatoveralllargely reductionsinmanufacturingcostsexistingandnew duetoreducedgovernmentivdreimbursementand programmeswillbeintroducedatmoresitesto lowerresearchfunding improveproductivityfurtherandachieveadditional costsavings salesintheemarketsgrewandaccountedfor overoftotaldivisionalsalesrevenuesincreased investmentinthesemarketsandstrongdemandfor immunoassaysandotherleadingedgerocheproducts contributedtothisstrongabovemarketgrowth thefirsttwomodulesofthecobasanalyser unless otherwise stated growth rates local currencies seriesforhighthroughputlaboratorieswerelaunched emea europe middle east africa lrochearengdiagnosticsindd roche business report diagnostics roches topselling diagnostics sales millions chf accuchekmobile cobase cobasc cobastaqman cobastaqscreen mpxtest accuchek blood glucose cobas e modules cobas c modules cobas ampliprep cobas ampliscreen meters insulin pump modular analytics modular analytics cobas taqman cobas taqscreen systems elecsys cobas integra market segment market segment market segment market segment market segment diabetes management immunoassays clinical chemistry virology blood screening lrochearengdiagnosticsindd industryleading portfolio products clinical testing blood screening life science research coaguchekxs ventanaihcreagents magnapurelc sysmexxti genomesequencerflx coaguchek meters immunohistochemistry magna pure systems sysmex analysers genome reagents light cycler systems sequencers market segment market segment market segment market segment market segment coagulation advanced gene expression hematology dna sequencing monitoring tissue staining research images scale yearonyear sales growth local currencies lrochearengdiagnosticsindd roche business report diagnostics business area highlights coagulationmonitoringsalesincreased reinforcingrochesleadershipinthissegment immunoassay sales professional diagnostics abovemarket growth salesofthetopsellingcoaguchekxsmonitor major major new products forpatientusewereupstronglyagainhelped growth driver increas rocheprofessionaldiagnosticsisaleadingsupplier bycontinuedrobustdemandineuropeandexpanded ing roughly three ofinstrumentstestssoftwareandservicesfor medicarereimbursementforhomecoagulation times market laboratoriesandofdecentralisedtestingproductsto testingintheusstudiesindicatethatselftesting growth rate new cobas modular supportclinicaldecisionmakingatthepointofcare helpspatientsonanticoagulantstokeeptheir system make inthebusinessareahadashareof medicationwithinthetherapeuticrangeandcan roche professional aglobalmarketestimatedatbillionusdollars reducecomplications diagnostics even stronger competitor professionaldiagnosticsfullyearsalesgrewnearly inaugustprofessionaldiagnosticsbeganrollingout immunoassay twiceasfastasthemarketrisingtomillion thecobasmodularanalyserseriesforhigh testing clinical swissfrancsimmunoassayandclinicalchemistry throughputlaboratoriesineuropeandothermarkets chemistry systemsforlaboratoriesthetwolargestsegments thatrecognisecemarkcertificationtheresponse bysalesremainedtheprimarygrowthdrivers tothisnewflagshipcobasplatformhasbeen regionallysalesoutpacedmarketgrowtheverywhere overwhelminglypositivewithmorethanorders exceptnorthamericawheretheindustryasawhole shippedbytheendoftwoclinicalchemistry experiencedflatornegativesalesgrowthinmost modulescandcwerelaunchedin segmentsasaresultoftheeconomicdownturn bytheendoffourcobasclinicalchemistry andimmunoassaymoduleswillbeavailableworld theimmunoassaybusinessgainedfurthermarket wideincustomisableconfigurationsthenew shareonsalesgrowthofthiswasroughlythree platformisbasedonthesameproventechnologies timesthemarketgrowthrateclinicalchemistrysales asthesmallercobasandcobassystems grewaheadofthemarketadvancingtheplace withexpandedsamplehandlingandworkflow mentrateforcobasmodularanalysersparticularly capabilitiesandenhancedqualitymanagement thecobasseriesformidsizelaboratories featurestomeettheneedsoflaboratoriesperforming remainedhighfuellingsalesinboththesesegments uptomilliontestsperyear professionaldiagnosticsimmunoassaybusiness inseptemberrocheconcludedanexclusivelicense hasconsistentlygrownatdoubledigitratesforthe agreementwithstvincentshospitalsydney lastnineyearsthankstoalargeinstalledbaseand australiaforworldwidepatentrightsrelatingto steadilyexpandingtestmenunewtestsintroduced theuseofgrowthdifferentiationfactorgdf inliketheelecsysilinterleukinimmuno forthediagnosisofcardiacdysfunctionelevated assayanaidinthemanagementofcriticallyill circulatinglevelsofgdfcanhelpidentifyhigh patientsandthehighsensitivityelecsystroponint riskindividualswithavarietyofcardiovascular assaydiagnosisofheartattackandcardiacrisk conditionsfromstablecoronaryarterydiseaseto stratificationwereimportantgrowthdriversin heartfailuretogetherwithanagreementsignedwith professionaldiagnosticslaunchedsiximmunoassays hannovermedicalschoolhannovergermanyin andfiveneworsecondgenerationclinicalchemistry januaryalsorelatingtogdfandroches testsforavarietyoftherapyareasincludingcardi ownpatentsinthisfieldthislatestagreement ologywomenshealthandcriticalcarein willfurtherstrengthenrochesleadingpositionin thebusinessareawillexpanditstestmenufurther thediagnosisofcardiovasculardiseases particularlyintheuswhereitexpectstolaunch eightimmunoassays lrochearengdiagnosticsindd new accuchek portfolio delivered solid sales growth difficult market diabetes care market leadership strengthened combowhichwaslaunchedinninemarketsduring excellent uptake rochediabetescaredevelopsandcommercialises andbycontinuedstrongdemandforaccu latest accuchek bloodglucosebgmonitoringandinsulindelivery chekinfusionsets products helped drive abovemarket sales systemsthatenablepeoplewithdiabetestomanage growth diabetes theirconditionmoreeffectivelyitistheindustry inseptemberdiabetescareannouncedinterim care leaderwithashareoftheglobalbgmonitoring datafromitsaccuchekviewoutcomestudy marketworthnearlybillionswissfrancsinglobal thedataindicatethatpeoplewithtypediabetes salesselfmanagementisacornerstoneofdiabetes whoarenotreceivinginsulincanimprovetheir carebecausesomanydailyactivitiesaffectblood glycemiccontrolbytestingandanalysingtheirbg glucoselevelsfrequentbgtestingcanlowertherisk levelsinastructuredwayandtranslatingtheresults ofseriouslongtermdiabeticcomplicationslike intoappropriateactionthemonthstudyunder strokeamputationandblindnesswhilehelpingpeople scoresrochescommitmenttoenhancingthemedical withdiabetestomaintainandimprovetheirquality valueofdiabetesselfmanagementthefinalresults oflife willbeannouncedinjune indiabetescaressalesincreasedto molecular diagnostics new products lay molecular diagnostics millionswissfrancsthiswassignificantly foundation future growth several important aheadofglobalmarketgrowthwhichwasflat rochemoleculardiagnosticsdevelopsandcommer new blood screening accounts duetotheeconomicdownturnallregionsexcept cialisesadvanceddiagnosticandbloodscreening contributing signifi japandeliveredsalesgrowthwithstrongsales platformsandtestsbasedonrochesproprietary cant competitive gains contributionsfromemergingmarketstheaccuchek realtimepolymerasechainreactionpcrtechnology markets avivaandaccuchekperformabgmonitoring thefastgrowinghighlycompetitivemolecu systemsremainedtheprimarygrowthdriversaccu lardiagnosticsmarketisvaluedatbillionswiss chekavivarochestopsellingbgmonitoring francsrocheistheleaderwithamarketshare systemcontinuedtopoststrongdoubledigitsales growth moleculardiagnosticsfullyearsalesadvanced tomillionswissfrancsgrowthwasledbysolid introducedinfebruarytheaccuchekmobile gainsintheemearegionespeciallyinthecore thefirstandonlystripfreebgmonitoringsystem bloodscreeningbusinessthefullyautomatedcobas experiencedexcellentuptakeinitslaunchmarkets taqscreenmpxtestavailableineuropesince andcontributedtomarketsharegainsinthehigh andlaunchedlastyearintheuscontributedstrongly valuecustomersegmentattheendofitwas togrowthinthissegmentwithsignificantcom availableinnineeuropeancountriesaccuchek petitivegainsinseveralmarketsthismultiplexblood mobilesenhancedeaseofuseisappreciated screeningtestdetectsfiveviraltargetsinvirology especiallybypeoplewithinsulindependentdiabetes thelargestsegmentbysalesmoleculardiagnostics whoneedtotesttheirbgfrequentlythelaunch retaineditsleadingmarketsharewithsales ofthesleekaccuchekavivananoandaccuchek growthstrongvirologysalesandnewbloodscreening performananodesignedespeciallyforyounger accountsinportugalspainthailandandtheuk usershasalsobeenasignificantsuccessattheend resultedinabovemarketdoubledigitsalesgrowth ofthesenewsinglestripmeterswereavailable intheasiapacificandemearegions inovermarkets sinceitseulaunchinaprilrocheslightcycler salesofinsulindeliverysystemsshoweddoubledigit mrsaadvancedtesthasexperiencedpositiveuptake growthfortheyearhelpedbyexcellentuptakeof incountrieswherereportingmethicillinresistant thenewinteractiveinsulinpumpsystemaccuchek staphylococcus aureusmrsainfectionsiscustomary lrochearengdiagnosticsindd technolo ggi lyre cns oa e na grm ie ne e rt ed f ee h r ri n e ts nd ii gbl cis c e ec se n st c r u e c u b se r un gn dte ec h sn io g lo g n fo rm ula tio n lle c e ts vir alresi sta nce n eur ode ge ner atio sn gn al li ng p h w ay n gi mg e yn ee ls ib ip n oi ncpo e alol tl e sg b c iy emol llo bg uy ioni loty gy pharma oncology inflammation neuroscience metabolism virology diagnostics anatnev gniniats eussit roche business report diagnostics excellence science expertise molecular biology major disease areas years roche divisions amassed tremendous expertise molecular biology today applying knowledge wide range technologies pursuit new tests targeted treatments five major focus areas oncology inflammation neuroscience metabolism virology time working together gain insights molecular mechanisms cause drive disease every cancer drug development programme roche example involves biomarker research aimed validating treatment targets identifying patients likely respond new drug almost years cancer research molecular level helped us develop new strategies move us closer ultimate goal one day curing cancer n l sif ee q us ec ni ce ngces xc ce el lll ai ng ae lyn sc ise ni mm icb rl oe arg ayn cobas r el ai lg tiht mec pc cl rer u n ss ayu c solt bi ap slex protein anac lo ysb isas lrochearengdiagnosticsindd roche developed test new pandemic flu virus within weeks virus first reported orrequiredstudiesindicatethatthetestsspeed ofdevelopingcervicalcancercouldhelpincrease tests hospital itreliablyidentifiesmrsacarriersinlessthantwo thesensitivityofscreeningforhpvinfectionsthatcan acquired infections hoursversusonetothreedaysusingconventional leadtocervicalcancerwhenhpvdnatestingis like mrsa human papillomavirus methodscanhelpsignificantlyreducethespreadof performedinconjunctionwithapapsmearmore infection two thispotentiallydeadlymicrobeinhospitalsscreening womenwillbeidentifiedwithprecancerouscervical fastestgrowing formrsaisoneofthefastestgrowingsegments diseaseduringthefirstroundofcancerscreening segments molecu inthenorthamericanmoleculardiagnosticsmarket enablingappropriatemedicalinterventionaddition lar diagnostics andisexpandinginemeaandsomeasiapacific allybecauseofthegreatersensitivityofhpvdna roche launched marketsrocheexpectstolaunchthelightcycler testingwomenwhoarehpvdnanegativemay competitive new products mrsaadvancedtestintheusin potentiallybedeferredtolongerscreeningintervals segments moreoveridentificationofhpvgenotypesand europe indecembermoleculardiagnosticslaunchedits providesactionableinformationguidingtheclinician newfullyautomatedcobassystemineurope toinvestigatefurtherthosewomenatthehighestrisk andothermarketsthatacceptcemarkcertification forcancer thesystemisdesignedtomeetthecurrentand longtermmoleculardiagnostictestingneeds applied science broadbased growth demand instru ofmidtohighthroughputlaboratoriesandroche rocheappliedsciencesuppliesscientistsinacade ments reagents expectsittobecomeasignificantgrowthdriver miaandthebiotechandpharmaceuticalindustries pandemic flu testing major thetestmenucurrentlycomprisesdualtargettests withinstrumentsandhighlyspecificreagentsandtest sales driver roche forchlamydia trachomatisctandneisseria kitsforabroadrangeofresearchapplicationsthe applied science gonorrhoeaengthebacteriathatcausechlamydia globallifescienceresearchmarketvaluedatbillion infectionsandgonorrheaandascreeningand usdollarsgrewapproximatelyin genotypingtestforhumanpapillomavirushpv themostcommonsexuallytransmittedinfection appliedsciencessalesfortotalledmillion whichisresponsiblefornearlyallcervicalcancers swissfrancsanincreaseofovertheprevious worldwideinaustraliaandnewzealandwhere yearthemagnapureandlightcyclerproductlines thecobassystemhasbeenavailablewiththe nucleicacidsamplepreparationnapandquanti ctngtestssinceseptemberthemarketresponse tativepolymerasechainreactionqpcranalysis hasbeenverystrongnextgenerationoncology wereagainthebiggestcontributorstogrowthwith andmicrobiologyassaysforthesystemareindevel salesuphelpedbystrongdemandforinstruments opment andreagentsforpandemicinfluenzatestingand surveillanceinmayappliedsciencedevelopedand inaugustmoleculardiagnosticscompletedenrolment launchedtherealtimereadyinfluenzaahn ofpatientsintoitspivotalathenaclinicaltrial detectionsetforresearchusejustweeksafterfirst thetrialinvolvingapproximatelywomen reportsofthenewpandemicfluvirusinmexico isdesignedtoassessthevalueofscreeningwomen thesetenablesrapidaccuratedetectionoftheviruss forcervicalcancerusingrochescobashpv rnageneticmaterialthefdagrantedemergency assaytogetherwithastandardpapsmearinitialtrial useauthorizationofthekitinnovembermakingit datawillbeavailableinfebruaryandrocheexpects availableforclinicaluseinspeciallycertifiedlaborato tofilethefullathenadatasetwiththefoodand riesintheusothersignificantnewproducts drugadministrationfdainthesecondquarterof includethefullyautomatedmagnapuresystem ifapprovedtheassaywhichprovidesan forhighthroughputnapuptakebyacademic aggregateresultforhighriskhpvgenotypesand andindustrialcustomershasbeenrobustsincethe individualresultsforhpvgenotypesand systemsgloballaunchinseptember thegenotypesthatputwomenatthegreatestrisk lrochearengdiagnosticsindd roche business report diagnostics significant product launches business area total cellanalysissystemsshowedverystrongsalesgrowth throughputbenchtopversionofthegenome indrivenmainlybythexcelligenceproduct sequencergsflxsysteminisexpectedto l linebutalsopartlyattributabletotheacquisitionof spurfurthergrowththegsjuniorsystemwillclose innovatisaginmarchappliedscienceslatestreal themarketgapbetweenlowthroughputtraditional timecellanalyserthexcelligencertcadp sequencingandtheultrahighthroughputofinstru dualplateinstrumenthasbeenagrowthdriver mentslikethegsflxsystemputtingnextgeneration sinceitsworldwidelaunchinaprilitsvalueasa sequencingtechnologywithinthereachofthousands cancerresearchtoolwasenhancedfurtherbythe ofadditionalresearchersworldwide novemberlaunchofthexcelligencesystem cimplateacultureplateenablingscientists tissue diagnostics rapid penetration new l tostudycellmigrationandinvasiondynamically markets e inrealtimeovertheentiretimespanofanexperiment rochetissuediagnosticsventanamedicalsystems thismayhelpresearchersidentifymoleculartargets innorthamericaistheworldsleadingsupplierof fornewdrugsthatinhibitcancercellsabilityto tissuebasedcancerdiagnosticsitsinstrumentsand invadenearbytissuesandmigratemetastasise reagentsystemsareusedinhistologycytologyand todistantpartsofthebody drugdiscoverylaboratoriesworldwideinthe unithadashareofthetissuediagnosticsmarket microarraysalesrosenearlyfourtimesthe whichisvaluedatoverbillionswissfrancs globalarraymarketgrowthrategrowthwasfuelled bycontinuedstrongperformanceofnimblegens tissuediagnosticsrecordedsalesofmillion innovativesequencecapturetechnologieswhich swissfrancsinaincreaseovertheeleven ideallycomplementthebusinessareasnextgenera monthssalesconsolidatedayearearlierfollowingthe tionsequencingsystemsandbytheintroduction ventanaacquisitioninfebruaryonacompa ofthehighresolutionhighthroughputms rablebasissalesrosesignificantlyoutpacing microarrayscanner themarketwhichisestimatedtobegrowingat salesofdnasequencingreagentsshowedarobust thebusinessareascoreadvancedtissuestaining increasebutoverallsalesofdnasequencing portfolioremainedtheprimarygrowthdriverwith systemswereflatduetotheeconomicdownturnand immunohistochemistryihcreagentsforcancer theresultingdeclineinresearchfundingparticularly diagnosisandadvancedstaininginstrumentsfuelling intheustheusadministrationsstimulus robustgrowthinthissegmentplacements packageforbiomedicalresearchisexpectedtoalle ofthefullyautomatedbenchmarkultrasuccessfully viatethesituationinthelaunchofamedium launchedinnorthamericaandeuropein lrochearengdiagnosticsindd roche biomarker programme every drug developing acceleratedsteadilyduringtheyearthisisthefirst research development andonlysystemtoperformsimultaneousihcand situhybridisationishtestingonasinglecontinu rochesdiagnosticsdivisioncontinuestoinvest diagnotics divi ousandrandomaccessplatformenablingsamples heavilyininnovationinresearchanddevelop sion focusing much tobeaddedandremovedatanytimewithoutinter mentrdcoststotalledmillionswissfrancs r spending highgrowth areas ruptingworkflowfullyearsalesofthesymphony anincreaseofoverrdcostsasaper like molecular diag slidestaininginstrumentandhematoxylinandeosin centageofsalesremainedstableatprojects nostics immuno reagentsforthehighvolumeprimarystainingmarket accountingforasignificantshareofrdspending assays tissue grew inandwhichwillremainfundingprioritiesin diagnostics includetheathenatrialofrochemolecular tissuediagnosticswonmarketshareinallregions diagnosticscobashpvscreeningandgeno withespeciallystronggainsinasiapacificandlatin typingtestintheusdevelopmentofthecobas roche working americaitsuccessfullyleveragedtheexistingroche modularanalyserseriesanddevelopmentof potential companion infrastructuretoexpeditethehiringofsalesperson anextgenerationmoleculardiagnosticplatform diagnostic tests groups key nelandtheintroductionofnewproductsinemea formidtohighthroughputivdtestingandblood disease areas inter asiapacificandlatinamericacontributingto screeningthedivisionalsoinvestedindeveloping est particularly oncol abovemarketgrowthintheseregionsbythecloseof newproductsinitstissuediagnosticsbusiness ogy thebusinessareahadestablisheditsownsales expansionoftheimmunoassaymenuwillbeafurther organisationsinsixoftheemarketsandmostofits majorfocusofrdinvestmentin majorinstrumentsandihcreagentswerealready registeredandavailableinbrazilindiachinaand thedivisionsrdproductivityhasimprovedin mexicorocheisaddressingtheincreasingdemand recentyearssincethenumberofmajorproduct forfullyautomatedproductsinemergingmarkets launcheshasincreasedsignificantlyandthedivision whichiscontributingtostrongmarketsharegains expectstobeanotherexcellentyearinterms ofstrengtheningitsproductportfolioseecharton pandthetablesofmajor product launches intissuediagnosticslaunchednewihc pp reagentstoaidindiagnosingvariouscancersinclud ingleukemialymphomaandcancersofthecolon thediscoveryandvalidationofbiomarkersisessential andprostateworkingcloselywithrochespharma torealisingthepromiseofpersonalisedhealthcare ceuticalsdivisionitcontinuedtodevelopexploratory inpharmaceuticalrdtheyhavemanyusesfrom teststhatmayonedayleadtocompaniondiagnostics identifyingnewtherapeutictargetsandscreeningout forrochetherapiesasadirectresultofthiscollabo unpromisingdrugcandidatestoselectingappropriate rationtissuediagnosticsexpectstwoherassays patientpopulationsforclinicaltrialsintheclinic toreceiveceivdmarkinginthefirsthalfof biomarkertestsincreasinglyprovideinvaluableinfor foruseasaidsinassessingbothbreastandgastric mationforearlydiagnosisandaboutdiseasepre cancerpatientsforwhomherceptintreatmentis dispositionprognosisandthelikelihoodoftreatment beingconsidered responseresponsepredictioncontributingtoear liermoretargetedtherapeuticinterventionsroches ivdportfolioalreadyincludescompaniondiagnostics contributingtomoreeffectivetreatmentinanumber ofconditionsincludingherpositivebreastcancer precancerouscervicalchangescausedbyhuman papillomavirusinfectionhepatitisbandcinfection andcytomegalovirusdisease lrochearengdiagnosticsindd roche business report diagnostics everydrugbeingdevelopedatrochehasabiomarker morelikelythanseronegativepatientstoachieve programmeassociatedwithitanddiagnosticsex asignificantimprovementintheirdiseasefollowing pertiseandadvicearemadeavailableforeachof mabtherarituxantreatmentthiscouldsignal theseprogrammesattheendofrochehad amajoradvanceoverthecurrenttrialanderror fivebiomarkertestsinlatestageandsixinearlystage approachtotreatingrainwhichpatientscycle clinicalvalidationforuseaspotentialcompanion throughvarioustreatmentoptionsuntilanoptimum diagnostictestsandoverexploratorystage responseisachievedrochealreadymarketsassays diagnosticprogrammesintheareasofoncology forrheumatoidfactorandanticcp metabolismvirologyautoimmuneandinflammatory diseaseandcentralnervoussystemdisordersthere hastobeastrongcaseforabiomarkersabilityto detectdiseaseorpredictaclinicaloutcomebeforeit movesintolatestagevalidationwheretheaimisto establishclinicalvalidityconclusivelythroughfurther testingonsamplescollectedinongoingdrugtrials giventhepharmaceuticalsdivisionsstrongoncology portfolioidentifyingandvalidatingbiomarkersto supporttheuseofrochesmarketedanddevelop mentalcancermedicinesisnaturallyamajorfocusof researchencouragingprojectsincludeapcrbased testforbrafveacancercausinggenemutation associatedwithpoorprognosisinseveralcancers includingmalignantmelanomadevelopedbyroche moleculardiagnosticsthetestwasprovenessential forselectingsuitablepatientsinaphaseitrial withthebrafkinaseinhibitorrginmetastatic melanomargwhichselectivelytargets andinducescelldeathintumoursharbouringthe brafvemutationmarkedlyprolongedprogression freesurvivalinpatientsinthetrialwhotestedpositive forthemutationthetesthasalsobeenused successfullyinclinicaltrialstoidentifymutation positivecolorectalcancersifrgisapproved rocheexpectstolaunchthebrafvetestasthe companiondiagnostic twootherhighlypromisingbiomarkersthathave alreadyreachedlatestageclinicalvalidationarerheu matoidfactorandanticycliccitrullinatedpeptide anticcpantibodiesthatarefoundinthebloodof manyrheumatoidarthritisrapatientsananalysis ofpooleddatafromtwoclinicaltrialswithmabthera rituxaninrashowthatpatientswhoareseropositive foreitheroftheseantibodiesaretwotothreetimes lrochearengdiagnosticsindd glossary immunoassay alaboratorytestthatdetectsor measuresatargetsubstanceinasampleusing biomarker acharacteristicthatcanbemeasured animmunochemicalreactioninwhichanantibody andevaluatedasanindicatorofanormalbiological bindstoaspecificantigenthetargetcanbeadrug processadiseaseprocessoraresponsetoathera aproteinoravirusforexample peuticinterventionelevatedlevelsoftheprotein herincancerforexampleareabiomarkerfora immunohistochemistry ihc amethodofstaining highprobabilityofresponsetoherceptin biologicaltissuesamplestodeterminethepresence levelandlocationofspecificproteinsincellsusedin cell analysis methodsofmeasuringtheproperties thediagnosisofcancerandotherdiseases ofcellsincludingtheirsizeandshapecellular parameterssuchasthepresenceofspecificproteins situ hybridisation ish amethodofstaining andcellularprocessessuchasproliferationand biologicaltissuesamplestoidentifythepresenceand growthcellanalysistechnologiesplayanimportant copynumberofspecificgenesorgeneticmutations roleindrugdevelopmentandproduction incellsusedinthediagnosisofcancerandother diseases ce mark certification certificationthatanin vitro diagnosticivdproductcomplieswithallsafety polymerase chain reaction pcr alaboratory healthandenvironmentalrequirementsforuseinthe methodwidelyusedinresearchandindustrytomake europeanunioncertifieddiagnosticsarereferred millionsofcopiesofadnasequenceofinterest toasceivds veryquicklyrealtimepcrsimultaneouslyamplifies copiesandquantifiesthetargeteddnamolecule clinical chemistry abranchofdiagnosticscom prisingteststhatdetectandmeasurechangesin virology inmoleculardiagnosticstestingtodetect thechemicalcompositionofbodyfluidsandtissues certainseriousandprevalentviralinfectionseghiv todiagnoseorpredictthecourseofadisease andhepatitiscortomonitortheirtreatment dna sequencing methodsofdeterminingthe orderofnucleotidesmolecularbuildingblocksin geneticmaterialknowinganindividualsdna sequencecanprovideinsightsintogeneticchanges whichcontributetohumandiseaseorinfluence treatmentresponsehighthroughputtechnologies readthousandsofsequencesatonce human epidermal growth factor receptor aproteininvolvedinnormalcell growthandfoundatincreasedlevelsinsome cancersincludingsomebreastandgastriccancers cancercellsmaybetestedinthelaboratoryfor herlevelstohelpchoosethemostappropriate treatment lrochearengdiagnosticsindd roche business report diagnostics product launches diagnostics division major product launches business area product market quarter professional diagnostics elecsys immunoassays plgf placenta growth factor sflt eu q soluble fmslike tyrosine kinase diagnosis preeclampsia elecsys il interleukin immunoassay aid management eu q critically ill patients elecsys troponin assay test cardiacspecific troponin levels eu q predict mortality risk patients acute coronary syndrome highsensitivity elecsys troponin immunoassay diagnosis eu q heart attack cardiac risk stratification us q sysmex xti mid highthroughput hematology analyser contractual territory test capabilities whole blood body fluids emea q cobas c clinical chemistry module cobas analyser series eu q highthroughput laboratories throughput testshour cobas p cobas p automated storage retrieval modules eu q barcoded primary secondary sample tubes cobas c clinical chemistry module cobas analyser series eu q throughput testshour diabetes care accuchek mobile integrated lancing blood glucose monitoring eu q device employing unique strip technology replaces test strips continuous tape tests accuchek aviva nano accuchek performa nano sleeker versions eu q accuchek aviva accuchek performa meters offering enhanced feature set accuchek combo interactive insulin delivery system combining insulin eu q pump blood glucose meter broad data management capabilities meter also functions pump remote control accuchek active new version existing meter featuring extended eu q memory number failsafe capabilities molecular diagnostics lightcycler mrsa advanced test automated realtime pcrbased test eu q methicillinresistant staphylococcus aureus test identify mrsa carriers two hours cobas p instrument amplilink software preanalytical eu q instrument unite primary tube handling fully automated sample prepa ration amplification detection molecular diagnostics cobas platform automated dna extraction realtime pcr eu q amplification detection tests human papillomavirus chlamydia trachomatis neisseria gonorrhoeae applied science nimblegen ms fully automated highresolution microarray scanner worldwide q use nimblegen dna microarrays xcelligence rtca dp dual plate system highly flexible mediumthroughput worldwide q system realtime noninvasive cell analysis lightcycler system highthroughput quantitative pcr analysis worldwide q magna pure highthroughput system preparing nucleic acid samples worldwide q pcr analysis tissue diagnostics inform egfr dna probe detects extra copies epidermal growth emea apac q factor receptor egfr gene abnormality associated nonsmall cell lung cancer benchmark xt advanced staining instrument latam apac q benchmark ultra advanced staining system continuous random additional european processing stat capabilities markets latam q japan q intended use confirm antiherneu primary antibody inform emea apac q dna probe expanded include analytical claims regarding perfor mance gastric well breast tissue samples eu european union emea europe middle east africa apac asiapacific latam latin america us united states lrochearengdiagnosticsindd major product launches planned business area product market quarter professional diagnostics cobas e immunoassay module cobas modular analyser series eu q highvolume laboratories throughput testshour us q eight elecsys immunoassays us six eu qq cobas c cobas c clinical chemistry modules cobas us q modular analyser series throughput testshour respec tively cobas p cobas p automated storage retrieval modules us q barcoded primary secondary sample tubes cobas c advanced clinical chemistry module cobas modular eu q analyser series features automated reagent loading enabling consolidation broader test menu throughput testshour cobas b benchtop multiparameter analyser blood gas electrolytes eu q cooximetry metabolites use point care hiv combi min improved combination assay hiv antigen p eu q hiv antibodies enabling reliable early detection infection human immunodeficiency virus diabetes care accuchek mobile integrated lancing blood glucose monitoring device additional eu employing unique strip technology replaces test strips markets qq continuous tape tests apac q accuchek combo interactive insulin delivery system combining insulin additional eu pump blood glucose meter broad data management capabilities markets q meter also functions pump remote control apac q us qq accuchek aviva nano sleeker version accuchek performa meter us qq offering enhanced feature set molecular diagnostics lightcycler mrsa advanced test automated realtime pcrbased test us q methicillinresistant staphylococcus aureus cobas ampliprepcobas taqman cmv ce ivd viral load monitoring test eu q enable physicians improve management cytomegalovirus cmv disease solid organ transplant patients cobas taqscreen dpx test multidye blood screening test designed eu q simultaneously provide quantitative result parvovirus b qualitative result hepatitis virus cobas ampliprepcobas taqman hiv v secondgeneration test us q unique dualtarget design enabling detection two separate regions hiv genome cobas taqman hiv v ce ivd high pure virology test offers manual eu q sample preparation option customers lowvolume workload applied science gs junior system economical benchtop nextgeneration dna sequencing worldwide q system smaller laboratories nimblegen cgx multiplex arrays microarrays highresolution analysis worldwide q chromosomal abnormalities capable analysing six samples simultaneously xcelligence rtca ht instrument automated highthroughput cell analyses worldwide q screening seqcap ez exome v insolution enrichment capture technology targeted worldwide q nextgeneration sequencing nextgeneration ultrahigh density nimblegen microarrays worldwide qq tissue diagnostics dual colourdual hapten situ hybridisation ish kit enabling target gene eu q detection control single slide use molecular markers specifically support testing ventana antiher neu b primary antibody ventana dna eu qq probe ce ivds assessing likelihood response herceptin treatment breast gastric cancer patients benchmark gx economical lowvolume advanced tissue staining platform eu apac q automates slide processing steps baking staining ceivd molecular probes targeting enzyme topa cell surface eu qq receptor igfr use aid diagnosing managing breast lung cancer discovery ultra platform immunohistochemistry situ hybridisation us eu q research offering significant improvements ease use workflow apac japan flexibility latam q planned launches may delayed occur result adverse regulatory decisions factors eu european union emea europe middle east africa apac asiapacific latam latin america us united states lrochearengdiagnosticsindd theyre reading genes help save lives one day precision speed count modern molecular diagnostics working improve genome sequencers read building blocks highly variable genes matter days instead weeks long takes achieve precision conventional sequencing methods may one day help extend improve lives transplant patients currently investigating use sequencers hla human leukocyte antigen genotyping blood stem cells stem cell transplantation performed treat number diseases including leukemia donors recipients cells need hlacompatible possible treatment successful studies shown genome sequencer flx system power ful research tool highresolution hla genotyping critical people needing transplants closer match donors recipients hla genes smaller risk transplant rejection life science research use diagnostic procedures bildstreckeengsindd bildstreckeengsindd corporate governance roches commitment stakeholders reflected operating businesses focus value creation management culture conforms modern standards corporate governance groups policy communicating transparently remuneration report roches success depends abilities dedication people recognition forms basis remuneration policy system lrochearengcorporate governanceindd corporate governance rochecomplieswithallrelevantcorporategovernance attheagmonmarchtheboardofdirectors requirementsinparticularwithallapplicablelaws willnominatedeannejuliusandbeatriceweder theswissstockexchangesixswissexchange dimauroforreelection totheboardandarthurd directivesincludingthecommentariestheretoand levinson william burns election new theswisscodeofbestpracticeforcorporategover members board term three years nancepromulgatedbytheswissbusinessfederation asprovidedbythearticlesofincorporationpeter economiesuissethecompanysinternalgovernance brabeckletmatheandhorstteltschikhavedecided frameworkparticularlyitsarticlesofincorporation toretireasmembersoftheboardofdirectorsafter andbylawsembodiesall theprinciplesneededto manyyearsofdistinguishedservicetheboardof ensurethatthecompanysbusinessesaremanaged directorsthanksfortheirdedicationandtheirmany andsupervisedinamannerconsistentwithgood contributionstoroche corporategovernanceincludingthenecessarychecks andbalances corporate executive ourprintedannualreportcontainsselectedlinksto committee therochewebsitewwwrochecomreadersare thusprovidednotonlywithasnapshotofourcom panyatthereportingdatebutarealsodirectedto william burns ceo division roche pharma sourceswhichtheycanconsultatanytimeforupto ceuticals jrgen schwiezer ceo division roche date informationabout corporate governance diagnosticsandjonathanknowlesasheadgroup rochewhereaseachannualreportcoversasingle researchretiredondecemberandtherefore financialyearendingdecemberourwebsite steppeddownasmembersofthecorporateexecutive containsinformationofamorepermanentnatureas committeetheboardofdirectorsthankstheleaving wellasthelatestrochenewsamendmentsto membersofthecorporateexecutivecommitteefor ourcompanysarticlesofincorporationandbylaws theirdedicationandtheirmanycontributionstoroche andchangesinthecurriculavitaeofthemembers oftheboardofdirectorsandthecorporateexecutive theboardofdirectorsofrocheholdingltdwill committee published timely fashion nominatewilliammburnsforelectiontotheboard ourwebsitewheretheycanbeaccessedbyanyone attheagmonmarch lookingforthisinformation aspartofthegenentechtransactionpascalsoriot wasappointedasceoofgenentechincandas board directors anewmemberofthecorporateexecutivecommittee inaprilpascalsoriotrelinquishedhisrole attheth annualgeneralmeetingagmof asceogenentechincasofdecemberand rocheholdingltdonmarchshareholders wasappointedascoodivisionrochepharmaceu reelectedjohnibellandrhoffmannandfranzb ticalsstartingonjanuary humerasmembersoftheboardofdirectorsfor atermofthreeyearsasprovidedbythearticlesof incorporationatitsorganisingmeetingimmediately followingtheagmtheboardofdirectorshas approveditscommitteesstructureanditscommittee membershipsasshownonpage httpwwwrochecomaboutrochecorporategovernancehtm lrochearengcorporate governanceindd roche business report corporate governance board directors per december left dr franz b humer prof bruno gehrig andr hoffmann prof pius baschera prof sir john irving bell peter brabeckletmathe lodewijk jr de vink dr andreas oeri dr deanne julius walter frey prof beatrice weder di mauro prof horst teltschik dr wolfgang ruttenstorfer lrochearengcorporate governanceindd board directors name year birth term ends first elected board directors dr franz b humer e chairman prof bruno gehrig c e vicechairman andr hoffmann c e vicechairman prof pius baschera e prof sir john irving bell c e peter brabeckletmathe e lodewijk jr de vink c e walter frey b e dr deanne julius b e dr andreas oeri e dr wolfgang ruttenstorfer b e prof horst teltschik b e prof beatrice weder di mauro b e new proposed members board directors nominated election annual general meeting william burns march dr arthur levinson secretary board directors dr gottlieb keller honorary chairman board directors dr fritz gerber corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director committee chairperson january lrochearengcorporate governanceindd roche business report corporate governance corporate executive committee per december left dr severin schwan william burns dr jrgen schwiezer dr erich hunziker silvia ayyoubi prof jonathan knowles dr gottlieb keller pascal soriot burkhard g piper osamu nagayama perolof attinger richard scheller ren kissling right new members january left daniel o'day jeanjacques garaud dan zabrowski lrochearengcorporate governanceindd corporate executive committee name year birth position corporate executive committee dr severin schwan ceo roche group dr erich hunziker chief financial officer deputy head corporate executive committee william burns ceo division roche pharmaceuticals dr jrgen schwiezer ceo division roche diagnostics prof jonathan kc knowles head group research dr gottlieb keller general counsel silvia ayyoubi head human resources pascal soriot ceo genentech inc coo division roche pharmaceuticals january daniel oday coo division roche diagnostics enlarged corporate executive burkhard g piper head business area roche diabetes care committee perolof attinger head communications osamu nagayama president ceo chugai richard scheller head genentech research early development gred head roche pharma january jeanjacques garaud research early development pred dan zabrowski head pharma partnering secretary corporate executive committee ren kissling kpmg klynveld peat marwick goerdeler sa reporting years statutory auditors kpmg ag since roche holding ltd auditor charge john morris since chief compliance officer dr urs jaisli member december new members january left daniel o'day jeanjacques garaud dan zabrowski lrochearengcorporate governanceindd roche business report corporate governance asofjanuarydanielodaywasappointedas majorshareholdersarelistedinthefinancereport coodivisionrochediagnosticsandasanew notes roche group consoli memberofthecorporateexecutivecommitteeas dated financial statements equity attributable ofdecemberburkhardpiperstepped roche shareholders related parties downasamemberoftheenlargedcorporateexecu pagesandandinnotetothefinancial tivecommitteeandisreportingtodanieloday statements roche holding ltd significant shareholderspage inaprilrichardschellerwasappointedto andrhoffmannvicechairmanoftheboardof theenlargedcorporateexecutivecommittee directorsandandreasoerimemberoftheboard hereportsdirectlytogroupceoseverinschwan ofdirectorsandchairmanoftheboardscorpo astheformerheadofgenentechresearchhe rategovernanceandsustainabilitycommittee leadsgenentechsresearchandearlydevelopment serveintheirrespectivecapacitiesontheboardand gredwhichwilloperateasanindependentcentre committees representatives share withintherochegroup holdersgroupwithpooledvotingrightsandreceive theremunerationsetforthintheremuneration jeanjacques garaudwasappointedasheadof reportonpageandinthefinancereport rochepharmaresearchandearlydevelopment notetotherochegroupconsolidatedfinancial predandasanewmemberoftheenlarged statementsrelatedpartiespageandnote corporateexecutivecommittee tothefinancialstatementsofrocheholdingltd boardandexecutiveremunerationpage danzabrowskiasheadofpharmapartneringwas nootherrelationshipsexistwiththeshareholders appointedasanewmemberoftheenlargedcorpo withpooledvotingrights rateexecutivecommittee therearenocrossshareholdings capital structure information relating informationonrochescapitalstructureisprovided inthefinancereportnotestothefinancial corporate governance statements roche holding ltd additionaldetailsarecontainedinthe group structure shareholders articlesofincorporationofrocheholdingltd rochesoperatingbusinessesareorganisedinto changesinequityaredetailedinthefinance twodivisionspharmaceuticalsanddiagnosticsthe report notes financial statements pharmaceuticalsdivisioncomprisesthetwobusiness rocheholdingltdpage segments roche pharmaceuticals chugai thecompanyhasasharecapitalof whereasgenentechastheformerthirdsegmenthas swissfrancsdividedintofullypaid beenintegratedintorochepharmaceuticalsthe bearershareswithanominalvalueofswissfranc diagnostics division consists following five eachtherearenorestrictionsontheexercise businessareasappliedsciencediabetescare ofthevotingrightsofthesesharesupondeposit moleculardiagnosticsprofessionaldiagnosticsand sharescanbevotedwithoutanyrestrictions tissuediagnosticsbusinessactivitiesarecarriedout thereisnoauthorisedorconditionalcapital throughgroupsubsidiariesandassociatedcompa inadditionnonvotingequity niessignificantsubsidiariesandassociatedcom securitiesneshavebeenissuedinbearerform paniesarelistedinthefinancereportnoteto therochegroupconsolidatedfinancialstatements httpwwwrochecomaboutrochecorporategovernance subsidiariesandassociatespagesto articleofincorporationhtm lrochearengcorporate governanceindd theydonotformpartofthesharecapitaland withtheexceptionoffranzbhumernoneofthe confernovotingrightseachnesconfersthesame membersoftheboardofdirectorshasbeena rights one share participate available memberofrochescorporateexecutivecommittee earningsandinanyliquidationproceedsfollowing orservedinanexecutivecapacityatanygroup repaymentofthesharecapitalrochesnes subsidiaryduringthethreefinancialyearspreceding andtherightspertainingtheretoincludingthe thecurrentreportingperiod provisionsprotectingtheinterestsofnesholders theinternalorganisationoftheboardofdirectors aredescribedinofthearticlesofincorporation andthedivisionofauthorityandresponsibilities ofrocheholdingltd betweentheboardandmanagementtheremitsof information debt instruments theboardcommitteesandtheinformationand beenissuedandonoutstandingbondsisprovided controlmechanismsavailabletotheboardinits finance report note roche dealingswithcorporatemanagementaregoverned groupconsolidatedfinancialstatementsdebt bythebylaws board directors roche holding ltd additionalinformationonemployeestockoptions organised ensure groups isprovidedinthefinancereportnoteto businesses conducted responsibly therochegroupconsolidatedfinancialstatements focusonlongtermvaluecreationtothisendthe employeestockoptionsandotherequity roche board delegated certain responsibilities compensationbenefitspage several committees composition rochehasissuednooptionsapartfromemployee chairpersons january described stockoptionsstocksettledstockappreciation committees authorities rightsssarsandoptionsissuedinconnection responsibilities defined detail bylaws withdebtinstruments board directors neithertheoptionsawardedtoemployeesnor allthecommitteesexceptthepresidiumarechaired thedebtinstrumentswhichhavebeenissuedhave byindependentdirectors anyeffectonrochessharecapital accordingtothebylawsoftheboardofdirectors attherequestofanyofitsmembersaboard board directors corporate executive meeting without chairman present may committee convened roche board meets year informationoneachmemberoftheboardof assessthechairmansperformancethismeeting directors including years attended chairman chaired electedandtheyearsinwhichtheirtermsend byoneofthevicechairmen member corporate executive committeeislistedonpagestocurricula vitaeandotherinformationincludinginformation httpwwwrochecomaboutrochemanagement boardofdirectorshtm board memberships available httpwwwrochecomaboutrochemanagement internet executivecommitteehtm theannualgeneralmeetingelectsthemembers httpwwwrochecomaboutrochecorporategovernance oftheboardofdirectorsinstaggeredelections articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance inwhicheachnomineeisvotedonseparatelysee annualgeneralmeetingshtm articles incorporation roche httpwwwrochecomaboutrochecorporategovernance holding ltdand minutes thannual articleofincorporationhtm general meeting roche holding ltd held httpwwwrochecomaboutrochecorporategovernance committeeshtm march httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm lrochearengcorporate governanceindd roche business report corporate governance theboardofdirectorshasestablishedasystemof remunerationcommitteethreemeetings controlswhichiscontinuouslymonitoredbythe approxtohourseach auditcommitteeandbythecorporategovernance themembersofthecorporateexecutivecommittee andsustainabilitycommitteeandconsistsofthe areinvitedtoattendforandreportinpersonon followingelements agenda items concerning reportsonfinancialandoperatingrisksrisk situation warrants members enlarged managementsystem corporateexecutivecommitteemayalsobeinvited systemofinternalcontrolsoverfinancialreport toattendtheboardcommitteesinvitethechair ingseepageandinthefinancereport man board corporate executive internalaudits committeememberstodeliverreportsatcommit groupcomplianceofficerandcompliance tee meetings may elect commission officersinsubsidiaries independentexpertreportsandcallontheservices safetyhealthandenvironmentalprotection consultants risk management system department subject continuous review findings corporatesustainabilitycommittee presented audit committee full scientificandethicsadvisorygroupseag board internalauditregularlybriefstheaudit forissuesrelatingtogeneticsandgeneticengi committeewithreferencetoongoingauditreports neeringestablishedin membersofinternalauditattendauditcommittee eachyearseveralblackoutperiodsareimposed meetingsasdoexternalauditorsforinformation duringwhichsenioremployeesareprohibitedfrom ontheexternalauditorsseepage tradingincompanystockthefollowingblackout management contracts fall periodsareineffectfor within scope subsection decembertofebruary sixdirectiveoninformationrelatingtocorporate apriltoapril governance junetojuly octobertooctober remuneration shareholdings loans blackoutperiodscanbechangedbythechairman alldetailsregardingremunerationshareholdings oftheboardofdirectorsifcircumstanceswarrant andloansaresetforthintheseparateremuner intheboardofdirectorsmetforfivemeet ationreportonpagestoandinthefinance ingseachfromtohoursinlengthoncefora reportnotesandtotherochegroup fulldaymeetingandonceforathreedayvisit consolidatedfinancialstatementsequityattribut toamajorsubsidiarywhichincludedaboardof abletorocheshareholdersandrelatedparties directorsmeetingtheboardcommitteesmet pagesandandarelistedinthenotes asfollowsin andtothefinancialstatementsofrochehold presidiumoftheboardofdirectorsnomination ing ltd board executive remuneration committeethreemeetingsapproxhours boardandexecutiveshareholdingspages auditcommitteefourmeetingsapproxto hourseach corporategovernanceandsustainabilitycom mitteethreemeetingsapproxhourseach remuneration committee members permitted con tribute attend remuneration committee meetings matters concerning deliberated decided figures indicate actual length meetings additional information provided finance report note include directors ' extensive premeeting preparations roche group consolidated financial statements risk postmeeting followup activities management lrochearengcorporate governanceindd participatory rights shareholders auditcommitteeseearticleofthebylaws theparticipatoryrightsofshareholdersaredefined thestatutoryauditorsparticipatedinallfour inrochesarticlesofincorporation asroche meetingsoftheauditcommitteein sharesareissuedtobearertherearenorestrictions onadmissiontoannualgeneralmeetingswith thereportsofstatutoryauditorsontheconsoli theexceptionthatsharesmustbedepositedwithin datedfinancialstatementsandonthefinancial aspecifiedperiodbeforethedateofameeting statementscanbefoundonpagesand andanadmittancecardmustbeissuedintheshare respectivelyofthisyearsfinancereport holders nameasprovidedinofthearticles incorporation shareholder elect kpmgreceivedthefollowingremunerationfor berepresentedbyanothershareholderatanannual theirservicesasstatutoryauditorsofrochehold general meeting articles incorporation ingltdandotherrochecompanies contain restrictions exercise voting rights quorum requirements stipulated conformity millions chf swiss codeofobligations auditing services underofthearticlesofincorporation auditrelated services shareholdersrepresentingshareswithanominal tax consultancy services valueofatleastmillionswissfrancscanrequest total theplacementofitemsontheagendaofan annualgeneralmeetingthismustbedoneno thestatutoryauditorsareelectedeachyearbythe laterthandaysbeforethedateofthemeeting annualgeneralmeeting change control defensive measures ernstyoungltdreceivedthefollowingremunera thearticlesofincorporationcontainnoprovisions tionfortheirservicesastheauditorsofgenentech onthemandatorybidruleswisslawapplies andchugai therearenochangeofcontrolclausesthose componentsofremunerationbasedonrochenes wouldbeterminatedintheeventofanacquisition millions chf andvestingperiodrestrictionsonpreexisting chugai genentech awardswouldberemovedsothatallsuchoptions chugai audits couldbeexercisedimmediately consulting services provided genentech relationship statutory auditors chugai attheannualgeneralmeetingofrocheholding total ltdonmarchtheshareholdersvoted toappointkpmgagkpmgasstatutoryauditors informationonhowlongtheauditorsandauditor inchargehavebeenservinginthesecapacitiesis providedonpagethestatutoryauditors participateinauditcommitteemeetingstheypre httpwwwrochecomaboutrochecorporategovernance parewrittenandoralreportsontheresultsoftheir articleofincorporationhtm auditstheauditcommitteeoverseesandassesses httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm theauditorsandmakesrecommendationstothe httpwwwrochecomaboutrochecorporategovernance boardforinformationontheresponsibilitiesofthe articleofincorporationhtm lrochearengcorporate governanceindd roche business report corporate governance information policy irregularitiesorcomplaintsintheircorresponding provided articles incorpora motherlanguageviaaspeakup hotlinethe tion corporatenoticesarepublishedintheswiss chiefcomplianceofficerreportsregularlytothe official gazette commerceandinotherdaily corporategovernanceandsustainabilitycommittee newspapersdesignatedbytheboardofdirectors basler zeitung finanz und wirtschaft lagefi nonapplicabilitynegative disclosure le temps neue zrcher zeitung itisexpresslynotedthatanyinformationnot rochereportsitshalfyearandfullyearresultsin containedormentionedhereinisnonapplicable businessreportspublishedinprintandonline oritsomissionistobeconstruedasanegative formatsandatmediaeventsinadditiondetailed declarationasprovidedinthesixswissexchange firstandthirdquartersalesfiguresarepublished corporategovernancedirectiveandthecom eachyearinaprilandoctoberthemostcurrent mentarythereto listofpublicationdatesisavailableinenglishand germanontheinternet allrelevantinformationanddocumentsincluding allmediareleasesinvestorupdatesandpre sentationstoanalystandinvestorconferencesare availableontheinternetfurtherpublications canbeorderedbyemail faxortelephonebasel webmasterrochecomtel fax thecontactaddressforinvestorrelationsis f hoffmannla roche ltd investor relations corporatefinancebaselswitzerland telfax additionalinformationincludingdetailsonspecific contactpersonsisavailableontheinternet chief compliance officer thechiefcomplianceofficerwithhiscompliance officersnetworkiscommittedtoensuringthat rochecorporateprinciplesareconsistentlycom pliedwiththroughouttherochegroupand alsoservesasacontactpersonforshareholders employeescustomerssuppliersandthegeneral publiconissuesrelatingtotheimplementationof andcompliancewiththeseprinciplesemployees andotherpartieswhobecomeawareofviolations ofrochecorporateprinciplescanbringthem totheattentionoftheirmanagersorsupervisorsor reportthemtothechiefcomplianceofficerurs jaislidirectphonenumber emailursjaislirochecomsuchdisclosures httpwwwrochecommediahtm willbetreatedconfidentiallyinadditionasofthe httpwwwrochecominvestorshtm endofemployeesmayanonymouslyreport httpwwwrochecominvestorscontactshtm lrochearengcorporate governanceindd remuneration report summary tionpolicyisdesignedtofostervaluecreationand rochessuccessdependsontheabilitiesand reinforceacultureofperformanceandinnovation dedicationofitspeoplerecognitionofthisforms anditappliestononmanagerialemployeesaswell thebasisofourremunerationpolicyandsystem astomanagersthekeyprinciplesunderpinningthis policyare oneoftheprimaryaimsofourremunerationpolicyis focusonvaluecreation toencouragealongtermfocusandalignmanage payforperformance mentsinterestswiththeinterestsofrochesshare enablingemployeestoshareinthecompanys holdersandholdersofrochesnonvotingequity success securitiesnes fairnessandtransparencyinremuneration decisions thisremunerationreportwillbesubmitted abalancedmixoflongandshortterm separatelyforapprovalattheannualgeneral remunerationcomponents meeting marketcompetitiveness theremunerationofcorporateexecutive committeececmembersandothersenior basepaybonusesblockednonvotingequity rocheexecutivesiscomprisedof securitiesnesawardsofstocksettledstock basesalary appreciationrightsssarsandaperformance bonus shareplansupporttheseprinciplestheseremu specialstockawardsnonvotingequity nerationcomponentsarelinkedtoourcompanys securitiessubjecttovestingperiodyears financialperformanceandcommercialsuccessand stocksettledstockappreciationrights thusaligntheinterestsofrocheemployeeswith ssars thoseoftheshareholderstheamountoftheseparate performanceshareplanpspawards componentsofremunerationforeachindividual withtheexceptionofseverinschwanandsilvia memberofthecorporateexecutivecommitteeis ayyoubinoneofthececmembersreceivedan shownintheindividualdescriptionoftheremunera increaseinbasesalaryin tionofthecorporateexecutivecommitteeinthis basedonrochessharepriceperformanceno report neswillbeawardedforthepspcycle thessarsgrantedinand base pay havestrikepricesabovethecurrentnespriceand basepaylevelsaredeterminedaccordingtomarket havenovaluefortherecipientsthiscanchange dataforspecificpositionsandindividualemployees ifrochesfuturenespriceimproves abilitiesexperienceandperformanceovertimepay therehasbeennochangeinthebaseremunera increasesarelinkedtoindividualperformanceand tionoftheboardofdirectorssince see stock optionsstocksettled stock appreciation rights pleaseseetherestofthisreportforfulldetails ssars april base pay corporate executive remuneration policy committee generally increased last time gottlieb keller resulted difference base pay rochefundamentallyreneweditsremunerationpolicy received calendar year see table inandreviseditwithminorchangesin due increase base pay april itispartofaframeworkofemployeepoliciesaimedat see also finance report note roche group consolidated financial statements related parties motivatingandretainingcurrentemployeesattracting notes financial statements roche holding talentednewonesandhelpingallrocheemployees ltd board executive remuneration board execu toperformatconsistentlyhighlevelsourremunera tive shareholdings lrochearengremuneration reportindd roche business report remuneration report alsotakeintoaccountprevailingmarketconditions isbasedonathreeyearcomparisonofthetotal affordabilityandthecompanysoveralleconomic shareholderreturntsrwithcompetingcompa situation niesintherewerethreeoverlappingperfor mancecyclespsppspand bonuses pspofwhichpspclosed bonusesareawardedinrecognitionofindividualcon ondecember tributionstovaluecreationwhichgobeyondnormaljob expectationsandtheyaremeanttobeanincentive detailsforthepspcalculationandaddi tocreateorstrengthennewbusinessopportunities tionalinformationaresetforthinremuneration andstriveforoutstandingresultsbonusamountsare ofmembersofthecorporateexecutivecommittee linkedtogroupordivisionalbusinessperformance dperformanceshareplanpsppage achievement individual functional measurableandqualitativeperformanceobjectives remuneration board directors theremunerationcommitteeoftheboardofdirectors corporate executive committee defined corporate executive committee eachyeartheremunerationcommitteewhichis membersbonusesindecemberbasedonresults entirelycomprisedofindependentexternalmembers achievedfor oftheboardofdirectorssetsremunerationforthe membersoftheboardofdirectorsandthecorporate special stock awards executivecommitteecashpaymentsbonuses innonvotingequitysecuritieshavebeen optionsstocksettledstockappreciationrightsand grantedtoaselectednumberofrocheemployees policydecisionsaboutpensionbenefitstheterms theawardsvestimmediatelybutareblockedfor oftheperformanceshareplanaredeterminedannu threeyearsrecipientshavetheoptiontoextendthe allybytheboardofdirectorsactinguponrecommen blockingperiodtotenyearsthegrantofthosenon dationsfromtheremunerationcommitteethe votingequitysecuritieswasawardedaspartofthe remunerationcommitteecontinuouslytrackssalary bonuspaymentsforwiththeaimtobothimme trendsinthemarketandreportstotheboardof diatelyrewardtheachievementofspecificobjectives directorsinformationonthiscommitteesremitand andtofostertheinterestinalongtermpositive itsproceduresformakingremunerationdecisions development canbefoundinthebylawsoftherocheboardof directors stocksettled stock appreciation rights ssars stocksettledstockappreciationrightswereintro followingtherevisionoftheremunerationpolicy ducedonjanuarythusestablishingauniform includingmarketcomparisonswiththeworldsmajor systemofremunerationthroughoutrochessars pharmaceuticalcompaniestheremunerationcom entitleholderstobenefitfinanciallyfromanyincrease mitteehasdeterminedthebonusesandremuneration inthevalueofrochesnonvotingequitysecurities ofthechairmanoftheboardofdirectorsthemem betweenthegrantdateandtheexercisedatedetailed bersofthecorporateexecutivecommitteetakinginto informationisavailableonpageandpageto considerationpersonnelchangesindoingsothe followingchangeswerenoted performance share plan themembersofthecorporateexecutivecommittee peer set abbott laboratories amgen astellas astra andothermembersofseniormanagementcurrently zeneca bayer becton dickinson biogen idec bristolmyers someindividualsworldwideparticipateinthe squibb eli lilly gilead glaxosmithkline johnson johnson merck co novartis pfizer sanofiaventis takeda performanceshareplanpspthepspwasestab httpwwwrochecomaboutrochecorporategovernance lishedinforperiodsofthreeyearseachand articleofincorporationhtm lrochearengremuneration reportindd afurtherimportantstepforthetransferofduties boardofdirectorsandbyeachmemberofthecorpo fromthechairmantotheceohasbeencompleted rateexecutivecommitteeforincomparison withthecompletionoftheintegrationofgenen withfiguresforpreviousyearsandanoutlookonthe techaccordinglytheboardplanstoreducethe chairmansremunerationdevelopmentfor chairmansbasepayinfordetailedinfor mationseepage remuneration ondecemberwilliammburnsjonathan remuneration members board kcknowlesandjrgenschwiezerretiredfrom directors inthemembersoftheboard company consequently stepped ofdirectorsreceivedtheremunerationshown membersofthecorporateexecutivecommittee inthetableremunerationofmembersoftheboard asofjanuarydanielodayhastaken ofdirectorsbelowfortheirboardactivities overaschiefoperatingofficercooofthe diagnosticsdivision remunerationofallmembersoftheboardofdirectors asofjanuarypascalsoriothastakenover willagainremainunchangedforthenon hisnewfunctionascooofthepharmaceuticals executivemembersoftheboardofdirectorswerenot division awardedanysharesnonvotingequitysecurities thefollowingpagesprovidedetailedinformationon list members positions committee mem theremunerationearnedbyeachmemberofthe berships chairmanship see remuneration members board directors additional compensation remuneration committee memberschairs chf chf additional special compensation fb humer see remuneration chairman board directors see b gehrig hoffmann p baschera ji bell p brabeckletmathe ljr de vink w frey da julius oeri w ruttenstorfer h teltschik compensation serving boards roche subsidiaries see b weder di mauro see exception members presidium vicechairmen board members receive chf year committee serve chf year committee chair see g highest total remuneration member board directors ' remuneration serving vicechairman board lrochearengremuneration reportindd roche business report remuneration report remuneration members corporate executive committee base pay chf annual salary annual salary annual salary schwan ayyoubi wm burns e hunziker ga keller jkc knowles j schwiezer p soriot total member corporate executive committee stocksettledstockappreciationrightsssars dollarsswissfrancsforherparticipation stockoptionsorrestrictedstockunitsrsusin atacourseonauditcommitteesinaneweraof horstteltschikreceivedhonorariaamountingto governanceatharvardbusinessschool eurosswissfrancsforservingon theboardsofseveralrochesubsidiariesingermany see stock optionsstocksettled stock appreciation rights beatricewederdimaurowasreimbursedus ssars bonus bonus bonus bonus special stock awards blocked nonvoting equity securities cash payment blocking value total cash payment cash payment chf number period years chf chf chf chf schwan ayyoubi wm burns e hunziker ga keller jkc knowles j schwiezer p soriot total member corporate executive committee day value grant nonvoting equity securities chf nes calculation value consideration reduction value due blocking period reduced market value years years excluding contribution ahvivalv swiss social security programmes providing retirement disability unemployment benefits day value grant nonvoting equity securities chf nes calculation value consideration reduction value due blocking period reduced market value years lrochearengremuneration reportindd forthemembersoftheboardofdirectors b bonus receivedremunerationtotallingswiss inthebonusforsomeofthemembersofthe francs corporateexecutivecommitteeisdividedintwoparts forthreeortenyearsblockednonvotingequity noadditionalremunerationwaspaidtomembersof securitiesgrantedinand theboardofdirectors cashpaymentdueforpaymentattheendof april remuneration members corporate executive committee thegeneralprovisions withtheelementofblockednonvotingequity assigningauthorityfordecisionsoncorporateexecu securitiesthebonusreflectsanevenstrongerlink tivecommitteeremunerationtotheremuneration tothelongtermperformanceofthecompany committeeandtotheboardofdirectorsareoutlined onpageofthisremunerationreportfor themembersofthecorporateexecutivecommittee see remuneration members board directors receivedremunerationtotallingswiss see remuneration members corporate executive francs committee af h excluding ahvivalv c stocksettled stock appreciation rights ssars ssars ssars ssars value chf value chf value chf schwan ayyoubi wm burns e hunziker ga keller jkc knowles j schwiezer p soriot total member corporate executive committee see stock optionsstocksettled stock appreciation rights ssars blackscholes value described stock optionsstocksettled stock appreciation rights ssars values according annual report atthepresenttimethestocksettledstockappreci franciscofrommarchtodecember ationrightsgrantedinandmostof receivedallowancesandtaxequalisationtotalling whichcannowbeexercisedfollowingtheendof swissfrancs thevestingperiodinfebruaryhavenovaluefor therecipients membersofthecorporateexecutive committeeadditionallyreceiveannualexpenseallow ancesofswissfrancstotallingswiss see strike prices table stock options ssars francswhilepascalsoriotwhowasbasedinsan lrochearengremuneration reportindd roche business report remuneration report performance share plan psp thesecuritiesmarketpricesanddividendyields themembersofthecorporateexecutivecommittee ieontotalshareholderreturntsrtoreducethe andothermembersofseniormanagementcurrently effectofshorttermmarketfluctuationssecurity someindividualsworldwideparticipateinthe pricesareaveragedoverthethreemonthsoctoberto performanceshareplanpsp decemberpriortothestartofaperformancecycle andoverthethreemonthsoctobertodecember inthepspmovedtooverlappingthreeyear attheendofthecycleifrochesecuritiesperform performancecycleswithanewcyclebeginningeach aswellasorbetterthanthoseofofthepeer yearintherewerethusthreecyclesinprogress setandinadditionrochestsrincreasesatleast psppspandpsp duringacycletheboardofdirectorscanelect thepspendedondecember toincreasethemaximumnesawardbyasmuch astwofoldintheeventthataninvestmentinroche undertheprovisionsofthisplananumberofnon securitiesunderperformstheaveragereturndelivered votingequitysecuritiesneshavebeenreservedfor bythepeercompaniesfewerornoneswillbe theparticipantsineachcyclethenumberofsecu awarded ritiesactuallyawardedwilldependonwhetherandto whatextentaninvestmentinrochesecuritiesshares inneswerereservedundertheplanformembers andnesoutperformstheaveragereturnonan ofthecorporateexecutivecommitteeasshownin investmentinsecuritiesissuedbyapeersetofcom paratorcompaniescomparisonsarebasedon see footnote performance share plan psp total estimated total estimated value value value psp awards psp awards psp awards target number target number nes nes psp nes psp awarded psp value chf value chf value chf schwan ayyoubi wm burns e hunziker ga keller jkc knowles j schwiezer p soriot total member corporate executive committee total estimated value psp none originally targeted nes awarded psp estimated value calculated using yearend price december chf per non voting equity security nes based number nes originally targeted subject changes number value nes awardable plan december december respectively spread relevant period time ie year board directors vote actual allocation nes originally targeted december december respectively according tsr achieved detailed calculation see annual report lrochearengremuneration reportindd thetableonpagetheboardofdirectorswill nonvotingequitysecuritiesnesuptoanamount decideontheactuallevelofnesorcashequivalent equaltooftheirannualsalaryatadiscount awardsfor cycles nespurchasedunderthisplanaresubjecttoa close theandfinancialyears holdingperiodwhichisfouryearsinswitzerland respectivelytheaimofthepspistoprovidean incentivetoparticipantstoachievesteadyvalue f remuneration emoluments loans growth gottliebkellerreceivedanonrecurringspecial payment swiss francs years attheendofthepspcyclebasedona serviceforthecompanyin pensionstotalling threemonthmovingaverageatconstantexchange swissfrancswerepaidtotwoformer rateswithdistributeddividendstotallingbil corporateexecutivecommitteemembersfour lionswissfrancsbillionswissfrancs membersofthecorporateexecutivecommittee billionswissfrancsbillion receivedatotalofusdollarsswiss swissfrancsthetsroftherochesecuritiesnes francsforservingonthechugaiboard andsharesrankedcomparedwithitspeer setofcompaniesoperatinginthesameindustry g highest total remuneration member thereforeaccordingtothetermsoftheplanthe board directors participantsreceivednoneoftheoriginallytargeted franzbhumerasthechairmanwasthemember nesseetableonpagefordetails oftheboardwiththehighesttotalremunerationfor seeremunerationofmembersoftheboard e indirect benefits ofdirectorspagetothechairmansremu employercontributionsmadeintosocialsecurity nerationconsistsofbasesalaryandbonusawards schemespensionplansandagroupwideemployee chairman board handover stockpurchaseplanrocheconnectinrespect executivefunctionasceoattheannualgeneral ofmembersofthecorporateexecutivecommitteeare meeting march receive showninthetableindirectbenefitsinbelow additionalssarsornesfromnewpspcyclesand rocheconnectisavoluntarystockpurchaseplan wasnolongerenrolledinanyrochestockoption offeringemployeestheopportunitytobuyroche planorssars indirect benefits payments pension fundsmgb ahvivalv roche connect tax consulting services chf chf chf chf schwan ayyoubi wm burns e hunziker ga keller jkc knowles j schwiezer p soriot total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits ahvivalv swiss social security programmes providing retirement disability unemployment benefits lrochearengremuneration reportindd roche business report remuneration report theboardofdirectorsintendstoreducethechair familieswhoarecloselyassociatedwiththembelong mansbasesalaryintomillionswissfrancs toashareholdergroupwithpooledvotingrights asofaprilhistotalremunerationincluding attheendofthisgroupheldshares bonusescontributionstopensionfundsandaddi ofissuedsharesdetailedinformationabout tionalcompensationexpenseallowancewilldepend thisgroupcanbefoundinthefinancereportnote ingontheachievementofobjectivesnotexceedthe totherochegroupconsolidatedfinancialstate maximumamountofmillionswissfrancs mentsrelatedpartiespageandinthenote tothefinancialstatementsofrocheholdingltd h highest total remuneration member significantshareholderspageinadditionas corporate executive committee ofdecemberthemembersoftheboard severin schwan ceo member ofdirectorsandpersonscloselyassociatedwiththem corporateexecutivecommitteewiththehighesttotal andthemembersoftheexecutivecommitteeand remunerationforseeremunerationofmem personscloselyassociatedwiththemheldsharesand bers corporate executive committee af nesasshowninthetableonpage pagetopagenoadditionalremunerationwas paid current former members corporate stock optionsstocksettled stock appreciation executive committee rights ssars atdecemberfranzb humerbeingtheonlymemberoftheboardofdirec security holdings directorsandrhoffmann torsholdingoptionsandasofjanuaryssars andandreasoeriandmembersofthefounders duetohisformerpositionasceoandthemembers highest total remuneration member board directors chf chf salary cash bonus special stock awards years blocked nonvoting equity securities total performance share plan total none awarded pension fundsmgb roche connect total value detailed calculation remuneration chairman ceo see annual report bonus form years blocked nonvoting equity securities nonvoting equity securities nes day value grant nonvoting equity securities chf nes calculation value including contribution ahvivalv consideration reduction value due blocking period reduced market value years franz b humer take part psp psp none originally targeted nes awarded psp award mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits includes additional compensation committee members payments tax consulting services remuneration serving chugai board including employer contribution ahvivalv chf lrochearengremuneration reportindd highest total remuneration member corporate executive committee chf chf salary cash bonus special stock awards years blocked nonvoting equity securities total ssars blackscholes value grant minus performance share plan total pension fundsmgb roche connect total value detailed information see annual report calculation see remuneration members corporate executive committee b bonus blackscholes value described stock optionsstocksettled stock appreciation rights ssars basic rules detailed calculation see remuneration members corporate executive committee performance share plan footnote respectively mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits includes annual expense allowance payments tax consulting services remuneration serving chugai board exclud ing employer contribution ahvivalv payments ofthecorporateexecutivecommitteeheldoptions forreasonsotherthanretirementwhilevested andstocksettledstockappreciationrightsssars optionsmustbeexercisedwithinalimitedperiodof firstintroducedonjanuaryasshowninthe timethefairvalueoftheoptionsiscalculatedat tablestockoptionsandssarson thedateofissueusingtheblackscholesformula andasiftheoptionsweretradablewithan alloftheoptionsshowninthetablewereissuedby deductionfortheaveragetwoyearvestingperiod rocheasemployeestockoptionseachoptionentitles theholdertopurchaseonerochenonvotingequity thessarsshowninthetableonwere securitynes introducedbyrocheonjanuaryinplace ofstockoptionsssarsentitleholderstobenefit underthetermsofthismultiyearoptionplanthestrike financiallyfromanyincreaseinthevalueofroches priceforoptionsshownwastheclosingpricefor nesbetweenthegrantdateandtheexercisedate rochenesonthelastdayoftradingpriortotheroche thestrikepriceforssarsunderthetermsofthis annualmediaconferencealloftheoptionsshown multiyearplanwastheclosingpriceforrochenes arenontradableonethirdoftheoptionsaresubject onthefirstdayoftradingaftertherocheannual toavestingperiodofoneyearonethirdhavea mediaconferenceallssarsvestwithinthreeyears vestingperiodoftwoyearsandonethirdavesting ofthegrantdateieonethirdvestattheendof periodofthreeyearsunvestedoptionslapsewithout oneyearonethirdattheendoftwoyearsandone compensationifemploymentisterminatedvoluntarily thirdattheendofthreeyearsvestedssarsmust lrochearengremuneration reportindd roche business report remuneration report security holdings december close relatives shares nes security holdings others number number numbertype number board directors fb humer stock options ssars see b gehrig hoffmann ubs longshort certificates linked roche bearer sharesroche nonvoting equity securities valor isin ch otc call options ubs ag roche nonvoting equity securities valor p baschera ji bell p brabeckletmathe ljr de vink american depository receipts adr rhhby us isin us w frey da julius nes oeri ubs longshort certificate linked roche bearer sharesroche nonvoting equity securities valor isin ch w ruttenstorfer h teltschik b weder di mauro total nes corporate executive committee schwan nes stock options ssars see ayyoubi stock options ssars see wm burns stock options ssars see e hunziker stock options ssars see ga keller nes stock options ssars see jkc knowles stock options ssars see j schwiezer stock options ssars see p soriot stock options ssars see total nes shares held shareholders group pooled voting rights listed sharesettled loan transaction august reported six swiss exchange lrochearengremuneration reportindd stock options ssars number stock options ssars held current former members corporate executive committee december ssars first issued total corporate execu tive committee schwan ayyoubi wm burns e hunziker ga keller jkc knowles j schwiezer p soriot total former corporate executive commit tee members fb humer none none strike price chf market price per nes december chf expiry date grant value per option starting per ssar chf blackscholes value minus ssars stock options franz b humer receive additional ssars beexercisedconvertedintoneswithinsevenyears strike prices expiry dates grant values ofthegrantdateandunexercisedssarslapse optionsandssarsareshowninthetableabove withoutcompensationthefairvalueoftheoptions thenumbersofoptionsandssarsascalculated iscalculatedatthedateofissueusingtheblack atthetimeofissuehavebeenenteredasvaluesin scholesformulaandasiftheoptionsweretradable thetableremunerationofmembersofthecorporate withandeductionfortheaveragetwoyear executivecommitteecstocksettledstockappre vestingperiod ciationrightsssarsonpage lrochearengremuneration reportindd hes sharpening weapons fight advanced breast cancer biotechnology infancy thirty years ago nobody would guessed would one day give rise completely new class powerful targeted medicines monoclonal antibodies mabs today mabs used successfully fight cancer also treat rheumatoid arthritis took courage skilful management longterm commitment enable roche invest technology early stage skill dedication people vital transforming mabs medical business success story today around two thirds roche drugs based biotechnology new approach joining mabs chemotherapy promises make treatment cancer even targeted fewer side effects tdm novel antibodydrug conjugate combines two antitumour strategies one medicine directed binding monoclonal antibody highly expressed cancer protein leading targeted delivery potent chemotherapy agent selectively kills cancer cells minimises damage healthy tissue bildstreckeengsindd bildstreckeengsindd corporate responsibility leading healthcare company goal develop make available products services address unmet medical needs real value society aim provide tangible improvements patients health quality length life core contribution responsible sustainable manner respects needs individual society environment make possible committed finding retaining talented people developing skills lrochearengcorporate responsibility partindd brief ourpursuitofscientificexcellenceenablesusto reportandonourwebsiteoureffortswererewarded addressunmetmedicalneedshelpingpatientslead inwhenrochewasnamedhealthcaresuper longerandbetterliveswepioneerdifferentiated sectorleaderinthedowjonessustainabilityindexes medicinesandtranslatethoseintobenefitsforpatients djsiforthefirsttimerochehasbeenincludedin throughoutreachprogrammesoureffortstounder thedjsiworldindexesforsixconsecutiveyearsand standdiseasebiologyandtodevelopmedicines isincludedintheftsegoodindex anddiagnosticsthatpreventdetectcorrectlydiag noseandeffectivelytreatdiseasehelpusachieve managing corporate responsibility ourgoalofpersonalisedhealthcarephcthroughout corporateresponsibilityisanintegralpartofourdaily ourvaluechain workratherthanthedutyofasingledepartment ourcorporatesustainabilitycommitteecscco asweseeitourgreatestresponsibilityistokeepup ordinatesourapproachwithrepresentativesfromall thisworkourmedicinestakebetweeneightand corefunctionsandbusinessesacrossthegroupthe twelveyearstobringtomarketsoafocusonlong cscreportstothecorporateexecutivecommittee termsuccessiscriticalwerunourbusinessina andtheboardscorporategovernanceandsustain sustainablemannerthatrespectsindividualssociety abilitycommitteethecscworkstoidentifyand andtheenvironmentandwefindretainanddevelop assesssignificantsocialethicalandenvironmental talentedpeopletomakethispossibleourvaluesof risksaswellasrelatedopportunitiesitalsodevelops integritycourageandpassionguidethedailybe andrevisescorporatepositionsandguidelineson haviouranddecisionsofallemployeesandweseek topicsofkeyinteresttoourstakeholdersinoctober evidenceofthesevaluesfromleadersinparticular thecschelditsfifthannualworkshop thesevaluesencapsulatetheworkingenvironment attendedbyaroundemployeesacrossthegroup andattitudesrequiredtocreateinnovativethinking maintopicsdiscussedwereaccesstohealthcare andthevalueofourproductsandservicesduring approach theyearthecscdevelopedfivenewpositionpapers wetrytobalanceeconomicprosperitysocialcommit ontopicsrelatedtocorporateresponsibility mentandenvironmentalprotectionineveryaspect ofourbusinesswebelievethiscreatesvalueforall objectives ourstakeholdersandhelpsearntheirtrustand remainoneofthetophealthcarecompanies commitmentengagingwithrelevantgroupsensures inthedjsi ourapproachiseffectivewehaveidentifiedsix integratebestpracticesfromgenentechs materialcorporateresponsibilityareas sustainabilityactivities innovationcapacities improveenergyefficiencygigajoulesper valueofrocheproductsandservices employeebybyfrom pricingandreimbursementconditions accesstorocheproductsandservices web relationshipwithstakeholders sustainability principles strategy management beinganattractiveandresponsibleemployer wwwrochecomprinciples stakeholder engagement wwwrochecomstakeholderdialogue wemonitortheeffectivenessofourapproachandour corporate sustainability committee charter progressintheseareasusingasetofkeyperfor wwwrochecomcsrcommittees manceindicatorskpisforwhichwenowhavetwo key performance indicators wwwrochecomsuskpipdf fullyearsofdatawhilethesekpisareforinternal safety health environment performance managementonlyweincludearangeofperformance wwwrochecomshefiguresandfacts measuresthroughoutthissectionofourannual employee topline figures wwwrochecomemployees lrochearengcorporate responsibility partindd roche business report corporate responsibility responsible practices howwedothingsisasimportantaswhatwedo providinginstantreportsandinformationbasedon thetrustofthemanydiversegroupsweencounterin historicalinformationcustomerfeedbackandmarket thecourseofourworkdependsonuscarryingout analysistoaidourplanning eachandeveryaspectofourbusinessresponsibly asaninnovationdrivencompanywefocusonunder customersatisfactionisparticularlyimportantin standingthemechanismsunderlyingthedisease consumerbusinessespatientswithdiseasessuchas andtranslatingthisintodevelopingproductsthat diabeteswhouseourproductsdailytendtogive improvepatientshealththisoftenmeansexploring regularfeedbackwhichispivotaltofutureproduct emergingtechnologiesastheycouldprovideim developmentwealsousedetailedmarketresearch portantmedicalbreakthroughsandformthebasisof andfocusgroupstodevelopproductsandservices ourproductpipelineinthelongtermatthesame thatsimplifydailydiabetesmanagement timewemustassessanyrisksorethicaldilemmas thatcuttingedgetechnologiesposewithgreat halfourdiagnosticsemployeesworkincustomer scrutinybeforeandwhileusingthem serviceandsupportwealsoencourageemployees withlittleornocontactwithcustomerstospend customer relationships timelearningabouttheirneedsforexampleroche ourcustomersrangefrompatientshealthcarepro diagnosticsinrotkreuzswitzerlandhasacustomer fessionalshospitalsandreferencelaboratoriesto orientationprogrammeduringwhichtechnical publicandprivatehealthcarepayersunderstanding specialistsspendninemonthsattendingworkshops andrespondingtotheirdifferentneedsandexpec visitinglaboratoriesandhospitalsandevaluating tationshelpstoimproveourcommercialeffectiveness whattheyhavelearnedbeforepresentingtheir variouscustomergroupsprovideinputinto findingstomanagementtheyworkedonprojects productprofilesforexampletheeaseofuseof includinganonlinesurveytohelpimprovetheway medicationinstrumentspecifications healthcareproviderscopewithmethicillinresistant clinicaldevelopmentplansforexampleby staphylococcus aureusamajorprobleminhospitals designingandparticipatingintrials publicationoftrialresults pandemic preparedness regulatoryfiling intheworldhealthorganizationwho developmentofhealthoutcomestudies declaredaglobalpandemicofhninfluenzainfor diseaseawarenessplansandproductinformation mationfromthewhoandtheuscenterfordis educationandawarenessprogrammes easecontrolandpreventioncdcindicatedthat treatmentguidelines tamifluwasoneofonlytwoapprovedantiviralswith activityagainstthenovelstraintheseeventstrig wealsoobtainfeedbackfromcustomergroups geredrochetoimplementitspandemicplanwhich throughourmedicalliaisonsandclinicalresearch hadbeenindevelopmentsincewithafocus associatesadvisoryboardsandeducationand onincreasingtamifluproductionanddistributionto awarenessprogrammesweareinvolvedin meetincreaseddemandandensurelowincome countrieshadaccesstothedrugourpoliciesforthe wecarryoutcomprehensivemarketresearchand prioritisationofdrugsupplywereinaccordancewith analysisoftenatadivisionalorlocalleveltohelpus preparing next influenza pandemic roles meetspecificmarketneedseachcountryorgani responsibilities roche stakeholders sationisresponsibleformanagingitsrelationship publishedinmay withitscustomersandsharingrelevantinformation withinthegroupwehavearangeofinitiativesto tamiflu stockpiles wehaveworkedwiththewho enablethissuchasuniteacompanywidedatabase andgovernmentstobuildstockpilesoftamifluand lrochearengcorporate responsibility partindd helpprepareforaflupandemicinwedo ahntestitallowsrapidandaccurateidentification natedthreemilliontreatmentcoursesforthewhos ofpatientsinfectedwiththevirussoappropriate rapidresponsestockpilewestoredthestockpile patientmanagementcanstartasearlyaspossible untilwhenthewhodistributedittoof theworldsneediestcountriesinwedonated emergingdataunderscoretheimportantrolethedrug andshippedanadditionaltwomilliontreatment playedinreducingtheimpactofthismostrecent coursesforthewhosregionalstockpilewhichhas flupandemicforexamplearecentstudybyjainetal alsobeendistributedtocountriesinneed fromtheuscentrefordiseasecontrolpublished inthenewenglandjournalofmedicinereportedon inmayweagreedtodonateafurtherfivemil theclinicaloutcomeofpatientshospitalisedwith lioncoursestoreplenishbothstockpileswealso hninfluenzainthestudyshowedthatanti agreedtoestablishastockpileoftreatment viraldrugsweretheonlytreatmentthatmadeastatis coursesofpediatriccapsuleswhichweprovide ticallysignificantdifferenceinhelpingpatientsto alongwithinstructionsformixingthecontentswith recoverandthatoseltamivirwastheantiviraltaken foodforchildrenunabletoswallowthemwhole inaroundofcases thisbringsthetotalnumberoftreatmentcourses donatedtoaroundmillion public policy theprivatesectorhasacrucialandlegitimaterole sincewehavebeenprovidinggovernments toplayindevelopingpublicpolicyweshareour tamifluatsubstantiallyreducedpricestoassisttheir expertisewithpolicymakerstohelpdevelopeffective pandemicpreparednesshoweverwerecognised lawsregulationsandpoliciesrelatingtopublic thatmanydevelopingcountrieswereunabletocreate healthaswellasmoregeneralareasaffectingour anadequatestockpileevenatreducedpricesinjuly businesssuchastaxpolicyourgoodpractice welaunchedthetamiflureservesprogramme guidelinesforworkingwithgovernmentofficialsguide toincreaseaccessinthesecountriesweproduce ouremployeesondoingsoinanappropriateand andstoretamifluforspecifieddevelopingcountriesat professionalmanner asignificantlyreducedpriceandspreadthecost overanumberofyearswewillshipthestockpileif muchofourpublicpolicyworktakesplacethrough thewhoannouncesaflupandemicorwhenagov ourmembershipofindustrybodiessuchasthe ernmentrequestsittodealwithanationaloutbreak europeanfederationofpharmaceuticalindustriesand associationsefpiatheeuropeandiagnostics tofurtherincreaseavailabilitywehavelicensed manufacturersassociationedmaandtheinterna companiesinchinaandindiatomanufacturegeneric tionalfederationofpharmaceuticalmanufacturers oseltamivirwehavealsosupportedtheeffortsofa andassociationsifpmaaswellastheirnational southafricanmanufacturerbygivingthemaccess memberswealsomeetdirectlywithpolicymakers totheknowledgeandskillsneededtoproduce suchasgovernmentspublichealthorganisations oseltamivirtheycannowproducethedrugfreelyas thinktanksandacademics wedonotenforcepatentsinsubsaharanafrica ourmajorpublicpolicyworkinincluded rochediagnosticsproducedapolymerasechain workingwiththeworldbusinesscouncilfor reactionpcrbasedtestforthehnstrainofthe sustainabledevelopmenteuropeanroundtable fluvirususingourlightcyclersystemwithinweeks ofindustrialistsandprinceofwalescorporate ofthevirusbeingidentifiedinnovemberthe leadersgrouponclimatechangeonpolicy usfoodanddrugadministrationgrantedemergency statementsaheadofthecopenhagenclimate useauthorisationofthisrealtimereadyinfluenza conferenceindecember lrochearengcorporate responsibility partindd roche business report corporate responsibility showingmembersoftheeuropeanparliament andareobtainedfromlivingsystemsusingadvanced aroundouranimalfacilityinbaselduringthe processesthatareverydifficulttoreproducemore developmentoftheanimalresearchdirectiveto testingisneededtodemonstratethesimilaritysafety demonstrateourwelfarestandardsandthe andefficacyoffollowonproductscomparedwiththe importanceofanimalresearchinhealthcare original coorganisingadinnerdebateonanimal researchintheeuropeanparliamentwiththe webelievebiosimilarsshouldbesubjecttowell europeanplatformforpatientorganisations definedandtransparentregulationsthatcoverdevel scienceandindustryepposi opmentapprovalandpostauthorisationprocedures explainingourpositiononproposedlegislation basedonthosefortheoriginalproducts coveringpharmacovigilanceinformationto patientsandcounterfeitmedicinestomembers inweworkedwithregulatoryauthoritiesand oftheeuropeanparliament industrybodiesparticularlytheinternationalfedera tionofpharmaceuticalmanufacturersandassocia combating counterfeits counterfeitpharmaceuti tionstoensurepolicymakersfullyunderstandbiosim calanddiagnosticproductsareillegalandaserious ilarsciencethisworkwillsupportthecreationof globalpublichealthproblemtheyendangerpatients appropriatepoliciesregardingfuturebiosimilarmono undermineconfidenceinhealthcaresystemsand clonalantibodiesandthenamingofbiopharmaceuti companiesinfringeintellectualpropertyrightsand calsrochehasalsomadescientificandmedical wastevaluablehealthcarebudgets presentationsonbiosimilarstoregulatorsscientists andotherkeyaudiencesandcontributedtoscientific wecontinuouslymonitorandimproveproductsecu journals rityandusetechnologytoquicklyidentifycounterfeits wetakepartinnationalandinternationalindustry political contributions rochedoesnotfinancially andgovernmentaleffortstostrengthenthelawim supportindividualpoliticiansanywhereusemploy proveenforcementtrainlocalofficialsandeducate eescanmakepersonalcontributionsthroughthe thepublic hoffmannlarochegoodgovernmentcommittee ggcavoluntarypoliticalactioncommitteeorpar inweupdatedourpositiononcounterfeiting ticipateintherocheactionprogramme whichisavailableonourwebsitewearetakingpart inanefpiapilotprojectinswedenofatracking integrity compliance systemwhichtracesdrugsbacktotheirsource therochegroupcodeofconductguidesour improvingpatientsafetyweapplyauniquebarcode employeesbusinessbehaviour toeachpackofmedicineproducedwhichpharma cistsscanwhendispensingthemedicinetocheckit indecemberwelaunchedtherochegroup isauthenticwecontinuetoprovideinputthrough speakuptelephonelineandwebservicefor efpiaintotheproposedeulegislationoncounter employeestoraiseconcernsaboutcompliancewith feiting thecodeofconductanonymouslyifpreferred athirdpartyorganisationoperatesspeakupand generic biosimilar products thepatentperi pricewaterhousecoopershasprovidedassurancethat odsforsomeinnovativebiologicalproductssuchas thesystemprotectsemployeesidentities proteinsandantibodiesareexpiringandproducts claimingtobesimilarareappearingonthemarket inbusinessethicsincidentswerereported whileitisrelativelyeasytocopychemicaldrugsbio tothechiefcomplianceofficerweinvestigatedthem logicalproductshavecomplexmolecularstructures allandtookcorrectiveactionswherenecessarywith lrochearengcorporate responsibility partindd employmentcontractsbeingterminatedasaresult inweintroducedasustainabilityriskmanage ofunethicalbehaviour mentprocessandtargetsforourmarketingagencies wealsointroducedanewstandardoperatingpro welaunchedseveralinitiativestostimulatetheshar cedureandrelatedtrainingtostrengthencompliance ingofbestpracticesamongrocheslocal withmarketingcodesinourpharmaceuticaland complianceofficersincludingacomplianceofficers diagnosticsbusinesses networkaseriesofregionalcompliancemeetings andadedicatedintranetsitethecomplianceofficers wedonotselloverthecountermedicinesandso helplinemanagerstocontrolriskslocallyandmeet donotadvertisedirectlytoconsumersinthemajority therequirementsofourgroupcodeofconduct ofourmarketsintheuswhereitislegaltoadver tiseprescriptionmedicineswehavedetailedpolicies wealsoupdatedourperformancemanagement inplacetoensurethisisdonelegallyandethically systemtoensureweassessemployeesnotjuston wesendalltelevisionadvertisingcampaignstothe whethertheyachievetheirobjectivesbutalsoon foodanddrugadministrationforapprovalbefore howtheyachievethem broadcast finallywesetupanexportcompliancecouncilto wedecidedtoendourmembershipofthepharma ensureourmanufacturinganddistributionsitesmeet ceuticalresearchandmanufacturersassociation thecomplexlegalrequirementsforsellingand phrmaintheunitedstatesandinsteadjointhe exportingourproducts biotechnologyindustryorganizationbioofwhich genentechwasalreadyamember risk crisis management ourriskmanagementcharterdefinesourrisk sustainable supply chain managementapproachandresponsibilitiesandis rochespentaroundbillionswissfrancsonprod availableonourwebsitealongwithafulllistof uctsandservicesintheserangefromraw riskstoourbusinessweincludesignificantsocial materialsandactivepharmaceuticalingredientsto environmentalandethicalrisksidentifiedinthe equipmentlaboratoryandofficesuppliesandser groupriskmanagementprocess viceslikeconsultancytravelandmarketingwemust ensurethesesuppliersmeetthenecessarysocialand responsible marketing environmentalstandardstosecurereliablesupplies therearestrictregulationsandindustryguidelines andenablethesustainablegrowthofourcompany onthesaleandmarketingofmedicinesanddiagnos ticstomakesuretheyareprescribedadministered ourapproachisto andusedcorrectlyandthatpatientsunderstand raiseawarenesswithoursupplyofficers thebenefitsandrisksoftakingthem raiseawarenesswithsuppliers helpsuppliersimprovetheirstandards healthcareprofessionalsneedtobeabletoselect developjointinitiativestoincreasetheirperfor thebesttreatmentoptionfortheirpatientswe mance providescientificandclinicallyrelevantinformation thatenablesthemtoprescribeoruseourproductsin weendorsethepharmaceuticalindustryprinciples circumstanceswhichdeliverthegreatestmedical psciprincipleswhichrequiresupplierstoimple benefittothepatientalistoftheexternalguidelines mentresponsiblesupplychainmanagementinthe andcodesofpracticewefollowwhenmarketing areasofethicssafetyhealthandenvironmentshe ourproductsisavailableonourwebsite socialresponsibilitymanagementsystemsinnovation andeconomicsustainabilityandarecommittedto lrochearengcorporate responsibility partindd roche business report corporate responsibility integratingtheseprinciplesintoourbusinessin clinicalresearchsuchaswhatthedifferenttrial wedevelopedanewsuppliercodeofconductwhich phasesareandwhattheendofatrialmeansforthe includesthepsciprinciplesandnowrequireallour patientstakingpart supplierstosignourcodeofconduct aspartofourclinicaltrialsprogrammewestore ourpharmaceuticalsanddiagnosticsdivisionsaudit biologicalmaterialsuchastissueorgansbloodand businesscriticalsuppliersandassessnewsuppliers otherbodilyfluidsinhumanspecimenrepositories toidentifyandcorrectproblemsusingexternaland orbiobankstheseareinvaluableforlearningmore internalauditorsweshareourexpertiseandprovide aboutdiseaseandexploringpossibletreatments trainingtohelpsuppliersimplementanyrequired theyalsocontainsensitiveinformationaboutthe improvementsinternalauditorscarryoutfollowup personwhoprovidedthesamplewearededicatedto inspectionstoensuresuppliershavemadethe protectingdonorsprivacyandensuringtheyarefully necessarychangesinweauditedsocialand informedabouthowtheirsampleanddatawillbe safetyhealthandenvironmentalstandardsat usedbeforetheyagreetotakepart existingsuppliersandcarriedoutfollowupaudits atfivewerejectedorceasedtradingwithonesup wehaveaclearprocedureforresolvingethical plierthatwecouldnothelptoimprovethemain dilemmasemployeesencounterintheirworkifthey areaforimprovementourauditsflaggedupwas cannotresolvetheissuewithintheirteamemployees industrialhygiene cancontactourglobalethicsliaisonofficewhich willconsultpeersandinternalexpertstofinda weareintheprocessofextendingoursustainable solutionaninternalcommitteehandlesanyremaining procurementactivitiestosuppliersofnonproduction concernsandourindependentclinicalresearch materialsandservices ethicsadvisorygroupcreagprovidescounselon thetoughestchallengeswealsoprovideregular wehaveestablishedafinancialriskmanagement onlineethicstrainingforemployeesintheglobal processinprocurementtoidentifysuppliersatriskof ethicsliaisonofficereceivedqueriesallwere bankruptcyandtomitigatethoseriskswecontinued resolvedwithoutescalation toapplyoursupplychainriskmanagementprocess toallsuppliersofkeyrawmaterialsdrugsubstances thecreagmeetsannuallytoreviewconcernsraised anddrugproductswealsoworkedwithsuppliers withtheglobalethicsliaisonofficeanddiscuss ofmaterialsforkeyrochedrugproductstoensure otherrelevanttopicsinweupdatedthecreag theyhavebusinesscontinuityplansforpandemicrisk onrecentquerieshandledbytheglobalethicsliai sonofficeaswellasonthestatusoftheemployee research practices ethicseducationprogrammesthecreagalso ethicalconcernssometimesariseaswepushscientific reviewedthelatestrevisionstothedeclarationof boundariesandexplorenewtechnologiestodevelop helsinkiastatementofethicalprinciplesformedical innovativenewtherapiesanddiagnosticswemust researchinvolvinghumansubjectsreleasedbythe exploreandcarefullymanagetheseconcernsto worldmedicalassociation ensuretheopportunitiespresentedarenotlost anotherindependentpanelthescienceandethics ethics r ourglobalpositiononclinical advisorygroupseagadvisesandguidesus researchcommitsustohighethicalstandardsand ongeneticsgenomicsandproteomicsinthe clarifiesourpositiononspecificareasofconcern seagadvisedonissuesincludingtheuseand weupdatedthispositionintoincludestraight storageofhumanbiologicalmaterialsinspecific forwardanswerstofrequentlyaskedquestionsabout researchprojectsweexpandedtheseagsadvisory lrochearengcorporate responsibility partindd breakdown animals used research inthescientificcategoryfirstplacewenttoateam whichfoundanewinvitrotestfordetectingtoxic compoundsbeforetestingnewdrugsonanimalsour mice diagnosticsbusinessdevelopedthetestwhichisnow rats availableforpharmaceuticalpreclinicalresearchthe winningprojectinthelabcareandanimalmanage guinea pigs mentcategorygraduallyrehabilitatedmonkeysthat hamsters hadbeenhousedindividuallybackintolargergroups gerbils increasingtheirsocialinteractionandimprovingtheir fish wellbeingwewillimplementtheseandotherprojects frogs intoouroperationswhereverpossibleandrunthe dogs rsawardagainin rabbits primates inwecreatedanewjointscienceandtechnol ogylaboratoryinbaselbetweenthepharmaceuticals anddiagnosticsdivisionsaimedatinvestigating organtoxicitiesofdrugsusinganinnovativecellana functionswiththeiragreementtocoverallinnovative lysersystemxcelligenceresearcherscantest technologiessuchasnanotechnologyandstemcell whetherpharmacologicallyactivesubstancesare research likelytoprovetoxictoorganssuchastheheartand liverbycontinuousrealtimeviewingofthecells animal welfare werecogniseandtakeseriously reactiontothemoleculethiscanbeperformedin publicconcernaboutanimalresearchhoweverwe theearlypreclinicalstageofresearchmakingmany couldnotdeveloplifesavingmedicinessuchascan animalstudiesredundant cerdrugswithoutitwhileweworkhardtofindand usealternativemethodsthelimitationsofthose wealsoestablishedaninternalanimalwelfareethics methodsmeanwestillneedtotestnewdrugsand committeetoexamineallstudiesinnonhuman technologiesonanimalsforsafetyandlegalreasons primatesbeforeregulatoryapprovalandtoadvise employeesworkingwithanimalsthiscommittee inweusedatotalofanimalsinour willbecomefullyoperationalin researchofwhicharoundweremiceandrats innovation new technologies evolvingtech wearecommittedtothersconceptofreplacing nologiessuchasnanotechnologystemcellresearch animaltestswherepossiblereducingthenumberof andsystemsbiologyhavemanypotentialbenefitsin animalsweuseandrefiningexistingscientificprac pharmaceuticalsanddiagnosticstheseadvantages ticesanimalwelfareandhusbandryallemployees mustbecarefullybalancedwiththeethicaldilemmas andcontractorswhoperformanimaltestingforus andpotentialrisksposedandweassessthesewith mustcomplywithapplicablelawsandmeetorexceed greatscrutinybeforeenteringnewfields industrystandards nanotechnologyisthemanipulationofmaterialson wecontinuedourrsawardforinnovationand ascaletimessmallerthanthediameterofa continualimprovementinanimalwelfarewithin humanhairithaspotentialinmanyareasparticularly rocheinfifteenteamsofscientistsandanimal drugdeliveryregenerativemedicineandsmallscale carespecialistsfromourresearchsitesenteredfor portablediagnosticshowevermanyquestions awardsintwocategories remainabouttheeffectsnanotechnologymayhaveon lrochearengcorporate responsibility partindd roche business report corporate responsibility peopleandtheenvironmenttherisksandbenefits lobbythroughefpiaontheproposedeu havetobecarefullyevaluatedbeforenanotechnology legislationoncounterfeitmedicinalproducts isusedinmedicalproductswebelievethatexisting establisharsdatabaseforsharingbestpractices safetytestsandregulationsprovideanappropriate inanimaltestingwithinroche frameworkfordoingso launchrochesethicscommitteeonanimal welfare stemcellsandtheirapplicationsofferanenormous commenceauditofsuppliersinindirectspend potentialforthetreatmentandreliefofchronic painandevenforthecureofdiseasesextendingand web enhancingthequalityoflifehowevertheresearch responsible marketing risk management compliance alsoraisesethicalquestionsbecausesomepeople wwwrochecombusinessintegrityandresponsiblemarketing wwwrochecomriskmanagementandcompliance believeembryonicstemcellsarehumanswitha pandemic influenza tamiflu information righttolifeandshouldnotbeusedinresearchor wwwrochecomrocheinfluenza treatments wwwpandemictoolkitcom pharmaceutical industry principles responsible supply chain management rocheiskeenlyawareofthetremendouspotentialof httppharmaceuticalsupplychainorg thisresourceforbasicscienceandfuturehealth patents counterfeiting biosimilars careapplicationswehavethereforeenteredinto wwwrochecommedicalvaluepatentsandpricing wwwrochecompatents researchcollaborationsforexampleweworkwith innovation new products technologies stemcellssafermedicinesscsmintheuk wwwrochecomcsrresearchanddevelopment andwithcellulardynamicsinternationalincinthe wwwrochecominnovationandtechnologies usrochebeganstemcellresearchanditsrelated position papers wwwrochecompoliciesguidelinesandpositions applicationasadiscoverytoolandweplantobegin researchtousestemcellsasapotentialtherapeutic modalityrochealsoplanstodevelopexpertise tobecometechnicallyenabledinthisresearcharea andtoconductresearchonhumanembryonicstem cellsandtheiruseindrugdiscovery inweheldastemcellresearchworkshopin partnershipwithcambridgeuniversityintheuk attendeesincludedrochespecialistsand academicexpertstheydiscussedstemcellscience andpossibleapplicationsaswellasstepsforindus trytotaketomaximisethemedicalandbusiness opportunitiespresented objectives implementtherochegroupspeakupline launchtherevisedrochegroupcodeofconduct andupdatethebehaviourinbusinesselearning programme rolloutnewsuppliercodeofconductandinclude compliancewiththisinourexistingsupplieraudit programme lrochearengcorporate responsibility partindd patients patientsinallaspectsofhealthcarebenefitfromour themajorityofhealthcarepayersrecognisethemedical productsandservicesourdifferentiatedmedicines andeconomicvalueofourproductsforexample anddiagnosticscomefromdiverseapproachesto whilecancerdrugssuchasherceptinandxeloda researchanddevelopmentweconstantlypursue mayseemcostlynotonlydotheyextendthelivesof scientificexcellencewhichhelpsustailorourprod patientswithterminalillnessandpreventdisease uctsandservicesinawaythatensurespersonalised recurrenceinpatientswithearlierstagecancer healthcarethismeanspatientscanleadlonger theycanalsoeasepressureonhealthcarebudgets andbetterlivesbecausetheyreceivetreatmentsthat byreducingorpreventinghospitalvisitssurgeryand moreeffectivelypreventandcurediseasealleviate theneedforpalliativecareinmanycasestheyhelp symptomsandhastenrecovery patientsreturntoworkmorequickly wecanamplifythiscontributiontosocietyby inwepublishedanewpositiononassessing helpingtoimproveaccesstoourproducts thevalueofourproductsandserviceswhichcontains ensuringtheyprovidevalueformoney aseriesofguidingprinciplesforcarryingoutsuch providingfactualinformationonourproducts assessmentsweemployexperiencedhealthecono listeningandrespondingtocustomersviews mistswhoworkwithhealthauthoritiestounderstand andproviderobustevidenceregardingtheeconomic value medicines diagnostics andhealthbenefitsofourproductsandservices differentpeopleexperiencediseaseandrespond withintherelevantregionalandlocalhealthcare totreatmentindifferentwaysourapproachof systems personalisedhealthcarephctakesthisintoaccount andfitstreatmenttodifferentgroupsofpatients wealsoengagewithhealthcarepayersthroughout weuseourdiagnosticexpertisetodeepenourunder aproductslifecycleweprovideguidanceonassess standingofdiseasehowtreatmentsworkandhow ingthevalueofourproductsandserviceshealth differentpatientsrespondthishelpsusdevelop technologyassessmenthtapriortothemdecid bettersaferdrugsandidentifythepatientswhowill ingreimbursementandfundingconditions benefitmostimprovingclinicaloutcomesand increasingcosteffectivenessinwepublished global access healthcare anewpositiononpersonalisedhealthcareto patientscanaccessourproductsthroughdoctors describeourapproachinmoredetail hospitalslaboratoriesandpharmaciesinroughly countrieswhilewesellthemajorityofourprod healthcarepayershavetomakedifficultdecisions uctsindevelopedcountrieswithadvancedhealth aboutgrantingaccesstoorprovidingreimbursement caresystemsaroundathirdoftheworldspopulation forhealthcareproductsandservicesbasedon lacksadequateaccesstohealthcaretheworld costeffectivenessandbudgetconstraintsaswellas healthorganizationwholistsmanyofourproducts medicalneedandclinicalimpactthesedecisions asessentialmedicines haveaprofoundeffectonpatientsandtheirfamilies andcaninfluencewhereresearchbasedcompanies ourindustryhasanimportantroletoplayinparts likerochefocustheirfutureinvestmentobjective oftheworldwherehealthcarestandardsandaware consistentandopenprocessesareessential nessofthecausespreventionandtreatmentof forassessingthetotalvalueofmedicalproducts diseasearelowerbuttherearemanyothersystemic toindividualpatientsandtosocietyasawhole problemscontributingtohealthinequalitiesand throughouttheirlifecyclesothatthedecisionsmade wecannottacklethesealoneweworkwithgovern arefair mentsnongovernmentalorganisationsngos patientgroupsandhealthcareproviderstotackle lrochearengcorporate responsibility partindd roche business report corporate responsibility healthinequalitiesandincreaseaccesstoour servicetospeedupthedeliveryofhivtestresultsin productswetailorourapproachindifferentregions remoteareas tocaterfortheirspecificneeds cancerkillsmorepeopleindevelopingcountrieseach access need theworldsleast yearthanaidsmalariaandtuberculosiscombined developedcountriesldcsarehardesthitbydis morethanhalfofallcancercasesareinthedevelop easeandhavethepooresthealthcaresystemstodeal ingworldbutonlyaboutofglobalcancer withthisburdentherearetoofewhospitalslabora resourcesarespentthereinternationalhealthcare toriesandhealthcareprofessionalstomeetdemand programmesfocusoninfectiousdiseasesandthere weaimtoincreaseaccesstohealthcareinpoor isverylittleoncologyinvestmentinfrastructureor countriesinsustainablewaysthatinclude expertiseasaleadingproviderofcancertherapies fairpatentandpricingpolicies wehaveanimportantroletoplayintacklingthis rdintodiseaseswithunmetmedicalneeds badlyneglectedproblem partnershipswithgovernmentsngosandothers educationtrainingandknowledgetransfer inweevaluatednewpartnershipstoimprove trainingincancercareforhealthcareworkersinsub ourapproachistojointlydevelopaccessprogrammes saharanafricawewillfocusonsharingourexpertise thatraiseawarenesseducateandtrainandassist ratherthansimplycashordrugdonationsaswe indevelopinghealthcareinfrastructurethiscollabo believethatbuildinglocalcapabilitieswillmakeabig rativeapproachensuresneedsaremetwhilefuture gerdifferenceinthelongtermtrainingwilltake businessopportunitiesforbothsidesareenhanced placelocallytoencouragehealthcareprofessionals throughtheincreasedcapabilityofinstitutionsand tostayintheirhomecountryratherthanleavingfor organisationsindevelopingcountries opportunitiesabroad theillustrationshowsthecircumstancesunderwhich wealsojoinedthechangingdiabetesinchildren wedonotfileorenforceanypatentsitalsoillustrates programmeinthisisapublicprivatepartner ournoprofitpricingpolicyinaction shipbetweennovonordisktheworlddiabetes foundationandgovernmentsinafricancountries inwecompletedourtechnologytransferini theprojectaimstomakelifebetterforthegrowing tiativettithroughwhichwesharedtheknowledge numberofdiabetespatientsinafricawherethe requiredtoproduceourhivtreatmentsaquinavir standardofcareisoftenpoortheobjectiveistopro withlocalmanufacturersfreeofchargeweworked ducecareguidelineseducatehealthcareworkersand withallinterestedmanufacturersandreached ensureallchildrenenteringtheprogrammeareregis agreementwithcompaniesintheldcswhichare teredandmonitoredsotheirconditioncanbecon nowfreetoproducesaquinavirorusethisknow trolledthefirstphasewilltargetcameroonthe ledgetoproduceotherproductswealsoheldthree democraticrepublicofcongoguineaconakry africangoodmanufacturingpracticegmptrain tanzaniaanduganda ingseminarstoimprovelocallyproducedessential medicines inwegavetheinstituteforoneworldhealth accesstoourchemicalcompoundlibrarysoitcould wealsocontinuedourpartnershipwiththeclinton searchfornewmedicinestotreatchildhooddiarrhea foundationshivaidsinitiativechaitogetherwe oneworldhealthcompletedthefirstscreeningin haveestablishedandtrainedsevenlabsforhivtest andidentifiedcompoundstoinvestigateas ingdevelopedanovelsolutionfordiagnosingand possiblenewtreatments monitoringhivininfantsanddevisedatextmessage lrochearengcorporate responsibility partindd people living hiv covered profit prices antiretroviral medicines global access healthcare pricing patents nopatentsfiledorenforcedonanymedicines leastdeveloped countries twoantiretroviralhivmedicinessoldatnoprofitcoveringofhivpatients valcytesoldatreducedpricestongostreatingaidsrelatedcytomegalovirus pricing patents nopatentsfiledorenforcedonantiretroviralhivmedicines subsaharan african countries twoantiretroviralhivmedicinessoldatnoprofit valcytesoldatreducedpricestongostreatingaidsrelatedcytomegalovirus pricing low lower twoantiretroviralhivmedicinessoldatreducedprofit middleincome economies planning pandemic influenza tamifludonatedtoworldhealthorganizationstockpilesforcountriesmostinneed tamiflusoldatreducedpricestodevelopingcountries tamiflureservesprogrammecreatesstockpilesfordevelopingcountries tamiflusublicensingagreementsinchinaandindiaandtechnologytransfer agreementinsouthafrica access programmes rochepatientassistanceprogramandgenentechaccesssolutionsprovideadvice wealthy nations andfinancialsupportforuninsuredorunderinsuredpatients overpatientsbenefittedfromthesepatientassistanceprogrammesin tackling hivaids aidstechnologytransferagreementsinbangladeshethiopiakenyasouthafrica developing world tanzaniaandzimbabwe employeesecondmentsinethiopianigerswazilandandtogo unicefeuropeancoalitionofpositivepeopleaidsorphanprogrammesinmalawi amplicaresupplieshivviralloadtestsinsubsaharanafricasouthamericaand theleastdevelopedcountries clintonfoundationhivaidsinitiativechaiinsubsaharanafrica broader healthcare partnerships phelophepahealthcaretraininruralsouthafrica developing world newoncologysustainabilityinitiativeinsubsaharanafricain changingdiabetesinchildrenwithnovonordiskandtheworlddiabetesfoundation incameroonthedemocraticrepublicofcongoguineaconakrytanzaniaanduganda instituteforoneworldhealthoninfectiousdiseases googleorgoninfectiousdiseasesinkenya lrochearengcorporate responsibility partindd roche business report corporate responsibility injulyweteamedupwithgoogleorgonanini access developed world weworkclosely tiativetohelppredictandpreventemerginginfectious withpayersinallcountriestodemonstratethemedi diseasesineastafricarochedonatedagenome calandeconomicvalueofourproductsandwe sequencingsystemtobeinstalledintheinternational establishpricesthatenableaccesshowevermany livestockresearchinstitutelaboratoryinnairobi peopleindevelopedcountriescannotaffordtreat kenyatheinitiativewillbeginbyinvestigatingrift mentortheinsurancetopayforitintheuswhere valleyfeveradiseasespreadbymosquitoeswhich asyetthereisnouniversalhealthcaresystemwe ispotentiallylethaltopeopleandlivestock providefreedrugstothoseinneedthroughboththe rochepatientassistanceprogrampapandthe weproducedourfirstaccesstomedicinesanddiag genentechaccesstocarefoundationgatcfin nosticsreportinthiscontainsmoredetailsof patientsbenefitedfromthepapand allourpoliciesandprogrammestoincreaseaccessto patientsreceivedfreetreatmentthrough ourproductsandisavailableonourwebsite gatcfwealsosupportindustryeffortstoraise awarenessofassistanceprogramsviathepartnership access emerging markets healthcareinmiddle forprescriptionassistance incomecountriesisimprovingandpresentsasub stantialopportunityforrochehowevereachcoun infollowingthemergerofrocheandgenen tryshealthcaresystemisatadifferentstageof techgatcfwillassumeresponsibilityfortheroche developmentandhasitsownspecificneedswe pappatientstocreateoneofthefivelargestcharita workinpartnershipwithgovernmentsinthesecoun blefoundationsintheus triestohelpestablishprocessesandclinicaltrialpro grammesandimproveeducation gatcfispartofgenentechsbroaderprogramme tohelppatientsgainaccesstoprescribedtherapies ourdedicatedmedicalaffairsgroupdevelops thegenentechaccesssolutionsdepartmentcom specificprogrammesforindividualemergingmarkets prisesnearlyemployeeswhohelppatientsnavi wheremanypatientscannotaffordthelongterm gatethecomplexusreimbursementlandscape treatmentnecessaryfordiseasessuchascancer hepatitiscandrheumatoidarthritisinchinafor forinsuredpatientsgenentechaccesssolutions exampleweoffercostsharingprogrammesforour clarifiesbenefitscoverageandreimbursementre oncologydrugstoensureaccesstothepatientswho quirementshelpingfindwaystoassistincovering willbenefitmostinsouthkoreaourreducedprices patientexpenseswherepossibleuninsuredpatients forcancerdrugscovertheentirepopulationwhilein orpatientswhoqualifyforassistancecanobtainfree egyptwhichhasoneofthehighestratesofhepatitis medicinefromgatcf cinfectionintheworldweprovidepegasysata speciallowpriceforpublicsectorpatients intheserviceadvisedpeopleaboutcov erageandreimbursementissuesandgatcfprovided wealsosupplyourproductstoprivatepayersin patientswithfreetreatmentworthatotalof emergingmarketsandworkwithinsuranceand millionusdollars reinsurancecompaniesinchinaandrussiato expandprivateinsurancecoverageandincrease injapanchugaiestablishedtheacademyforad accesstoourmedicineswecontinuetosupply vancedoncologychaaointohelpbring twohivmedicinesatreducedpricesinthelow standardsofcancerresearchandtreatmentuptothe andlowermiddleincomecountriesdefinedbythe samestandardsasthoseineuropeandnorthamerica worldbank lrochearengcorporate responsibility partindd impact access programmes patients facilities benefiting clinical trials excludes genentech hivinfected patients living countries eligible number clinical trials noprofit medicines number healthcare centres hivinfected patients involved living countries eligible number patients phase reducedprice medicines iiv clinical trials patients benefiting usa patient assistance programmes presentbothresearchandclinicalfindingsatmedical andscientificmeetingsandengagewithkeyleaders clinical trials ineachfield clinicaltrialsareessentialtodemonstratethesafety andefficacyofnewdrugstheyalsoprovideeduca wecollecttheinformationgainedthroughclinical tionalfinancialandmedicalsupportforparticipating trialsandpostmarketingsurveillanceandusethisfor hospitalsandaccesstothelatesttreatmentsfor acontinuousassessmentofthebenefitsandrisks cancerarthritisandotherdiseasespatientstaking ofaproductindevelopmentoranestablishedmedi partintrialsreceivefreeaccesstothemostadvanced cinewealsouseittobetterplannewclinicaldevel therapiesduringthetrialandwhentherearenovalid opmentprogrammesweprovidethisinformationto therapeuticalternativesthiscontinuesuntilthedrug regulatoryauthoritiesasrequired isavailableforsaleoronprescriptionwedonot performclinicaltrialsincountrieswherewedonot weapplystrictdataprotectionprinciplestoall plantomarketthedrug personalmedicaldatacollectedduringclinicaltrials inlinewithourdirectiveontheprotectionofpersonal peopleseekingnewclinicaltrialstotakepartinor datatheseprinciplesapplyequallytodataabout wishingtolearnfromtheresultsofcompletedtrials ourcustomerssuppliersandemployees canaccessthisinformationatwwwrochetrialscom patient safety asofdecemberthesitecontaineddetails allmedicinesmaycauseadverseeffectssideeffects ofpharmaceuticalprotocolsdiagnosticproto insomepatientsourpriorityistomakesuretheben colsandtrialresultsthesestudiescovermore efitsoftakingourproductsinclinicaldevelopment thanconditionsincludingalzheimersdisease andourmedicinesoutweighanyidentifiedorexpec asthmaaroundcancerscardiovasculardisease tedsafetyriskwehaverobustprocessesoperating depressiondiabeteshepatitishivaidsinfluenza worldwidetounderstandourmedicinesandtheir andobesitythewebsitehadmorethan adverseeventsandtominimisetheirlikelihoodmedi pagevisitsinrepresentingmorethan cinesareregularlyanalysedagainstvariousreference visitorsdetailsofourclinicaltrialsarealsoavailable databasestohelpusdetectpotentialsafetysignals throughtheinternationalfederationofpharmaceu allourproductsinclinicaldevelopmenthavean ticalmanufacturersandassociationsifpmaclinical individualsafetymanagementplanandallourmedi trialsportalatwwwifpmaorgclinicaltrialsand cineshaveariskmanagementplanreviewedand theusnationalinstitutesofhealthsglobalregistry approvedbymajorhealthauthorities atwwwclinicaltrialsgovwepublishourclinical trialdatatoensurethatalllessonsfromthesetrials continuousmonitoringandworkingwiththehealth aremadeaccessibletothewidercommunitywealso authoritiesenableregularupdatestoprescription lrochearengcorporate responsibility partindd roche business report corporate responsibility instructionslabellingandproductinformation wesupportwepubliclylistpatientgroupswegive includingemergingsafetyinformationcontraindica nonfinancialsupporttoifthesupportissignificantor tionandspecialprecautionsofusewhennecessary meaningfulasguidedbyeuropeanfederationof lettersaresenttophysiciansandhealthcareprovid pharmaceuticalefpiaindustriesandassociations ersallowingthemtoadjusttheirmedicalpractice examplesofpatientadvocacywesupportedin diagnosticsproductsmaygiveerroneousresults includetheworldhepatitisalliancesworktoraise causedbyaproductperformanceoruserhandling awarenessofviralhepatitisandpromoteactionto issuethiscouldeventuallyleadtoanincorrectther improvepatientcarewecontinuedtosupportthe apyforapatientduringthedevelopmentofdiagnos europeanpatientsrightsdayorganisedbyactive ticproductsextensivetestingisperformedusing citizenshipeachyearinpatientgroupsin patientsamplesundervariousrealisticconditionsto europeancountriescelebratedthethirdpatients ensureoptimalperformanceofthefinalproduct rightsday weinvestigateallreportedadverseeventstoascer education awareness tainiftheyarerelatedtoourproductsifthereisa ouraffiliatesoftengetinvolvedininitiativestoraise linkwereevaluatewhetherthebenefitsofthemedi awarenessofdiseaseforexamplerocheturkey cineordiagnosticproductstilloutweightherisks heldaonedaycyclingeventatashoppingmallin wealsohaverobustproceduresinplacetopromptly istanbulinpartnershipwiththeturkishbicycle informpatientsphysicianshealthcareproviders federationandtheministryofhealthscancercontrol andregulatorsofanynewproductsafetyinformation departmentrochemadeadonationtothepatient organisationhandinhandagainstcanceronbe wehavearobustprocesstoensurethatproducts halfofeachpersontakingpartdemonstrations canberecalledrapidlyandwithdrawnfromcirculation onprostheticbreastshelpedtrainwomeninself ifunanticipatedissueswiththeirqualityarisein examination therewerenorecallsinvolvingthepublic inbrazilmillionpeoplehavediabetesbut patient advocacy donotrealiseitrochediabetescarechallenged wesharewithpatientgroupsaninterestinhelping fashionstudentstodesignapracticalandfashionable patientsunderstandandmanagetheirdisease accessoryforcarryingaccuchekbloodsugartests andgainaccesstotheinformationandtreatment andotherdiabetescareitemstoraiseawareness theyneed ofthediseaseamongteenagersandyoungadults whiletheiraimsvaryeachpatientgroupinteracts goals withmanypatientsandcarersunderstandstheir initiaterocheoncologysustainabilityinitiativein needsandprioritiesandknowshowtoprovideemo subsaharanafrica tionalsupportandpracticaladvicewedescribe expandpartnershipwithalberteinsteincollegeof ourapproachtoworkingwithpatientgroupsinour medicineinethiopiatoincludeoncologytraining positionstatementandguidelinesforworkingwith hostincollaborationwithnovonordiskandthe patientgroupswhichareavailableonourwebsite worlddiabetesfoundationwdfaleadership foruminafricatoaddressthediabetesepidemic transparencyisfundamentaltosuccessfulpartner shipswithpatientgroupsinwelistedallthe patientgroupswesupportfinanciallyonourwebsite bycountryandwithashortdescriptionoftheactivity lrochearengcorporate responsibility partindd web personalised healthcare wwwrochecomphcinrd roche position statements personalised healthcare access medicines diagnostics pricing neglected diseases working patient groups wwwrochecompoliciesguidelinesandpositions access medicines report wwwrochecomsustaccesspdf programmes ldcs wwwrochecomprogrammesinleastdevelopedand developedcountries programmes developed countries wwwpparxorg wwwgenentechaccesssolutionscom roche trials patient safety wwwrochetrialscom wwwrochecomclinicaltrials wwwrochecommanagingmedicationsafety list patient groups supported wwwrochecompatientgroups lrochearengcorporate responsibility partindd roche business report corporate responsibility people foroveracenturyrochehasstoodforinnovationand isillustratedbyourconsistentrankingasanemployer entrepreneurshipourhistoryofachievingourbusi ofchoiceseethetablebelowforaselectionofour nessgoalsandexcellinginscienceandinnovationis awards aresultofconsistentlyemployingthebestpeople itrulybelievethatwereinthegoldenageofdisease wesucceedbecauseofourpeoplepeoplewhoare researchanddrugdiscoveryitisnowpossibleto passionateaboutmakingadifferencetopatients tacklediseasebiologywiththesamerigourasbasic livespeoplewholeadanddrivechangepeoplewho biologybecauseofthisconvergenceofmedicine liveourcorporatevaluesintegritycourageand andscienceicantthinkofabetterplacetobethan passionwehaveemployeesbehindourcur genentechthequalityofthesciencehereison rentsuccess parwiththatoftopacademicinstitutionsitisexhila ratingtoexperiencethecombinationofscientific wekeepouremployeesengagedandperformingat excellencewithstateoftheartresourcesenormously thehighestlevelbycreatingaworkingenvironment talentedcolleaguesandthecultureofrisktakingwe inwhicheveryonefeelsvaluedandrespectedwhere havehere theycandeveloptotheirfullestpotentialandcan marc tessierlavigne phd executive vice president maketheirownmarkourprogressinachievingthis research chief scientific officer employer choice selected external awards rankings award roche site rank description science magazines top employer genentech st genentech biopharmaceutical industry prize seventh time san francisco business times genentech st rank based employee responses best place work questionnaire includes companies bay area employees total equality germany roche germany na total equality awarded second time roches successful sustained equal opportunities commitment arizona bioindustry association ventana medical st award recognised ventanas bioscience company year systemsroche development growth tissue diagnostics best places work survey roche denmark st roche voted best pharmabiotech best pharmabiotech company company denmark fourth consecutive year second amongst sectors actualidad econmica roche spain st roche ranked st pharma industry best companies work th overall trendence top employer roche switzerland rd switzerlands students voted roche countrys third best employer technology science edition lrochearengcorporate responsibility partindd employees fte operating divisions engaged employees thegloballisteningtoyousurveyconductedinearly variance aimedtomeasuretheeffectivenessofinternal new pharma communicationsandemployeesattitudestothecom chugai panyandtheirworkoveremployees diagnostics responded total overallofrespondentsexpressedsatisfactionin theirjobandfelttheywereappropriatelyengaged fulltime equivalent fte byrochethevastmajorityfeltproudtowork employees contract types forrocheandwouldrecommendthegrouptoothers asagoodplacetowork variance regular fte nearlysaidtheyhaveaccesstotheinformation temporary fte theyneedtodotheirjobwellemployeesfeltwell headcount informedaboutourmajorproductsbusinessstrategy full time hc andfinancialperformancewewillcarryoutanother part time hc surveyin roche employees worldwide employees variance europe todayweemploysome north america employees asia aroundmorethan inallofthem aredrivenbythesame spiritandpursuethe samegoaltocreate newandbetterwaysto preventdiagnoseand africa australia treatnewdiseases latin america lrochearengcorporate responsibility partindd roche business report corporate responsibility duringtherochegenentechintegrationwepro certaincandidatesandtodemonstrateprogress videdrelevantinformationtoemployeesquicklyand towardsgovernmentgoalsforwomenandminorities transparentlyusinganintegrationwebportaland employeeroadshowstheelectronicplatformallowed wesponsorandsupportanumberofemployeeaffinity ustocommunicatemanagementdecisionsinstantly groupsassociationsandnetworksthegoe andattractedonaverageuniquevisitorsper genentechoutequalgroupaimstopromote weekbetweenaprilandaugustmainlyfromthe aworkplaceenvironmentthatembracesallemployees usandswitzerlandweheldroadshowsatallaffected regardlessoftheirsexualorientationaaib sitesandusedthemtointroducenewmembersof africanamericansinbiotechnologyisdedicated themanagementteamwefilmedtheseeventsand toachievingaculturallydiverseenvironmentwhich postedthevideosonlinetogetherwithkeypresenta improvesthedevelopmentofdrugstoaddress tionsthesevideosprovideddirectinputonstrategic theunmetmedicalneedsofamoreculturallydiverse directionandothernewsstoriespicturesandper patientpopulation sonalstoriesfromemployeeshelpedpeoplefrom eachcompanyconnectmoreeasily theintegraprojectatrochespainalsoencourages greaterunderstandingofdisabilityamongemployees asurveyatgenentechshowedthatemployeesremain andaimstoincreasethenumberofhireswithdis positiveafterthemergerdespitehavingexperi abilitiesinitalycollaborationwithlocalinstitutions enceduncertaintyandlossasaresultgenentech overthelasttwoyearshasenabledustorecruitand employeesremainproudoftheircultureanditsposi onboardfiveadditionaldisabledpersons tiveimpactonpatientslives peoplefromovercountriesfromaustralia thesurveyalsoshowedthatgenentechsfocus uruguaytosouthafricaworkforrocheinswitzer onpatientsandcommitmenttoscienceinspiresand landintotalmorethannationalitiesarerepre motivatesemployeesalmostallemployees sentedworldwideatroche arecommittedtothesuccessofthemergedcompany wanttostaywiththecompanyforatleastayear womenaccountfornearlyhalfofemployeesand orwanttostayatgenentechforalongtime ofmanagersgloballywomenalsomakeupmore thanoftheworkforceinoverofouraffili atesinwomenaccountformorethanofman fostering diversity agementexamplesincludeaustraliawherewomen ourfocusistoensurediversityinourworkforce accountforofemployeesandofmanage aninclusiveworkenvironmentallowsustoleverage mentandhungarywithandrespectively thepotentialofallemployeesirrespectiveofage genderethnicitydisabilityworkstyleexperiences gender diversity familysituationorworkingneeds wedonottoleratediscriminationofanyformas women total statedinourworldwideemploymentpolicywe workforce havemanagementtrainingprogrammesandawide women management rangeofinitiativesataffiliateleveltoencourage women senior andsafeguardemployeediversityforexampleour management nutleysiteintheushasadedicateddepartment women executive tomanagediversityitsetsannualplanstoevaluate management positions howemploymentdecisionsmayadverselyaffect ie top lrochearengcorporate responsibility partindd womeninleadershipnetworkbaselandgenentech genentechchallengesourscientiststodiscovernew womenprofessionalsbothaimtoprovideaforum biologyandtotranslatethesefindingsintonovel forwomenwhichrecognisestheiruniquestrengths medicinestohelppatientssuccessrequiresafear andtalentsandinwhichexperiencescanbeshared lessnessandwillingnesstoattackthemostdifficult andleveraged scientificandclinicalproblemsandnottobedeterred bythetrialsandtribulationsofscientificdiscovery encouraging innovation andunknownsofmedicineifeelfortunatetohavethe rocheisaglobalinnovationledcompanywehave opportunitytoworkalongsideourresearchdevelop tobalancetheneedforefficiencyandconsistency mentandclinicalscientiststomeetthesechallenges throughstandardisationwithacompetitiveenviron andrew c chan md phd senior vice president immunology mentinwhichinnovationthrives antibody engineering innovationisdrivenbydifferentandoftenconflicting approachesideasandexperienceswhileensuring werecogniseinnovationamongouremployeesthrough thatourmainfunctionalprocessesarealignedacross internalawardstheseincludeprizesforimproving therochegroupincludinggenentechwedecided animalwelfareinourtrialsimplementinginnovative tokeeptheresearchanddevelopmentlaboratories informaticssolutionsandproposalsthatimprove genentechresearchandearlydevelopmentgred patientslivestherochepharmaceoawardsrecog independenttoensureitsinteractionwithexternal niseteamsthathavepassionatelypursuedinnovative researchinstitutionswasnotdisruptedgredhasits solutionsforpatientscreativelyimprovedtheway ownbudgetportfoliomanagementandcultureall weworkandpushedsciencemarketingandopera ofwhicharefundamentaltoinnovationwecreated tionstothenextlevelinmorethanteams aparallelpharmaresearchandearlydevelopment fromeveryregiondiseasebiologyareaandfunction organisationpredcomprisingthevariousrd participatedintheprogrammewinningteams centresoutsidegenentechtostimulatethedifferent includedrocheemployeesateverystageintheir perspectivescriticaltosuccessfulinnovation careersfromyoungpostdocstoseniorresearchers withdecadesofexperience employees fte function ourpostdocfellowshipprogrammeawardsourbest scientistswithgrantstoconductexploratoryresearch servicing whichhelpsusreinforceourtalentpipelineinrd manufacturing logistics knowledgeisanessentialaspectinrochethatmulti marketing plieswhenitissharedandcleverlyusedthekey distribution istodevelopaparticipatorymanagementstylewhere research teamssharetheirideasanddevelopdifferentways development ofdoingthingsinaframeworkofmutualunderstand general ingitisaprivilegetoworkinacompanythatrecog administration nisestheperformanceandpotentialofitstalents total regardlessoftheirbackgroundandexperienceseven wherethesemightnotreflectthetraditionalrouteor theexpectedprofilerocheencouragesitsemployees torisetoandfaceprofessionalchallengesthus allowingthemtogrowandreachdifferentpositions mara jess alsar oncohematology director spain lrochearengcorporate responsibility partindd roche business report corporate responsibility attracting employees turnover regular employees weworkhardtokeepourrecognitionasanemployer ofchoicethisiscriticaltoourabilitytohireand retainoutstandingpeoplewhoarecommittedtoour total goalofimprovingpeopleshealthandqualityoflife europe latin america rochesstrongandsustainablebrandenablesus north america toattracttherightpeoplewehavebuiltalargeand asia diversepoolofcandidatesdedicatedinhouse australia recruitmentteamsandgloballyalignedrecruitment africa processesstandardsandtechnologyourcareers including non standard temporary contract ends websiteexpandedintoimprovethelocalvisibility ofallavailablepositionsincludingatgenentech thesitehadsometwomillionuniquevisitorsin reasons leaving andregisteredmorethanspontaneous applicationswealsocontinuedtorollouttaleoour globalerecruitingplatformlaunchedin employerrelated injustthreecountriestaleoisnowavailableinover employeerelated countriesworldwide neutral temporary contract ends health issues retirements wecontinuedtodeployourglobalemployerbrand inmakeyourmarkimprovelivestoimprove rochesturnovershowsastrongdecreasingtrend awarenessofrocheasanemployerofchoiceand thistrendisconfirmedparticularlybythe todifferentiateusfromourcompetitors numberofemployeesleavingoftheirownaccord fromintoinoverofour hiring retention alargeintegrationrequires employeeshavebeenwithrocheformorethan asharpfocusonretentionourdecisiontomaintain tenyears genentechsuniqueresearchoperationswasone measuretoaidretentionaccompaniedbyadditional developing employees healthbenefitsoutplacementservicesandcash developmentisapriorityforallemployeesinaninno paymentswehavecontinuedtoattracttopscientists vationdrivenorganisationwewantemployeesto andotherhighprofiletalentsincethedealwas developtotheirfullestpotentialandsupportthemat closedgenentechhiredpeopleinin everystageindoingso creasingitstotalworkforceby performance management regularfeedbackand staffing rates anopendialoguebetweenemployeesandtheir managersisacriticalactivityforwhichweholdboth managersandemployeesaccountablein number vacancies ofouremployeestookpartinperformancemanage new hires mentprogrammesandinformalcareerdevelop internal staffing rate mentplanning external staffing rate lrochearengcorporate responsibility partindd employee training potentialleadersoftotalheadcountofwhich onethirdarewomen total training spend millions withinthegloballeadershipportfoliowehavepro chf grammesaddressingeachcategoryofhighpotential training spend per employee leadersfromthosewhowillassumeaglobal chf leadershippositioninthelongtermtothosewhocan total number training hours succeedakeypositionholderintheshortterm million intheseprogrammestargetedthetopof average training hours per employeesandincluded employee explorationsincludesanassessmentofleader number postdocs students shipskillsfeedbackandcoachingbysenior interns leadersearlyinanemployeescareertoenable themtobuildfocuseddevelopmentplans excluding genentech chugai inemployeesparticipatedwomen learning rocheoffersextensivesupporttoem perspectivesatwoyearprogrammeinwhich ployeesforthedevelopmentoffunctionalprofes weprepareearlyhighpotentialleadersfor sionalandleadershipskillsourmajordiagnostics significantmanagementresponsibilitiestheywork andeuropeanpharmaaffiliatesaccountingfor infourdifferentfunctionsandregionsin ofthetotalrochepopulationofferednearly participantsjoinedforthefirsttimewomen coursesinthroughourcommon horizonsgivesmidtermhighpotentialemploy chrisplatformovertrainingsessions eesanacceleratedglobalandcrossfunctional classroomandwebtookplaceandweregistered developmentexperienceincriticalareassuchas closetobookings leadershipinnovationrisktakingcustomer orientationandchangeinemployees succession talent management inanorgani participatedwomen sationcharacterisedbychangeleadershipskills reflectionsprovidesanassessmentofthemost areincreasinglyimportantduringweensured seniorhighpotentialemployeesontheirindividual fullcoverageofourgloballeadershipprogramme strengthsareasofimprovementandpotential portfolioprovidingkeyprogrammesateverystagein basedontherochevaluesleadershipcompe theleadershipdevelopmentpipelineinroches tenciesincandidateswomentook learninganddevelopmentdepartmentwillcreate part acommonframeworkforleadershipdevelopment linkinggloballeadershipprogrammeswithexisting atatimeofsignificantorganisationalchangeswe localregionalandfunctionalinitiativesthiswill filledmorethanofouropenpositionsinternally giveemployeesandmanagersaccesstoacatalogue ofleadershipprogrammes international mobility whilesomevacancies ofthetotalarefilledbyexternalcandidates highpotentialleadersarepeoplewiththeabilityto weofferprofessionalandpersonaldevelopment takeoncriticalseniorrolesintheshortmidor opportunitiestoourownemployeesthroughinternal longtermidentifyinganddevelopingtheseemployees movesthisnotonlyhelpsrocheretainkeypersonnel ensureswehavearobustanddiversepoolofcan itenablesustoleveragepotentialwithinthegroup didatesforcriticalpositionsweidentifyandconfirm anincreasingamountoverofthismobility theseindividualsintalentassessmentsandreviews goesacrossaffiliateandnationalboundariesofour duringtheyearinweidentifiedhigh expatriatesandcrossboundaryemployees lrochearengcorporate responsibility partindd roche business report corporate responsibility arewomenallofthemrepresentingdifferent wealsoreviewedcompensationpracticesatroche nationalities andgenentechandmovedgenentech employeestorochelongtermincentivesthismeans toencouragemobilitywithinthegroupinwe thatapartfromchugaiemployeesalllongterm introducedtheintercompanytransferandlocal incentivesinthegrouparenowonthesameroche foreignhirepolicythisfacilitatestherecruitmentand holdingssecuritiesmorechangestoalignroche relocationofforeignhiresandofpermanentcross andgenentechcompensationpracticesandthe bordermoveswithinthegrouplocalmobilityinitia performancemetricsusedforincentiveswillcome tivessuchasourlocalpluspolicyinchinahelp intoeffectin attracttoptalenttochinaespeciallyindividualswho haveinternationalexperienceandwanttoreturn benefits throughcompetitivebenefitsprogrammes wehelptocreateanattractiveworkplace wehavealsorevisedourinternationalassigneespolicy toimprovetheflexibilityneededtoaddressmarket overofouraffiliatesofferextensivebenefitsplans trendschangingdemographicsandevolvingbusiness mostgobeyondgovernmentschemesandinclude needsthisrevisionrespondstothefindingsof healthchecksandfreeaccesstoawiderangeof asurveyofassigneesandtheirpartnersthe medicalserviceswehavealsointroducedprogrammes revisedpolicieswillberolledoutin thatencourageahealthylifestylethroughwellness programmeshealtheducationfitnesscentresswim rewarding recognising employees mingpoolsandrelaxationinitiativeswenowhave thetotalcompensationpackageweoffermakes taichiclassesatourbrazilianitalianandmexican asignificantcontributiontoattractingrewarding affiliatesandhaveincorporateditinworkshops recognisingandretainingtherightpeople appliedbyourlifecycleteamswehavebeentrialling powernappingandareofferinghealthyfoodoptions ourtotalremunerationcostsinamountedto atourheadquartersinbaselwecontinuetooffer billionswissfrancsanincreaseoffrom benefitstoourretireesatseveralofouraffiliatessuch ourbasepaypackagesrewardindividualperform asswitzerlandincludingaccesstoemployee ancerecognisingbothwhatwasachievedandhow restaurantssportsandleisureactivitiesandtravel itwasdonethroughvariablepayweincentivise checks employeeswhocreatenewopportunitiesandstrive foroutstandingresultsvariablepayisdrivenby wehaveincreasedourfocusonflexibleworking individualandteamobjectivesandbythegroupdivi arrangementsaftersuccessfulpilotsatourwelwyn sionalandaffiliateperformance siteintheukourbaselheadquartersintroduced apilottoaccommodatedifferentworkingstyles wewantouremployeestoshareinoursuccess orfamilysituationsthroughhomeworkinganddesk throughrocheconnectemployeesinmostcountries sharingthepilotaimedtoidentifymoreattractive canpurchaserochesnonvotingequitysecurities andflexibleworkingarrangementsforofficeworkers atadiscountofuptoinemployees aswellastestingefficientandsustainableuseof incountriesofthoseeligibleparticipated officespaceandinfrastructure inrocheconnectmorethaninwealso awardnonvotingequitysecuritiestomanagersbased genentechintroducedanonlinetoolallowing ontheirperformancethroughtherochelongterm employeestoassesswhethertheirtasksareeligible incentivesplanatotalofmanagerstookpart forflexibleworkarrangements inwithjoiningforthefirsttime lrochearengcorporate responsibility partindd wealsoaimedtoincreasetheconsistencyofour human rights labour relations benefitsprogrammesaroundtheorganisationour rochehasacomprehensiveemploymentpolicy goalistoalignbenefitprogrammeswithincountries whichcovershumanrightsthegroupcompliance sowecanofferattractivebenefitstoallourem officermonitorsthispolicyandservesasacontact ployeesregardlessofaffiliateordivisionconsistently forallemployees andefficiently rocherespectstherightofemployeestofreedom inwestartedtheharmonisationofthebenefit ofassociationandcollectivebargainingmorethan plansofournorthamericanaffiliatescoinciding ofouremployeesareunionmembersand withthegenentechintegrationwewilllaunchthenew overaremembersoforganisationsthatfreely programmeinoctoberanditwillcomeinto representthemincountrieswherethisislegal effectonjanuarysimilarbenefitharmonisa therocheeuropeforumrepresentsnearly tionprogrammesareongoinginswitzerlandspain employeesincountriesatgloballevelwehave franceandtheunitedkingdom recentlyinstalledanemployeerelationsofficer asaresultofthefinancialcrisisandthefallinglobal ourdirectiveontheprotectionofpersonaldatasafe equitymarketssomeofourpensionfundsaroundthe guardsinformationaboutemployeesandcomplies worldfacedchallengesmaintainingahealthyfunding withtherelevantlocallegislationwhereappropriate positionwhereunderfundinghasarisenroche wehavenegotiateddataprivacyagreementsbetween hastakenstepstodevelopappropriatestrategies differentpartsofthebusinessorwithworkscouncils inaccordancewiththelocalstatutoryregulations andpracticesandinconsultationwithemployee web representativesincludingadditionalcashinjections employees wwwrochecomemployees andrecoveryplanssomeofourmajorpension group policies positions guidelines wwwrochecompoliciesguidelinesandpositions fundshaveremovedearlyretirementincentivesand global careers portal httpcareersrochecom haveintroducedmoreflexibleretirementmodels employment policy wwwrochecomemploymentpolicypdf anticipatetheimpactofanageingworkforce core standards wwwrochecomcommitments simplifying aligning processes human resources allofourhrprocessesexceptthoseatgenentech andchugainowrunononecommonhrinformation solutionchristhisusestransactionalandreport ingsystemsandisalignedwithtaleoourglobal erecruitingsolution introducedinjulychrisreplacesseveral legacysolutionsandenablesstandardisedstreamlined andsimplifiedhrprocessesacrosstherochegroup ouraimistoensureconsistenthrservicesand increasedefficiencychriscoversaffiliatesand representativeofficesandofrocheemployees genentechandpharmanorthamericawillfully joininchrisismanagedbyaglobalsupport organisationandnetworkofservicinghubs lrochearengcorporate responsibility partindd roche business report corporate responsibility society oursupportforcommunitiesfocusesonprogrammes community support area andareasthatarealignedwithourbusinessmodel webelievewecanenhancetheinnovationsustainabil total ityandimpactofourbusinessthroughappropriate humanitarian social projects donationssponsorshipandemployeevolunteering science education thisinspiresandmotivatesourstaffandensures arts culture rocheremainsacommittedcorporatecitizen community environment monitoringtheimpactofourcommunityworkgives supporting future science amoreaccurateassessmentofourprogrammes youngscientistsareourfutureemployeesnurturing successthanpublishingdetailedfinancialinformation theirtalentensuresrocheremainsaninnovative aboutourdonationsforexampleourgenetics andsuccessfulcompanyforexamplewehavefoun educationprogrammeforeducatorsinswitzerland dationstosupportresearchandeducationpro andgermanyreachednearlypeoplewith grammesaroundtheworldincludingthefondation teachersenrolledintheworkshopsthesubsequent dentrepriserocheinfrancetheglobalroche knowledgetransferreachedtheircolleaguespupils organtransplantationresearchfoundationandthe andevenfriendsandfamilywewillexpanditin genentechandrochefoundationsintheus switzerlandandneighbouringregionsofgermany therochepostdocfellowshipprogrammecompleted itsfirstfullyearintheprogrammeaims allphilanthropicdonationsandnoncommercial toencouragecreativityinscienceandstrengthen sponsorshipsaremonitoredinternallythroughthe academicnetworksthroughsupportfortalented financialgroupreportingsystemthecorporate postdoctoratestudentsontwotofouryearresearch sustainabilitycommitteeisresponsibleformonitoring projectswithleadingacademicinstitutionsin theirimpact weofferedpostdoctoratestakingourtotalsince theprogrammelaunchedintopeople intherochegroupapprovedanupdatedcorpo weplantoincreasethatnumbertobytheend ratepolicyonphilanthropicdonationsandnon ofnextyear commercialsponsorshipthepolicystipulatesthatall philanthropicprojectsshouldfocusoninnovation inwepilotedtheresearchexchangescholars collaborationqualityandsustainabilityitcomfirms programmetheinitiativesupportsscienceeducation ourpriorityareasashumanitarianandsocialscience bygivinggiftedsecondaryschoolstudentsthechance andeducationcultureandartsandcommunityand togooninternationalexchangesthefirstexchange environmentourhumanitarianandsocialprogrammes featuredtwobiotechnologyspecialistschoolsfrom involvepromotingsustainableaccesstoourmedi theusandgermanythreestudentsfromeach cinesanddiagnosticsweonlydonatedrugsindisas schoolundertookasixweekinternshipattheother terandpandemicsituations whichincludedindividualmentoringat alocaluniversity thepolicyalsoensuresourdonationstargeta focusednumberofnongovernmentalorganisations thecongressoftheeuropeansocietyformedi ngostowhichwecanmakeasignificantdiffer caloncologyesmoawardedrocheinrecognition enceratherthandilutingourdonationsamong ofoursupportforitsyoungoncologistfellowship alargenumberofngosweexcludegovernmental programmewehavesupportedesmosinceitwas politicalandreligiousorganisations foundedinthroughclinicalandtransnational fellowshipsthesehavehelpedyoungoncologistsgain lrochearengcorporate responsibility partindd researchexperienceinrenownedeuropeancancer wesetuptherocheemployeeactionandcharity centresourongoingeducationprogrammesinclude trustreactinasanindependentcharity atwodaybioethicsteachingworkshopforsecondary organisationtomanageemployeedonationsit schoolteachersintheusandourpartnershipwith distributesfundstocommunityprojectsanddisaster thenewjerseyinstituteoftechnologytosupport reliefeffortsaroundtheworldsinceanearthquake aonedayeducationprogrammeforprimaryand inreacthasmaintainedongoingassistance secondaryteachers andreconstructioninthetownofchocosperu intheprojectbuiltacommunitycanteenand encouraging innovation arts newhomescapableofwithstandinganother wesupportmusicandtheartsbecausethecreativity quakeaswellascompletingthecommunitysdam andinnovationofthosedisciplinesreflectsour businessmodelwebelievelessonscanbeshared theannualrochechildrenswalkhasbeengoing betweenartsandscienceinweheldthe sincehoweveritdidnottakeplaceinas thirdrochecontinentseventtoencourageartistic ithasbeenmovedfromdecembertojulytoincrease involvementamongyoungpeoplearoundfuture participationnonethelessreactsworkwith chemistsbiologistsmedicspsychologistsmusi theeuropeancoalitionofpositivepeopleandunicef cianssetdesignersrecordingengineersandopera switzerlandwhichbothhavelongtermprojects singersfromuniversitiesallovereuropeattended tosupportchildrenimpactedbyhivaidsinmalawi artandscienceworkshopsandcontemporaryclassical continuedrocheemployeeswerestillinvitedto musicperformancesatthesalzburgfestival donateinandweguaranteedfinancialcoverage toensurethechildrendonotsufferintheinterim roche commissionsseesussponsoranewmusical todatethewalkhasraisedenoughmoneytobuildand piecebyanoutstandingcontemporarycomposer furnishnewclassroomsaccompanyingteachers everytwoyearstoshiohosokawawillpresenthis officesandsanitationandhygienefacilitiesfornearly workininadditionchugaiagainsponsoredthe primaryschoolchildrenthesponsoredwalk starphilharmonicchristmasconcertinyokohama hasalsohelpedfundeducationforsecondary japanwhichsupportsearlycancerdiscoveryand schoolstudentsandfivefurthereducationstudents treatment inruralsouthafricathereisjustonedoctorforevery supporting communities patientsthephelophepahealthcaretrain wewantemployeestocontributetotheirlocalcom aimstoreducetheburdenbyprovidingamobilehealth munitiessoweencouragethemtoidentifythe clinictomorethanpeoplewehavesupported projectsthattheyfeelwouldbemostworthwhile theservicesinceitbeganyearsagoandin whilerochehasarangeofgroupprojectswe additionalfundingfromrochecontributedtoacancer encouragestafftofundraiseandvolunteeralongside healthawarenessservicethenewserviceincludes theirworkcommitments cancerscreeningtrainingforstaffcommunitycancer awarenesseventspatientcounsellingandeducation genentechgoestotownisacommunityrelations focusedonbreastcervicalandprostatecancer projectsetupingenentechgivesemployees usdollarsworthofvoucherstospendinlocal web shopsovertwoweeksencouragingthemtodevelop roche social programmes localbusinessestheprogrammehasspentmore wwwrochecomsociety roche n jazz wwwrochenjazznet thanmillionusdollarsinlocalshopssinceincep act httpreactrochecom tionwithmorethanbusinessesparticipating lrochearengcorporate responsibility partindd roche business report corporate responsibility safety security health environmental protection safetysecurityhealthandenvironmentalprotection wetrainemployeeswhohandlechemicalsaspartof shearecriticalforourbusinesswetakeshe theirworktousethemproperlyandweprovide intoconsiderationinallouractivitiestherochecor safetydatasheetsforoverspecificchemicals porateprinciplesandshepolicycommitustothe onourwebsite highestshestandardsinweinvestedmil lionswissfrancsinsheinfrastructureandmillion weholdourecompetitioneverythreeyearstoraise swissfrancsinsheoperatingcosts awarenessofenvironmentalissuesamongemployees byencouragingthemtosuggestnewwaystoreduce management ourimpactsthecompetitionourfifthelicited astrongteamcoordinatesshewithinrochewe morethanproposalsfrompeopleatsites havefulltimesheemployeestoensureour thewinnersincluded performancenewsheofficersattendedatraining rochepaloaltousretrofittingcoolingequip weektolearnaboutourshepolicystrategyguide menttoreplacehalogenatedhydrocarbon linesandprocessesattendeesdiscussedroches hcfcwithhydrocarbonrefrigerantspropane sheresponsibilitiesandhowtoaccessrelevant orpropylene expertisetheyalsolearnthowtoestablishandmain rochejacarepagubrazilrecoveringsolutions tainariskmanagementsystemattheirsiteswe fromtubingusingapolystyreneplugratherthan heldregionalworkshopsforexistingsheofficerson waterandnitrogen topicssuchasenergyefficiencysecurityandindus chugaipharmajapanregeneratingemergency trialhygiene batteriesinuninterruptedpowersuppliesinstead ofreplacingthem everyoneatrocheisresponsibleforensuringhealth andsafetyandforminimisingtheenvironmental theannualrocheresponsiblecareawardsencour impactsofouroperationsweneedeveryonetounder agesitestosuggestenergyefficiencyimprovements standourshestandardssoweoffersitespecific insubmissionsfromsitesstoodout trainingincludinglecturesandpracticalcourseswe including havealsobegunabasiconehoursheelearning rochebezaresmexicosolarboilersinstalled moduleforallemployeesinemployees toprovidehotwater receivedanaveragehoursofshetrainingeach rochediagnosticsuscontrolledlighting duringquietperiods itisimportanttounderstandsherisksacrossthe rochediagnosticsindiaaspecialglassfaade businesssowecandeveloplocalsafetymeasuresas wasinstalledtosaveenergycosts wellasgrouplevelresponseswelistallsherisks onawebbasedinventoryaccessiblebyallmanagers security acrossthebusinessindividualsitemanagersand weappointedacorporatesecurityofficercso sheofficersimplementtheshepolicyandguide ininwesetupanetworkofmore lineslocallyinthepharmaceuticalsanddiagnostics thansitesecurityofficersssosandissued divisionsecodelegatesraiseawarenessofenviron acorporatedirectivetodefinetheirresponsibilities mentalissues aswellasoursecurityprinciplesandgeneral processesthedirectivedescribesminimumstand wemonitortheimplementationoftheshepolicy ardstoprotectemployeesvisitorsphysicalassets usingregularsiteauditsandweusetheresults productsandbusinesssensitiveinformation toimproveperformanceinweconducted auditsrevealingnomajordeficienciesbut wealsointroducedaglobalsecurityincident highlightingtheneedtoupdatesiteriskanalyses reportingtoolthatallowsssosandthecsotoanalyse lrochearengcorporate responsibility partindd incidentsandestablishcorrectivemeasuresin agrouplevelbodyinvestigatessignificantshe wefocusedoncounterfeitproductsandpreventedthe incidentsandcommunicatestherelevantfindings saleofsignificantquantitiesoffakeproducts acrossthecompanyincludingforuseintraining programmeswheresuitable health safety therocheaccidentraterarmeasuresthe environmental footprint numberofworkingdayslostduetooccupational ourenvironmentalfootprinttakesintoconsideration accidentsperemployeeperyear researchandproductionaswellasproductpackag ingdistributionuseanddisposal intherarwasthisrepresentsa improvementfromandiscomfortablybelowthe weusetheswissagencyfortheenvironments groupgoalfor bafuecobalancemethodtocalculateourenvi ronmentalfootprintitreflectsresourceuseas health safety wellasemissionsandwasteinourecobalance wasanimprovementoffromthis reflectssignificantlyreducedemissionstoairand roche accident rate organicmaterialsdischargedtowaterweare occupational accidents currentlyoperatingwithinourtargetecobalanceof occupational illnesses workrelated fatalities workrelated accidents wealsomeasureenvironmentalexpenditureinrela per million working tiontosalestohelpensurewetargetourinvestment hours intheareaswhereitwillhavethemostimpact thecalculationgivesusanecoefficiencyrateeer weexpectcontractorswhoworkonrochepremises asshowninthetablebelowthiscombinesdata tofollowthesamesafetyrulesasemployees onenergyusewasteemissionstoairandwaterwith contractorswereinvolvedinaccidentsin expenditureonenvironmentalprotectionandsales inadditiontothosereportedforemployees adetaileddefinitionisavailableontherochegroup resultinginaninjuryfrequencyrateofaccidents websiteinoureerwasanimprove perworkinghours mentof employeessufferedcasesofoccupationalillnesses ecoefficiency rate inadecreasefrominthenumber ofworkingdayslostwasthesamelevelasin locomotordisordersespeciallyrepetitivestrain sales million chf injuriesaccountedformorethantwothirdsofthe environmental expend totalweworktoreducetheseinjuriesthroughlocal iture million chf ergonomicprogrammesimprovedofficeequipment environmental damage andindividualassessmentsgenentechsergonomics millions environ programmeaddressescumulativetraumaand mental damage units includesadedicatedtrainingwebsitethesouthsan eer franciscositehasthreeergonomicsshowrooms allowingstafftotestproductsfortheofficeplantand therocheenvironmentalawarenessinchemical laboratory technologyreactprogrammepromotessustainable chemistrypracticesinourrdlabsaroundtheworld lrochearengcorporate responsibility partindd roche business report corporate responsibility reactsetssustainablechemistryguidelinesto energy use type measurethebenefitsforexamplethemassintensity factormeasurestheratioofinputsofrawmaterials fuel used againstoutputswhilesolventselectionguidelineshelp company vehicles employeeschooselessharmfulsolventsthepro oil grammeaimstosupportrochessustainabilitygoals fuel due business sharebestpracticesaroundthegroupraise air travel employeeawarenessincreaserecognitionforrds sustainabilityworkandreducecosts grid electricity energy climate change ourpositionpaperongreenhousegasesandclimate district heating changeguidesourgroupstrategyfordecreasing waste emissions renewable energy natural gas weregularlyanalyserochesvulnerabilitytothe changingclimatewehavenotidentifiedanysig nificantriskstoourbusinessfromclimatechange sionsfactorsatsomesiteswhoseelectricityproviders oranyspecificbusinessopportunities recalculatedthelessemissionintensiveproportionof theirenergymix rochesenergyandfueluseintotalled terajoulesanincreaseoffromthis greenhouse gas emissions tonnes co equivalent ismainlyduetotheinclusionofgenentechscar fleetforthefirsttimeenergyuseisapproximately gigajoulesperemployeeasmalldecreasesince total emissions total emissions per million chf energy use terajoules sales thereductioninemissionsinrelationtosales total energy use showsthatrocheisreducingenergyusewhilethe total energy use businessgrows per million chf sales total energy use inwedevelopedastandardforintegrating per employee energyefficiencymanagementintobuildingprojects thisaccompaniedanewgroupwidemanualon ourclimatestrategyfocusesonenergyusewhich energyefficientdesignwhichwillhelpusdesign accountsformostofourcarbondioxideco emis futurefacilitiesandrefurbishedbuildingstominimise sionsweconvertamountsofco andothergreen energyuse housegasghgemissionssuchashalogenated hydrocarbonsleakingfromrefrigerationequipment milanhasaproblemitisoneofthemostpolluted intocoequivalentsinweemittedthou citiesineuropesmogisatarecordlevelfarabove sandtonnesofcoequivalentsanabsolutedecrease europeanunionlimitsrochemonzaitalybegan offromthisreductioncomesdespite aprogrammetoreduceitsenvironmentalimpactsin increasedenergyconsumptionduetorevisedemis bymodifyingtransportincreasingrecyclingand lrochearengcorporate responsibility partindd reduce total energy consumption greenhouse gas emissions energy use selected types fuel used company vehicles introducedanewtargetforoureuropeancom panycarfleettoincludeonlyvehiclesproducing nomorethangramsofcarbondioxideco perkilometrebytheendof fuel due business air travel videoandteleconferencingfacilitieshavebeen establishedatallsitesandarewidelysupported employeesareencouragedtousetrainsand toconsolidateseveralbusinesstripsintoone grid electricity natural gas ourfirstpriorityistoreduceusageofenergy fortheenergywedousewelookforwaysof improvingtheefficiencysuchasheatrecovery inadditionweencouragetheuseofgreen energywhereversensibletohelpdrivethisin wereleasedourgroupwidemanual onenergyefficientdesignfortheconstruction offuturefacilitiesthatminimiseenergyuse reducingenergyusethroughsensorlightsand genentechmetitsownghgemissionsreduction energysavinglightbulbsinthesiteincreased goaltwoyearsaheadofscheduleitwillnowjointhe itsfocuslifegateanexternalenvironmentalorgani restofrochesusaffiliatesinpursuinganewgoalof sationbasedinmonzanowmonitorsenergyand decreasingemissionsbyby waterusewastedisposallogisticsandemployee transportthesitehasalsostartedbuyingofits rochehasagroupdirectiveonenergyconservation energyfromrenewablesourcesinadditionaninter whichpromoteslocalinitiativesitincludesenergy nalawarenesscampaignhasencouragedemployees efficiencystandardsfornewandexistingelectrical togetinvolvedinenergysavinginitiativessofar equipmentandrequiressitestoconductenergy thesitehasreducedco emissionsbyaround audits theusenvironmentalprotectionagencyepahas theauditsidentifiedopportunitiestoimprove commendedourusaffiliatesformeetingtheirgoalto ourbuildingsutilitiesplantsandprocessesincluding reduceghgemissionsbybetweenand thoseatgenentechtheseincludeimprovedmetering aheadoftimerocheushaspledgedtoreduce andmonitoringretrocommissioningbuildings emissionsbyafurtherfromto andadaptinglightingandairconditioningsystems lrochearengcorporate responsibility partindd roche business report corporate responsibility despitethesecentralfunctionswegivesitesthe ozone depletion freedomtodeveloptheirownemissionsreduction thetargetdateforrochesdirectivetophaseout strategieswebelievethisapproachimprovesresults halogenatedhydrocarbonscfcsandhcfcswhich becausesitesaremorefamiliarwiththeirownneeds damagetheozonelayerandaffecttheclimatehas andcircumstancesforexamplerocheshanghai beenextendedfromtoordepending hasanongoingprojecttoincreaseenergyefficiency onthelocalsituationthisisduetoalackofaccepted theprogrammehasseentheintroductionoftriple alternativesinsomecountriesgenentechhasnot anddoubleglazingoptimalinsulationgeothermal yetdefinedatargetdatebutiscommittedtophasing heatingandcoolinglowpowerenergysystemsand thesegasesout solarwaterheating replacementsforhcfcsandcfcssuchashfcs businesstravelaccountsforapproximatelyof hydrofluorocarbonsandpfcsperfluorinated ourtotalco emissionsoverallandourcarfleetis carbonsdonotaffecttheozonelayerbuttheycan responsibleforapproximatelyemployeesare contributetoclimatechangeandarepersistentin encouragedtousetrainswhentravelisnecessary theenvironmentsowedonotconsiderthemalong andtoconsolidateseveralbusinesstripsintoone termalternativerochehasatargettophaseout videoandteleconferencingfacilitiesalsohelpusmini hfcsandpfcsbygenentechandotherrecent misetravelforexamplerochefinlandworkedwith acquisitionswillworktoaseparatedeadlinetobe wwffinlandtohosttheamericansocietyofclinical definedinsometechnicalproblemscontinueto oncologysannualmeetingvirtuallyinjune preventusfromreplacingtheseinallapplications aroundcustomersattendedtheconferencefrom butweareworkingtofindalternativetechnologies theirclinicsparticipatingthroughvideostreaming severalsitesnowusetelepresencesystemswhich ozonedepleting chemicals tonnes significantlyimprovethequalityofvideoconferencing encouragingincreasedusage halogenated anewtargetforoureuropeancompanycarfleet hydrocarbons holdings aimstoensurewewillusevehiclesproducingnomore halogenated thangrammesofco perkilometrebytheend hydrocarbons ofthiswillcutco emissionsbytonnes emissions andsavetwomillionlitresoffuelperyear rocheshalogenatedhydrocarbonsinventoryincreased anumberofsiteshavelaunchedinitiativestoencour induetotheintroductionofgenentechs agestaffnottouseprivatecarstocommutetowork holdingstothegrouptotalwithoutthisincrease atgenentechforexamplethegrideprogrammehas rochesholdingswouldhavedecreased promotedalternativessuchasvanpoolingmass transitcyclingwalkingandgenenbusshuttlessince emissions air theshuttleswereupdatedinwithnewer emissionstoairfromouroperationsincludevolatile moreefficientmodelsthatmeettheusepas organiccompoundsvocsparticulatesnitrogen standardforparticulateemissionsatrotkreuz oxidesnoandsulphurdioxideso weaim x switzerlandwehaveintroducedanannualbonusof toreducetheseemissionswhichcancontributeto swissfrancsforstaffwhocommutetowork airpollutionsmogandacidraininwereduced withoutusingacarormotorbike vocemissionsbytotonnesouremis sionsofparticulatesno andso weretonnes x lrochearengcorporate responsibility partindd tonnesandtonnesrespectivelythesefluctuate wemonitorlandfillsitestoensureourchemicalwaste atlowlevelsfromyeartoyear doesnotposearisktohumanhealthortheenviron mentsomelandfillsneedtobesustainablyremedi emissions air tonnes atedinwecompletedaprojecttoremediatethe hirschackerlandfillingrenzachgermanyroche voluntarilyfinancedthisprojectinwemade vocs availableapproximatelymillionswissfrancsfor particulates othersuchprojects nitrogen oxides sulphur dioxide water weneedcleanwaterformanufacturingbutwe waste understandtheneedtoreduceourwaterusebased aroundofourchemicalwasteisincinerated ontheglobalreportinginitiativesdefinitionof thedisposalmethodwiththeleastenvironmental waterconsumptionwaterusedinproductscooling impactinweproducedtonnesofchemi andirrigationouruseincreasedbywe calwasteandecreasefromthisdoes usedmillionmofwaterin notincludewastethatcanbereusedasrawmaterials byothercompaniesinwesoldaround thewaterweusecanbecontaminatedduringmanu tonnesmostlysolventsforreuse facturingsowetreatwastewatertoensureitis safeforpeopleandtheenvironmentwecontinueto inweengagedinsignificantbuildingactiv developwaystoincreaseourcapacitytotreatwaste itywhilewascharacterisedbybuilding wateraroundthegroup demolitionwegeneratedlessgeneralwaste tonnesbutourrecyclingratesincreased oneofthewinningsubmissionsofecompetition duetotonnesofbuildingrubblemade camefromrochepenzberggermanythesubmission availableforrecyclingmostlymetalsandconcrete outlinesaproposaltouseresidualwaterfromthe soldtoothercompaniesforreuseexcludingthis distillationofpurifiedwatertogeneratesteamforthe buildingrubblewerecycledtonnes plantsboiler morethanlastyearwedecreasedgeneralwastesent tolandfillbyofthetotaltwere inwedecreasedtheamountoforganicmaterial incinerated dischargedintowatercoursesaftertreatmentby totonnesthisismainlyduetoarecalcula waste tonnes tionofdatafromtwositesbecauseinvestigationsinto differencesatsimilarsitesrevealedthattheyhad overreportedinpreviousyearswealsoreleased general waste kilogramsofheavymetalssuchaschromium produced copperandzinclessthanin general waste per million chf ournewgoaltoreducetoxicityofdischarged sales wastewaterreflectsthegenerallylowertoxicityof chemical waste organicmatterfrombiotechoperationsthanfrom produced chemicalproduction chemical waste per million chf sales lrochearengcorporate responsibility partindd roche business report corporate responsibility water compliance incidents rochedidnotreceiveanysignificantshefinesin wemeetalllocallawsorregulationsasaminimum water withdrawn howeverourgrouppoliciesareoftenstricterthan million cubic metres thesewecontrolsubstancesthatcouldbemisused water used toproducenarcoticstoxinsorchemicalandbio million cubic metres weaponsthesesubstanceswhichwekeepinsmall wastewater discharged supplyareoftenregulatedandweensurecompliance treatment plant withallapplicablelegislation million cubic metres organic matter objectives discharged reducetherocheaccidentratebyby watercourses fromthebaseline treatment tonnes improvetotalecobalancebybyfrom heavy metals baselinepointsemployee discharged reducetotalenergyconsumptionbyby watercourses frombaselinegigajoulesemployee treatment receivenosignificantsherelatedfines kilogrammes medium longterm objectives pharmaceuticals environment pie averagefourhoursofshetrainingperemployee tracesofpharmaceuticalproductsendupintheenvi reducetherocheaccidentraterarto ronmentraisingfearsthattheymaylaterbefoundin andworkrelatedaccidentspermillionworking foodandwatersourcesthisisusuallyduetonormal hourstobelowby patientusealthoughmanufacturingandimproper improveourecobalancebybyfrom disposalalsocontributeweofferretailersfinancial abaseline incentivestoreturnunusedoroldproductssowecan improveenergyefficiencymeasuredasgigajoule discardthemproperlyweanalysetheriskofpharma peremployeebybyandby ceuticalsenteringtheenvironmentinourlifecycle comparedwith approachtoproductdevelopmentminimising increasetheproportionofrenewableenergyused releaseswherepossiblemanufacturingsitesare toby designedandoperatedtoreduceactiveingredients reducethetoxicityofdischargedwastewaterby enteringwastewater byfromabaseline althoughcurrentevidencesuggestslittlepresenceof web piewerecognisetheneedformoreresearchinto performance longtermeffectsinweundertookathorough wwwrochecomsheperformance safety security health environmental protection riskassessmentoftheactiveingredientoseltamivir wwwrochecomenvironment tamiflubeingexcretedintotheenvironmentduring safety security health environmental protection heavypandemicusetheassessmentfoundno signifi policy cantriskourpositionpaperonpiedescribes wwwrochecomsafetyhealthandenvironmental protectionpdf ouraimtomonitorrisksandrocheisamemberof group fact sheets positions policies guidelines internationalandlocalbodiesstudyingtheimpactsof wwwrochecompoliciesguidelinesandpositions tracechemicalsinsurfaceandgroundwater genentech sustainability report wwwgenecomgeneaboutenvironmental lrochearengcorporate responsibility partindd independent assurance report tothecorporatesustainabilitycommitteeof therochecorporatesustainabilitycommitteeisresponsible rocheholdingltdbaselroche forboththesubjectmatterandthecriteriaourresponsibilityis toprovideaconclusiononthesubjectmatterbasedon wehaveperformedassuranceprocedurestoprovideassurance ourassuranceproceduresinaccordancewiththeinternational onthefollowingaspectsofthecorporateresponsibility standardonassuranceengagementsisae reportingofroche main assurance procedures subject matter ourassuranceproceduresincludedthefollowingwork dataandinformationdisclosedinthecorporateresponsibility evaluation application group guidelines reportingofrocheanditsconsolidatedsubsidiariesexcluding reviewingtheapplicationoftherocheinternalcorporate chugaipharmaceuticalcoltdforthebusinessyearended responsibilityreportingguidelines decemberonthefollowingaspects site visits visitingselectedsitesofrochespharmaceuti themanagementandreportingprocesseswithrespectto calsanddiagnosticsdivisionsinswitzerlandgermany thecorporateresponsibilityreportingandtothepreparation francespainitalyandchinatheselectionwasbasedon ofsheandpeoplekeyfiguresaswellasthecontrol quantitativeandqualitativecriteria environmentinrelationtothedataaggregationofthese interviewingpersonnelresponsibleforcompliancematters keyfigures internalcorporateresponsibilityreportinganddata theshekeyfiguresinthetablesonpagestoand collectionatthesiteswevisitedandatthegrouplevelto someselectedpeoplekeyfiguresdisclosedonpages determinetheunderstandingandapplicationofroche tooftherocheannualreportand internalcorporateresponsibilityguidelines complianceinformationconcerningthecompliance visitingthepremisesofpeopleintouchinamsterdam functionsthecomplianceorganisationandthemanagement interviewswithpeopleintouchstaffinvolvedindesign ofcasesreportedthroughtherochegroupspeakupline implementationandoperationsofthespeakupsolution thelatterwithafocusondataprivacyandprotectionof assessment key figures performingtestson individualsanonymityasdisclosedonpageoftheroche asamplebasisofevidencesupportingselectedsheand annualreportexcludingethicalincidentdata peoplekeyfiguresrocheaccidentrateenergyconsump tionco emissionsrelatedtoenergyconsumptionrelease criteria ofhalogenatedhydrocarbonsuseofwaterfinesinrelation therochegroupinternalcorporateresponsibilityreporting tosafetyandenvironmentalprotectionheadcountftedata guidelinesbasedontheresponsiblecareprogramme staffturnoverseniormanagementpositionsandlabor healthsafetyandenvironmentalprotectionreporting practicesinformationconcerningcompletenessaccuracy guidelinespublishedbytheeuropeanchemicalindustry adequacyandconsistency councilceficandthesustainabilityreportingguidelines review documentation analysis relevant gpublishedonoctoberbytheglobalreporting policies basic principles reviewingtherelevant initiativegriand documentationonasamplebasisincludinggroupsustain thedefinedproceduresbywhichsheandpeoplekey abilitypoliciesmanagementandreportingstructuresand figuresaregatheredcollatedandaggregatedinternally documentation therochegroupbusinessprinciplestheinternalgroup assessment processes data con solidation speakupguidelinesbasedonthedirectiveonuseof reviewingtheappropriatenessofthemanagementand rochegroupspeakuplineandgoodpracticeprocedures reportingprocessesforcorporateresponsibilityreporting bywhichcompliancefunctionsandspeakuplinesare andassessingtheconsolidationprocessofdataatthe designedmanagedandoperated grouplevel assessment speakup processes systems responsibility methodology case management walkthroughthespeakupprocess theaccuracyandcompletenessofcorporateresponsibilityindi byusingapracticalexampleandassessingthefollowing catorsaresubjecttoinherentlimitationsgiventheirnatureand protectionagainstunauthorisedaccessconnectionsand methodsfordeterminingcalculatingandestimatingsuchdata processestoexternalserviceprovidersandexternal ourassurancereportshouldthereforebereadinconnection businesspartnersprocessesinplaceforadministration withrochesinternalguidelinesdefinitionsandprocedureson loggingmonitoringandbackuprestoreallinrelationtothe thereportingofitscorporateresponsibilityperformance dataprivacyandanonymity lrochearengcorporate responsibility partindd roche business report independent assurance report conclusions global reporting inouropinion initiative sustainability theinternalcorporateresponsibilityreportingguidelinesare beingappliedproperly reporting guidelines theinternalreportingsystemtocollectandaggregateshe andpeoplekeyfiguresisfunctioningasdesignedand withthisyearsannualreportwecontinueourapproachof providesanappropriatebasisforitsdisclosureand aligningoursustainabilityreportingtotheguidelinesofthe therochegroupspeakuplinesystemsandprocessesare globalreportinginitiativegri designedfollowinggoodpracticeprocedureswithregardto dataprivacyandanonymity forthethirdtimerocheisoftheopinionthatthealevel ofthegrigguidelinesappliestoitsannualreport basedonourworkdescribedinthisreportandtheassessment thiswascheckedwithandconfirmedbythegri ofcriterianothinghascometoourattentionthatcausesusto believethatthedataandinformationmentionedinthesubject detailsofhowwereportagainsteachindicatorcanbefound matteranddisclosedwiththesustainabilityreportingin atwwwrochecomreportingandindices therocheannualreportexcludingethicalincidentdata doesnotgiveafairpictureofrochesperformance zurichjanuary pricewaterhousecoopersag drthomasscheiwiller stephanhirschi severinschwan lrochearengcorporate responsibility partindd published cautionary statement regarding forwardlooking f hoffmannla roche ltd statements basel switzerland annual report contains certain forwardlooking state tel ments forwardlooking statements may identified fax words believes expects anticipates projects intends seeks estimates future similar expressions discussion among things strategy media office goals plans intentions various factors may cause actual group communications results differ materially future reflected basel switzerland forwardlooking statements contained annual report tel among others pricing product initiatives competi fax tors legislative regulatory developments eco nomic conditions delay inability obtaining regulatory investor relations approvals bringing products market fluctuations currency exchange rates general financial market condi basel switzerland tions uncertainties discovery development tel marketing new products new uses existing products fax including without limitation negative results clinical trials research projects unexpected side effects pipeline world wide web marketed products increased government pricing pres wwwrochecom sures interruptions production loss inability obtain adequate protection intellectual property rights corporate sustainability committee litigation loss key executives employees adverse publicity news coverage tel email corporatesustainabilityrochecom statement regarding earnings per share growth profit forecast interpreted mean order publications roches earnings earnings per share tel subsequent period necessarily match exceed fax historical published earnings earnings per share roche email baselwebmasterrochecom trademarks mentioned enjoy legal protection next annual general meeting links third party pages provided convenience march express opinion content third party pages expressly disclaim liability third party information use roche annual report published german english printed nonchlorine bleached fsccertified paper roche annual report issued f hoffmannla roche ltd basel group communications cover photograph shows ribbon diagram rituximab therapeutic protein heart mabtherarituxan targeted bio logic medicine used treat nonhodgkins lymphoma chronic lymphocytic leukemia rheumatoid arthritis lrochearengimprintindd e roche annual report key figures key figures indexed figures annual report exceptional items full index global reporting initiative gri proposed board directors indicators used report see development phase iv wwwrochecomreportingandindices calculation ecoefficiency rate see wwwrochecomenvironment e lrochearengkey figuresindd roche finance report fr hyr eng ceonvge rc ver uhr usheri es eite rroocchhee afinnnaunacle r reeppoortrt fhopfufmbalinshnelda bryoche ltd f bhaosfefml asnwnitzlear lranodche ltd basel switzerland aallll ttrraaddeemmaarrkkss mareen lteiognaellyd pernojtoeyc lteegdal protection trademarks mentioned enjoy legal protection wwwrochecom roche halfyear report wwwrochecom leading biotechnology improving patient care excellence science umschlagausgeschossenengindd lrochearengfront coverindd